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Abstract I 
 
Dendritic cells (DC), being key players in antigen presentation and initiation of 
virus-specific T-cell responses, have been reported to exhibit functional 
impairment in HBV carriers. Possible explanations for this phenomenon are 
infection of DCs with HBV or alteration of DC function by HBV. Therefore it was 
analysed whether DCs support the different steps of HBV infection: uptake, 
delivery of the HBV genome to the nucleus, antigen expression, and progeny 
virus release. When HBV genomes were artificially introduced into monocyte-
derived DCs (moDC) by adenoviral vectors, low-level expression of hepatitis B 
surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) but no HBV 
replication was detected.  
When subjecting moDCs to recombinant HBV expressing Renilla luciferase 
either under a non–liver-specific promoter or under a HBV promoter, no 
luciferase activity was detected. After incubation with wild-type HBV, 
intracellular HBV rcDNA was detected in a low percentage of cells, but nuclear 
cccDNA was not formed. This indicates that either uncoating or 
nucleocytoplasmic transport were blocked.  
To verify the observation in the in vivo situation, myeloid (mDC) and 
plasmacytoid DCs (pDC) were isolated from blood of high viremic HBV carriers, 
and analysed by quantitative polymerase chain reaction (PCR) and electron 
microscopy. Although circulating DCs had in vivo been exposed to more than 
104 HBV virions per cell, HBV genomic DNA was hardly detected, and no 
nuclear cccDNA was detected at all. By using electron microscopy, subviral 
particles were found in endocytic vesicles, but virions were undetectable, as 
were viral capsids in the cytoplasm. Quantitative PCR analysis of B cells, 
monocytes and an enriched T-cell fraction of chronic HBV carriers showed 
uptake of HBV particles in low amounts, but no establishment of an infection.  
In conclusion, circulating DCs may take up HBV antigens, but neither support 
nucleocytoplasmic transport nor replication of HBV. It can be excluded that HBV 
infects DCs with a frequency sufficient to explain the functional impairment of 
the virus-specific T-cell response in chronic HBV carriers. One can hypothesise 
that the contact of DCs with HBV antigens, which are present in sera of infected 
persons in high amounts, influences DC and T-cell function.  
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Abstract II 
 
Fluorescent labelling of viral proteins and viruses, or virus-like particles, has 
been shown to provide a powerful tool for investigating unexplored aspects in 
viral life cycles. A commonly used technique is the genetic incorporation of 
fluorophores into virus proteins. The insertion of GFP into the Gag protein of 
HIV for instance allowed studying the trafficking of this protein, as well as 
production of infectious virions (Müller et al., 2004). In case of adeno-associated 
virus, Lux et al. (2005) were able to directly monitor the cytosolic and nuclear 
trafficking with GFP-tagged virus particles.   
Since many aspects of the HBV life cycle still remain unclear, the visualisation 
of viral (VP) and subviral (SVP) HBV particles is a promising approach to 
elucidate different steps of virus entry and egress. GFP or RFP fused HBV S, M 
and L surface proteins were constructed and analysed for their fluorescence 
and stability properties. To ensure that the fusion did not alter the characteristic 
properties of the HBV surface proteins, they were compared to the parental 
proteins with regard to their localisation in cellular compartments and the ability 
to form subviral and viral particles. The GFP fused proteins did not co-localise 
with the parental proteins within the cell, suggesting that they were unstable. 
The RFP fusion proteins clearly co-localised with the parental proteins. But 
although they behaved similar to the parental proteins with regard to their 
distribution in the ER and golgi compartment, neither of them contributed to the 
formation of SVP or VP.   
Thus, GFP and RFP fusion to HBV surface proteins is not suitable to generate 
fluorescent HBV particles. The main impediment is most probably misfolding of 
the fusion proteins. The bulky GFP and RFP domains seem to have topological 
and sterical effects, affecting stability, correct integration into the ER membrane 
or assembly and secretion of properly formed particles. Labelling with small 
fluorescent molecules can minimise or overcome these problems and therefore 
perhaps provides a better strategy. 
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Zusammenfassung 
 
Die Infektion mit dem Hepatitis B Virus (HBV) stellt weltweit ein großes 
gesundheitliches Problem dar. Mit mehr als 2 Mrd. Infizierten, darunter ca.     
350 Mio. chronische Träger, ist es eine der häufigsten Infektionskrankheiten. 
Die chronische Hepatitis B führt häufig zu Leberzirrhose und hepatozellulärem 
Karzinom, an dessen Folgen jährlich schätzungsweise 1 Mio. Menschen 
sterben. Trotz der Verfügbarkeit eines wirkungsvollen Impfstoffs steigt die Zahl 
der Infizierten,  vor allem in den Entwicklungsländern, stetig an.  
HBV gehört zur Familie der hepatotrop-assoziierten DNA-Viren und weist eine 
enge Organ- und Wirtsspezifität auf. Soweit bekannt ist, kann HBV nur primäre 
Hepatozyten infizieren und ist im Fall des humanen HBV auf Menschen und 
humanoide Primaten als Wirt beschränkt. Da HBV über ein RNA-Intermediat 
mittels reverser Transkription repliziert, wird es zu den Pararetroviren gezählt.      
Die 42 nm großen viralen Partikel (VP) enthalten ein 3.2 Kilobasen (kb) großes 
zirkuläres DNA-Genom, welches nur partiell doppelsträngig und deshalb nicht 
kovalent geschlossen ist (rcDNA, relaxed circular DNA). Es enthält vier sich 
teilweise überlappende offene Leseraster, von denen durch mehrere 
Initiationsbereiche während der Translation sieben virale Proteine gebildet 
werden. Das Genom befindet sich im Nucleokapsid, das aus dem viralen Core-
Protein aufgebaut ist. Eine Lipid-Doppelmembran umhüllt das Kapsid. Sie 
besteht aus einer wirtseigenen Membran, die vom endoplasmatischen 
Retikulum (ER) stammt. In diese sind die viralen Hüllproteine eingelagert. Die 
drei Hüllproteine S (small),  M (middle), und L (large) sind eng verwandt: M 
besteht aus der Aminosäuresequenz von S, mit einer N-terminalen 
Verlängerung um 55 Aminosäuren (aa). Diese zusätzliche Sequenz nennt man 
PreS2. L besteht aus der Aminosäuresequenz von M, die N-terminal um die 
PreS1 Sequenz aus 119 aa verlängert ist. Neben den infektiösen viralen 
Partikeln werden im Rahmen einer Infektion auch nicht-infektiöse Partikel, so 
genannte subvirale Partikel (SVP), gebildet. Diese bestehen lediglich aus der 
Lipid-Doppelmembran und enthalten weder DNA noch Kapside. SVP sind im 
Vergleich zu VP in einem bis zu 10000-fachen Überschuss im Serum Infizierter 
nachweisbar. Deshalb sind sie stark immunogen. Die Bedeutung der SVP ist 
bislang ungeklärt, vorstellbar ist aber, dass sie anti-HBV Antikörper abfangen, 
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die vor allem gegen Epitope auf dem S Protein gerichtet sind. Im 
immunologischen Kontext werden die SVP deshalb auch als HBs-Antigen 
(HBsAg) bezeichnet. Ein weiteres Antigen, das in hohen Konzentrationen im 
Serum nachweisbar ist, ist das HBeAg. Dieses virale Protein wird von infizierten 
Zellen sekretiert, seine Funktion ist unbekannt. 
HBV infiziert Hepatozyten über bislang unbekannte Rezeptoren. Nach dem 
Eintritt in die Zelle wird das Kapsid freigesetzt und das virale Genom, die 
rcDNA, wird in den Nukleus transloziert. Dort wird das partiell doppelsträngige 
Genom von der zellulären Polymerase 2 vervollständigt. Dadurch entsteht ein 
doppelsträngiges, kovalent geschlossenes DNA-Molekül, welches als cccDNA 
(covalently closed circular DNA) bezeichnet wird. Diese Form der HBV-DNA 
kommt lediglich im Nukleus infizierter Zellen, in Form extrachromosomaler 
Moleküle, vor. Die cccDNA dient als Matrize für die RNA-Synthese. Virale 
Proteine werden synthetisiert, und zunächst werden Kapside gebildet. Neben 
den mRNAs wird auch eine prägenomische RNA synthetisiert, welche 
zusammen mit der viralen Polymerase in die Kapside verpackt wird. Dort erfolgt 
die reverse Transkription des RNA-Intermediates in das rcDNA-Genom. Die 
rcDNA enthaltenden Kapside können entweder ihre DNA wieder in den Kern 
translozieren und so den Pool an cccDNA auffüllen, oder die Kapside werden 
am ER umhüllt. Die ER-Membran enthält bereits die viralen Hüllproteine S, M 
und L, da sie direkt in die ER-Membran synthetisiert werden. Während der 
Synthese werden die Hüllproteine teilweise glykosyliert. Über Disulfid-Brücken 
bilden sich zunächst Homo- und Heterodimere, die sich zusammenlagern und 
entweder in Form von SVP oder nach Kontakt mit dem Kapsid in Form von VP 
in das ER-Lumen abgeschnürt werden. Die Information für die Bildung 
subviraler Partikel liegt in der Sequenz des S Proteins, welches alleinig zur SVP 
Bildung ausreichend ist. Während des vesikulären Transports durch ER und 
Golgi-Apparat werden die Hüllproteine weiter modifiziert. Über den 
Exozytoseweg werden die subviralen und viralen Partikel freigesetzt.  
Das Virus wird vertikal über Blut und Körperflüssigkeiten übertragen, weiterhin 
kann eine perinatale Übertragung von der Mutter zum Kind erfolgen. Das 
Risiko, eine chronische Hepatitis B zu entwickeln ist altersabhängig. Bei 
Säuglingen liegt die Wahrscheinlichkeit bei 98%, während eine Ansteckung im 
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Erwachsenenalter nur in 5-10% der Betroffenen zu Ausprägung einer 
chronischen Infektion führt.        
Der Verlauf einer HBV-Infektion hängt von der adaptiven Immunantwort des 
Wirts ab. Das Virus an sich ruft weder Entzündungsreaktionen noch 
Leberschäden hervor. Um eine akute Infektion, die meist symptomlos verläuft, 
zu kontrollieren, ist eine polyklonale zytotoxische T-Zell-Antwort sowie eine 
starke T-Helferzell-Reaktion notwendig. Eine chronische Infektion ist hingegen 
gekennzeichnet von einer oligospezifischen T-Helferzell-Antwort, eine virus-
spezifische Antwort der zytotoxischen T-Zellen findet meist nicht statt. Neben 
der eingeschränkten T-Zell-Funktion scheinen auch dendritische Zellen (DC) 
funktionelle Defizite aufzuweisen. DC präsentieren Antigene und aktivieren       
T-Zellen, die dieses Antigen erkennen. Können DC diese Funktion nicht oder 
nur eingeschränkt ausüben, hat dies dementsprechend große Auswirkungen 
auf die spezifische T-Zellantwort. Eine funktionelle Beeinträchtigung der DC, 
z.B. ausgelöst durch eine Virusinfektion, könnte deshalb eine Erklärung für die 
Defizite in der T-Zellantwort chronisch HBV Infizierter sein. Eine Dysfunktion 
von DC ist bereits von anderen chronischen Virusinfektionen bekannt. 
Beispielsweise infizieren das Hepatitis C Virus oder das Humane 
Immundefizienz Virus DC, und entgehen mit dieser Strategie der spezifischen 
Immunantwort. Eine Beeinträchtigung der DC-Funktionalität muss aber nicht 
unbedingt durch einen direkten Einfluss des Virus  hervorgerufen werden, 
vorstellbar ist auch eine Interaktion von HBsAg oder HBeAg mit den 
Oberflächenproteinen der DC. 
 
Im ersten Teil dieser Arbeit wurde untersucht, ob DC mit HBV infiziert werden 
können. Dafür wurde zuerst in einem in vitro- System analysiert, ob DC die 
diversen Schritte einer HBV-Infektion unterstützen: Virusaufnahme, Transport 
des viralen Genoms in der Nukleus, Antigenexpression sowie Produktion und 
Freisetzung neuer Viren. Dafür wurden Monozyten isoliert und zu unreifen und 
reifen DC differenziert. Diese aus Monozyten generierten DC (moDC) besitzen 
viele Eigenschaften der schwer zu isolierenden im Blut zirkulierenden DC und 
werden deshalb häufig als Modell verwendet. Zunächst wurde das HBV-Genom 
mittels eines adenoviralen Vektors in unreife und reife moDC eingebracht. 
Danach konnten im Zellüberstand sehr geringe Mengen HBsAg und HBeAg 
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mittels ELISA gemessen werden. Replikation und Freisetzung neuer Viren 
hingegen fand nicht statt, wie eine Untersuchung des Überstandes auf HBV-
DNA ergab. Nach Inkubation von moDC mit HBV-basierten Vektoren, die 
Luziferase entweder unter einem HBV-spezifischen Promoter oder aber unter 
dem nicht leberspezifischen CMV-Promoter exprimierten, konnte keine 
Luziferase-Aktivität festgestellt werden. Um auszuschließen, dass Wildtyp-HBV 
sich anders verhält als rekombinantes HBV, wurden die Zellen auch mit 
Wildtyp-HBV inkubiert. Mit Hilfe einer quantitativen Echtzeit-Polymerase 
Kettenreaktion (PCR, polymerase chain reaction) wurden die moDC auf die 
Präsenz der cytoplasmatisch in Viruspartikeln vorkommenden HBV rcDNA und 
der nukleären cccDNA hin untersucht. Speziell ausgewählte Primer 
ermöglichten, beide Formen der HBV DNA zu unterscheiden. Während geringe 
Mengen rcDNA in den Zellen detektiert wurden, konnte cccDNA nicht 
nachgewiesen werden. Diese Ergebnisse weisen darauf hin, dass zwar eine      
– vermutlich unspezifische – Aufnahme von HBV in die Zellen erfolgte, eine 
Infektion jedoch nicht etabliert wurde. Vermutlich waren die Kapsid-Freisetzung 
oder die Translokation des Genoms in den Nukleus blockiert.                 
Um diese Daten in der physiologischen Situation zu überprüfen, wurden die 
Hauptpopulationen zirkulierender DC, die myeloiden und plasmazytoiden DC 
(mDC, pDC), aus dem Blut chronischer HBV Träger isoliert. Mittels quantitativer 
Echtzeit-PCR wurden die DC auf das Vorhandensein von rcDNA und cccDNA 
hin untersucht. Die genomische rcDNA konnte in einigen Fällen in geringer 
Konzentration in den DC detektiert werden, cccDNA wurde nicht gefunden. In 
B-Zellen, Monozyten und angereicherten T-Zellfraktionen der chronisch 
Infizierten befanden sich ebenfalls geringe Mengen HBV Partikel, wie sich in 
der rcDNA-PCR zeigte, cccDNA war jedoch nicht vorhanden. 
Elektronenmikroskopisch wurden einige subvirale Partikel in endozytischen 
Vesikeln in mDC nachgewiesen, das Zytoplasma war jedoch frei von intakten 
Virionen oder Kapsiden. In pDC wurden keine Hinweise auf virale oder 
subvirale Partikel gefunden.  
Schlussfolgernd wurde in dieser Studie gezeigt, dass zirkulierende DC in 
geringen Mengen HBV Antigene aufnehmen, einen DNA-Transfer in den Kern 
sowie die Replikation von HBV jedoch nicht unterstützen. Deshalb ist eine 
Infektion dieser Zellen mit HBV in einem Maße, welches die Beeinträchtigung 
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der T-Zell-Antwort in chronischen HBV Trägern erklären könnte, 
auszuschließen. Diese Arbeit lässt jedoch keine Rückschlüsse darüber zu, ob 
andere Populationen der sehr heterogenen dendritischen Zellen, wie z.B. 
leberständige DC, mit HBV infiziert werden können und eine Toleranz gegen 
das Virus auslösen. Unter Berücksichtigung der Ergebnisse dieser Arbeit sowie 
Daten anderer Studien erscheint es aber wahrscheinlicher, dass eine 
Interaktion von HBsAg oder HBeAg mit DC-Oberflächenproteinen einen 
Funktionsverlust hervorruft.  
 
Der zweite Teil dieser Arbeit beschäftigte sich mit der Generierung 
fluoreszierender HBV-Hüllproteine durch die Fusion mit GFP (grün 
fluoreszierendes Protein) oder RFP (rot fluoreszierendes Protein). Dies würde 
mikroskopische Analysen, z.B. in lebenden Zellen erlauben, die – wie schon für 
andere Viren gezeigt wurde – Aufschluss über diverse Fragestellungen geben 
können. Zum einen könnte das Verhalten der Proteine in Zellen verfolgt 
werden, sowie der Weg viraler und subviraler Partikel aus der Zelle, da beide 
die Hüllproteine in großer Zahl enthalten. Dies setzt jedoch voraus, dass die 
Fusionskonstrukte in der Lage sind, Partikelstrukturen auszubilden. Zum 
anderen könnten mit dieser Strategie auch die frühen Schritte der HBV Infektion 
visualisiert werden, wenn fluoreszierende VP und SVP aus dem Überstand 
transfizierter Zellen isoliert und für eine Infektion primärer Hepatozyten 
eingesetzt  werden könnten.   
Zunächst wurde GFP sowohl an den N- als auch an den C-Terminus der 
Hüllproteine fusioniert. Fluoreszenzmikroskopische und Western blot-   
Analysen zeigten, dass die N-terminale Fusion von GFP an das S Protein in 
einem instabilen Fusionsprotein resultierte, welches schnell degradiert wurde.  
Das kann vermutlich damit erklärt werden, dass das Fusionsprotein entweder 
gar nicht, oder in einer falschen Topologie in die ER-Membran synthetisiert 
wurde. Da die Signalsequenz am N-Terminus der Hüllproteine lokalisiert ist, ist 
sie möglicherweise nach Fusion des globulären GFP nicht mehr funktionell. 
Eine falsche Lokalisation oder Faltung von Proteinen führt zu einer schnellen 
Degradierung.   
GFP und RFP wurden infolgedessen nur an den C-Terminus der Hüllproteine S, 
M und L fusioniert. Die Eigenschaften der Fusionsproteine wurden im Hinblick 
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auf Veränderungen gegenüber der wildtypischen (wt) Proteine charakterisiert. 
Dafür wurden die Fusionsproteine einzeln oder in Kombination mit wt-Proteinen 
in Zellen der humanen Hepatomlinie HuH7 exprimiert. Mittels konfokaler 
Fluoreszenzmikroskopie und Western blot wurde untersucht, ob die 
Fusionsproteine fluoreszierten und stabil exprimiert wurden. Alle GFP-
fusionierten Proteine waren stark fluoreszierend,  wobei die Fluoreszenz sowohl 
im Zytosol als auch im Nukleus detektiert wurde. Die Färbung von S-GFP mit 
einem Antikörpern gegen das HBV S Protein ergab eine geringe Kolokalisation 
von S mit GFP im Zytosol. Dies ließ darauf schließen, dass die Fusionsproteine 
instabil waren und auch freies GFP oder Fusionsproteinfragmente in Zytosol 
und Nukleus vorhanden war. Eine Lokalisation im Nukleus ist typisch für GFP, 
nicht jedoch für die HBV Hüllproteine. Western blot- Analysen bestätigten, dass 
die GFP-fusionierten Proteine instabil waren, und auch durch die Koexpression 
der wt-Protein nicht stabilisiert werden konnten. 
Im Gegensatz dazu wurde nach Transfektion der RFP-Fusionsproteine keine  
nukleäre sondern nur cytosolische Fluoreszenz detektiert. Weiterhin 
kolokalisierte RFP zum größten Teil mit Antikörpern gegen S. Das bedeutete, 
dass die RFP-Fusionsproteine weitgehend intakt in den Zellen vorlagen.  
Im Folgenden wurden nur die RFP-fusionierten Proteine näher charakterisiert. 
Da bekannt ist, dass die HBV Hüllproteine in die ER Membran synthetisiert und 
später in Form von SVP ins Golgi transportiert werden, wurde die Lokalisation 
der RFP-Fusionsproteine in der Zelle genauer untersucht. Eine mittels 
Konfokalmikroskopie durchgeführte Kolokalisationsstudie der Fusionsproteine 
mit ER- und Golgi-Markern ergab, dass diese ebenso wie die wt-Proteine 
zunächst im ER und später auch im Golgi nachweisbar waren. S-Fusionsprotein 
enthaltende subvirale Partikel wurden jedoch nicht sekretiert. Wurde wt-S 
koexprimiert, konnten geringe Mengen SVP im Medium durch 
Immunpräzipitation nachgewiesen werden. Diese enthielten jedoch lediglich S, 
aber kein S-Fusionsprotein. Im Vergleich zu den Kontrollzellen, die nur mit wt-S 
transfiziert wurden, schien die Sekretion von wt-SVP in kotransfizierten Zellen 
eingeschränkt zu sein. Nach Koexpression von Fusionsproteinen und den HBV 
wt-Proteinen wurden keine Viruspartikel gebildet. Welcher oder welche Schritte 
in der SVP und VP Bildung beeinträchtigt war, blieb bei diesen Versuchen 
offen. Eine falsche Faltung der Hüllprotein-Domäne oder falsche Topologie in 
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der ER-Membran, sowie sterische Hinderungen durch das globuläre Fluorophor 
könnten einen Einfluss auf verschiedene Schritte der Partikelbildung haben: 
sowohl eine Behinderung der Glykosylierung als auch der Dimerisierung z.B. 
durch Verdecken der Bindestellen würde zur Folge haben, dass die Proteine in 
der Membran verbleiben und später degradiert werden. Alternativ ist denkbar, 
dass die Proteine zwar in Vesikeln in das ER abgeschnürt werden, diese jedoch 
nicht sekretiert werden können.        
 Abschließend kann gesagt werden, dass sich mit den in dieser Arbeit 
generierten Fusionsproteinen keine fluoreszierenden HBV-Partikel herstellen 
ließen und diese Konstrukte auch zur Beobachtung der einzelnen Proteine in 
Zellen nicht geeignet waren. Die Eigenschaften hatten sich im Vergleich zu den 
wt-Proteinen verändert und spiegelten nicht mehr die natürliche Situation wider. 
Die Markierung mit kleinen Fluoreszenz-Farbstoffen könnte eine geeignete 
Alternative zur Fusion mit GFP und RFP darstellen. Ein vielversprechender 
Ansatz ist die Markierung mit einem so genannten Tetracystein-Tag System. 
Hierfür muss lediglich eine sechs aa große Erkennungssequenz in die 
Proteinsequenz eingebracht werden. Dies minimiert  die Gefahr, dass wichtige 
Proteinstrukturen verändert werden. Ein nicht fluoreszierendes Molekül, FlAsH 
genannt, bindet spezifisch an die Erkennungssequenz und wird durch die 
kovalente Bindung in ein fluoreszierendes Derivat umgewandelt. Mit diesem 
Ansatz könnten virale Proteine sowie subvirale und virale Partikel in der Zelle 
beobachtet werden. Weiterhin könnten mit markierten VP die frühen Schritte 
einer HBV Infektion visualisiert werden. Eine biochemische Markierung der 
Virushülle – beispielsweise mit fluoreszierenden Alexa-Farbstoffen über eine 
Succimidylester-Bindung – stellt eine weitere Alternative zu den Fluorophoren 
dar.  
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   1. Introduction 
 
 
1.1 The Hepatitis B Virus.  
 
The Hepatitis B Virus (HBV) is a noncytopathic enveloped deoxyribonucleic acid 
(DNA) virus belonging to the family of hepadnaviridae (hepatotrop associated DNA 
viruses) (Gust et al., 1986). It is highly species and organ specific, and as far as 
known it reproduces only in hepatocytes. Because DNA synthesis occurs via 
reverse transcription of a ribonucleic acid (RNA) intermediate, HBV classes 
among the pararetroviruses.  
Infection with HBV can cause acute hepatitis, and in some cases a persistent 
infection manifests. Pathological consequences of a chronic hepatitis B are often 
liver cirrhosis and hepatocellular carcinoma (HCC).  
The human HBV infects only humans and humanoid primates, such as 
chimpanzees (Vaudin et al., 1988), orang utans (Warren et al., 1999), gibbons 
(Norder et al., 1996) or gorillas (Grethe et al., 2000). Relatives of the human HBV 
in the group of orthohepadnaviridae are the wooly monkey (Lagorithrix lagotricha) 
hepatitis B virus (Lanford et al., 1998), the woodchuck (Marmota monax) hepatitis 
B virus (Summers et al., 1978), and the ground squirrel (Xerus inauris) hepatitis B 
virus (Marion et al., 1980). The peking duck (Anas platyrhynchos) hepatitis B virus 
(DHBV; Mason et al., 1980), the heron (Areidea) hepatitis B virus and the snow 
goose (Anser caerulescens) hepatitis B virus belong to the group of 
avihepadnaviridae.  
The establishment of an animal model is hampered by the species specificity of 
the virus and the fact that the animal species, which can be infected with a human 
related HBV, are not characterised and difficult to keep. To date, HBV transgenic 
mice serve as a model for chronic HBV infection. Transduction of mice with 
adenoviral vectors containing the complete HBV genome or hydrodynamic 
injection of HBV plasmids mirror an acute HBV infection (Liu et al., 1999; Sprinzl et 
al., 2001; Yang et al., 2002). The repertory of cells that can serve as a cell-culture 
model is limited by the hepatotropism of the virus. Human hepatoma cell lines, 
such as HuH7 or HepG2, are useful to study intracellular facets of the viral 
replication cycle (Sureau et al., 1986; Sells et al., 1987). However, they cannot be 
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infected with HBV in culture. The viral genome has to be transferred into the cells 
via transfection or adenoviral vectors. To gain insight in the early steps of HBV 
infection, the culture of primary human hepatocytes (PHH) provides a necessary 
and valuable tool (Schulze-Bergkamen et al., 2003).       
 
 
1.1.1 Epidemiology. 
 
HBV was discovered by Blumberg in 1963, in Australian Aborigines and termed 
Australia antigen (Blumberg et al., 1966). A few years later it was identified as the 
infectious agent of a viral hepatitis (Blumberg et al., 1969). 
Hepatitis B is a major disease of mankind with over 2 billion people infected, 
predominantly in the developing world. 350 million people are chronic carriers with 
high risk to develop liver cirrhosis and HCC, diseases that cause approx. 1 million 
deaths per year (WHO, 2007).      
Infection occurs via blood and body fluids and can be transmitted horizontally 
through sexual contacts or parenteral inoculation from adult to adult, or vertically 
from the infected mother to the newborn. The course of the disease is variable and 
depends on age and immune status of the patient.   
Primary infection is followed by a six weeks to four months long incubation period. 
It proceeds either asymptomatically or is accompanied by nausea, fatigue and 
jaundice. The acute phase is characterised by elevated serum transaminase 
levels, indicating liver inflammation. Infection is completely cleared in most of the 
cases due to a multi-specific and polyclonal cytotoxic T-cell response and a strong 
type 1 T-helper cell response. Thereby patients develop immunity against HBV.  
An unusual and severe form of the acute hepatitis is the fulminant hepatitis, 
leading almost always to death.  
Approx. 30% of HBV-infected infants and 90% of perinatal infected newborns 
develop persistent hepatitis. With increasing age the likelihood of a chronic 
manifestation of the infection decreases. In 5 to 10% of infected adults the virus is 
not cleared and the patients become either silent carriers or develop chronic 
hepatitis. Hallmarks of a chronic HBV infection are active viral replication for more 
than six months and variable but persistent viral titers for at least twenty weeks. 
The T helper-cell response is mostly oligoclonal, cytotoxic T-cell activity is weak or 
undetectable (Ferrari et al., 1990). 
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HBV prevalence varies and is most endemic in Southeast Asia, China and Africa 
with about 10% HBV carriers in the population. Intermediate infection rates of 1 to 
8% are found in the Middle East, Russia, India and Brazil, whereas developed 
countries (Europe, Australia, North America) are regions of low prevalence. 
Despite the availability of a potent vaccine infection levels increase, predominantly 
in the developing world (WHO, 2007).       
 
 
1.1.2 Particle structure. 
 
HBV is an enveloped virus with a partially double-stranded (ds) DNA genome. The 
intact virion, also referred to as Dane particle, has a spherical structure with 42 nm 
in diameter (Dane et al., 1970). The envelope consists of a host derived lipid 
bilayer with three viral surface proteins integrated: The small protein (S), the 
middle protein (M) and the large protein (L). The M and L proteins are expressed 
at levels of about 1 - 2% and 5 - 15% compared to S protein (Robinson, 1995). 
Homodimers of the viral core protein, arranged with triangulation numbers of three 
or four, build the 27 nm icosahedral capsid inside the envelope (Crowther et        
al., 1994). The capsid encloses the 3.2 kilo base pairs (kb) viral genome, with the 
viral polymerase (P) covalently linked to the negative strand via its terminal protein 
(TP) domain (Bartenschlager and Schaller, 1992).   
HBV-infected cells secrete not only infectious virions but also non-infectious 
subviral particles (SVP), consisting only of surface proteins without capsid or DNA 
(Ganem and Prince, 2004). The spherical SVPs, so-called spheres, are small with 
a diameter of 20 nm and octahedral symmetry. The filamentous SVPs, also named 
filaments, are present in less quantity and are of variable length (Ganem and 
Schneider, 2001). They comprise almost only S protein and low levels of M and L. 
The role of the highly immunogenic SVPs is not yet understood, but since they are 
present in 100 to 10000-fold excess to virions in serum of infected persons, they 
may capture and thereby neutralise anti-HBV antibodies (Heermann and Gerlich, 
1991). These are predominantly directed against the S protein, which is present in 
high amounts on the surface of the SVPs. Figure 1 provides an overview of the 
different HBV particles.    
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Fig.1: Structure of hepatitis B virus particles.  
Fig.1a) shows the structure of an infectious 40 nm Dane particle, in b) the two forms of subviral 
particles (spheres and filaments) are illustrated. c) Electron microscopic image of HB virions, 
filaments and spheres (Copyright Linda M. Stannard, Department of Medical Microbiology, 
University of Cape town, South Africa).   
 
 
1.1.3 Genome and proteins. 
 
The 3.2 kb DNA genome present in the virion is a partially ds relaxed circular (rc) 
molecule. The minus strand is of unit length and linked to the viral polymerase via 
the terminal protein at the 5` end. The 5` end of the plus strand is of variable 
length so that a part of the minus strand is single stranded (ss). Fig. 2 provides an 
overview over the viral DNA and RNAs. The gap in the duplex genome is repaired 
in the host-cell nucleus by a host-specific polymerase, generating a fully duplex 
genome. This form of the hepatitis B viral genome exists only inside the host-cell 
nucleus and is termed covalently closed circular DNA (cccDNA). It serves as a 
template for the viral messenger RNAs (mRNA). The small genome is organised 
compactly with four partially overlapping open reading frames (ORF), without non 
coding regions (Ganem and Schneider, 2001):  
1) Product of ORF P is the viral polymerase (P). 
2) ORF C encodes the core protein (C) and the precore protein.  
3) ORF S/pre-S products are the surface proteins S, M and L.  
4) ORF X codes for the X protein (X).  
Four promoters (preC/C, preS1, preS2/S and X promoter) regulate transcription, 
whereby the resulting transcripts have to be distinguished into pre- and             
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sub-genomic RNAs. The former is bi-functional, being a template for reverse 
transcription as well as a message for viral proteins. The latter have exclusively 
messenger RNA functionalities. mRNA transcription starts at the different 
promoters and stops at one common polyadenylation signal (Cattaneo et             
al., 1984).  
Two enhancer elements (enh1 and enh2) influence the promoters. Enh1 increases 
transcription from all four promoters, in contrast to enh2, which only up-regulates 
transcription from the preS2/S promoter. Enh2 activity requires liver-specific 
transcription factors, and is therefore restricted to hepatic cells (Hu and Siddiqui, 
1991; Yuh and Ting, 1993).      
The longest transcript is the 3.5 kb pre-genomic RNA (pgRNA). It includes the 
complete genomic information of the virus and serves as a template for reverse 
transcription of the HBV genome. Furthermore, it encodes the polymerase, 
precore and core protein. Essential for transcription of the pgRNA is the 
transcription factor hepatic nuclear factor (HNF) 4 (Raney et al., 1997). Therefore, 
the transcription of pgRNA is liver-specific.   
The protein product of the polymerase gene encompasses three functional 
domains, the RNAseH domain, the reverse transcriptase (RT) domain, and the   
TP domain. The polymerase drives packaging of the pgRNA into the capsids by 
binding to the encapsidation signal (ε) of the RNA. As soon as the                   
RNA-polymerase complex is encapsidated, the polymerase reverse transcribes 
the pgRNA into DNA and removes the RNA with its RNAseH activity.  
Expression of preC and C proteins is highly liver specific, because liver-enriched 
transcription factors are required. PreC protein, in the immunological context also 
referred to as HBeAg, contains the identical amino acids (aa) as the core protein 
plus additional 29 aa at the N terminus. It is a non-structural protein, which is 
secreted in high amounts from infected cells (Seeger and Mason, 2000). Because 
serum levels of HBeAg correlate with viral replication levels, it is a serological 
marker for infection. The function of HBeAg is yet unknown. 
The core protein is the structural component of the viral capsid. It possesses     
self-assembly properties, building first homo-dimers, which then aggregate to form 
capsids (Zhou and Standring, 1992).   
Subgenomic RNAs of 2.4 kb and 2.1 kb encode the L protein, and the S and           
M protein, respectively. Whilst the preS2/S promoter is active in a wide range of 
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cells, the preS1 promoter is liver specific, requiring, amongst others, the 
transcription factor HNF 1 (Courtois et al., 1988). All surface proteins share the   
S-protein sequence. The N terminus of the M protein is extended by the 
hydrophilic 55 aa long preS2 domain. L contains the S and preS2 domain and 
additionally the preS1 domain.  
 
 
Fig.2: Genome organisation of HBV. 
Outer circles depict the transcripts (genomic and subgenomic RNAs). The triangles indicate the 
transcription starts, the square symbols the encapsidation signal (ε). The bold black lines represent 
the partially ds genome. Enhancers (Enh1, Enh2) and direct repeats (DR1, DR2) are outlined in 
squares. The arrows illustrate the four open reading frames (ORF) with their protein products X, C, 
P and the surface proteins S, M and L. (Modified from Protzer et al., 1999). 
 
The S protein is expressed in vast amounts in comparison to M and L, and the 
distribution of the surface proteins differs between virions and subviral particles. 
While the virion envelope is enriched for L, the SVP are composed of S protein 
with variable amounts of M and L. It is known that S and L protein are necessary 
for virus assembly and binding to cellular receptors, respectively. M protein is not 
required for infection and its function remains to be elucidated.   
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The 0.7 kb subgenomic RNA encodes the X protein. Its function is controversially 
discussed. On the one hand, it is a prerequisite for HBV and WHV infection in vivo, 
on the other hand, it is not conserved throughout the family of hepadnaviridae, 
implying a minor role in the HBV life cycle. Involvement in liver cancerogenesis is 
likely (Su et al., 1998).  
 
 
1.1.4 Replication cycle. 
 
The early steps of HBV infection are still obscure, but current data suggest that      
L protein is responsible for attachment and binding to still unknown cellular 
receptors. Results obtained with the DHBV model demonstrated that the entry 
occurs via endocytosis of the virion and fusion of the viral envelope with the 
endosomal membrane in the acidic milieu (Kock et al., 1996; Breiner and Schaller, 
2000; Funk et al., 2004; Stöckl et al., 2006). This process seemed to be pH 
independent (Rigg and Schaller, 1992; Kock et al., 1996). The replication cycle of 
HBV is schematically outlined in fig. 3.  
After uncoating the capsid translocates microtubule dependent to the nucleus, 
likely via a nuclear localisation signal harboured at the C terminus of the core 
protein. Whether the capsid releases the rcDNA genome at the nuclear pore, or 
whether it translocates in intact form into the nucleus, remains to be investigated. 
Considering the sizes of the nuclear pore (25 nm) and the intact capsid (30 to     
34 nm), it is likely that capsid disorganisation is induced, so that only the          
DNA-polymerase-complex enters the nucleus.  
Within the nucleus, the gap in the rcDNA is repaired by cellular enzymes, resulting 
in the covalently closed circular form (cccDNA). In rare cases, HBV DNA 
integrates into the host genome. This event does not have an impact on the virus 
life cycle, but is proposed to promote the development of HCC (Ganem, 1990; 
Wang et al., 1991; Tu et al., 2006).  
The cellular RNA polymerase transcribes the four viral mRNAs, which are 
transported into the cytoplasm without splicing. Translation of the viral surface 
proteins S, M and L takes place at ribosomes at the ER, where they integrate into 
the ER membrane. The products of the pgRNA (core, precore and polymerase) 
are synthesised at free ribosomes (Ganem and Schneider, 2001).   
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The TP domain of the polymerase recognises a stem-loop-formation at the 5` end 
of the pgRNA. This structure serves as an encapsidation signal (ε) and is 
covalently bound by the polymerase-protein-complex (Ganem and Schneider, 
2001).  
 
 
Fig. 3: Replication cycle of HBV. 
Virions bind to a receptor on the cell surface and enter. The nucleocapsids uncoat and the partially 
ds DNA genome is imported into the nucleus. DNA reparation leads to cccDNA formation and 
transcription of viral RNAs. After translation and capsid formation, the pgRNA is encapsidated. 
Reverse transcription takes place within the capsids. Nucleocapsids are either re-imported into the 
nucleus or bud into the ER, obtaining their envelope. Virions, as well as budded SVP, are 
transported to the cell surface and are secreted.        
 
As soon as a sufficient amount of core protein has been produced, it                 
self-assembles into capsids. The pgRNA-protein-complex is packaged into the 
capsids, and the polymerase starts to reverse transcribe the DNA minus strand. A 
tyrosin residue at the terminal protein serves as a primer. Simultaneously, the 
RNA plus strand is eliminated by the RNAse H activity of the viral polymerase. 
Then synthesis of the DNA plus strand, initiated at direct repeat 2 (DR2), occurs, 
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resulting in the rcDNA genome with an overlapping minus-strand segment. A short 
capped oligoribonucleotide at the 5` end of the pgRNA is required here for priming. 
Complementary sequences at the 5` end of the plus strand and the 3` end of the 
minus strand lead to circularisation of the DNA molecule (Ganem and Schneider, 
2001).  
The originated mature nucleocapsids can now follow two different pathways. 
Some translocate to the nucleus and re-import the DNA to refill the cccDNA pool. 
Others bud into the ER, thereby receiving their envelope, consisting of the viral 
surface proteins S, M and L integrated into the ER lipid bilayer. SVP self-assembly 
is thought to occur at a post-ER/pre-golgi compartment, the so-called ER-golgi 
intermediate compartment (ERGIC; Huovila et al., 1992). Both VPs and SVPs 
traverse the golgi before being exocytosed. Little is known about the transport and 
sorting mechanisms, which HBV uses to be efficiently exported in order to infect 
neighbouring cells and new hosts. However, it is likely that cell polarity plays a role 
in this process. Hepatocytes are polarised cells with distinct apical and basolateral 
sides, facing bile canaliculi and hepatic sinusoid, respectively (Wisher et al., 1975).  
For DHBV, Funk et al. (2004) assumed that the virus is transported predominantly 
to the basolateral sites of primary duck hepatocytes. 
      
 
1.1.5 The HBV surface proteins.  
 
The HBV envelope consists of three closely related viral surface proteins, 
integrated into a host derived lipid bilayer. The S, M and L surface proteins are 
expressed from one ORF. A promoter upstream the ORF and another internal 
promoter initiate transcription and give rise to L and M protein. An additional 
translation initiation site within the smaller transcript leads to the formation of the 
small S protein. S, M and L share the common C terminus containing the               
S polypeptide, which harbours self-assembly properties. M is extended by the      
55 aa preS2 sequence, L contains the preS2 sequence and an additional 108 or 
119 aa sequence called preS1. The surface proteins are synthesised at the ER as 
integral membrane proteins. Their topology is not completely elucidated, but 
experiments with cell-free systems revealed that both N and C termini of S locate 
in the lumen of the ER, implying at least two membrane-spanning domains (Eble 
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et al., 1987). This goes together with the fact that S contains three known 
hydrophobic domains. Current models, based on theoretical considerations, 
propose up to four membrane spanning domains, leading to the model shown in 
fig. 4 (Bruss, 2007).  
The first hydrophobic domain at the N terminus, designated signal 1, belongs to a 
topogenic signal sequence. It initiates chain translocation across the membrane, 
without however being cleaved by the host signal peptidase. The second 
hydrophobic domain, signal 2, functions as a stopping signal, which anchors the 
protein in the bilayer, and acts as a translocation signal for the distal region. This 
results in a cytoplasmatic loop between signal 1 and 2 (Eble et al., 1987). The 
sequence between signal 2 and the third hydrophobic domain forms a luminal 
loop, accommodating the immuno-dominant surface epitope and a glycosylation 
site, which is N-glycosylated in approx. half of the S proteins. Another cytoplasmic 
loop is proposed between hydrophobic domains three and four, implying that the C 
terminus is orientated towards the ER-lumen. Fusion studies, revealing that           
C-terminally fused foreign domains are located in the ER lumen support this 
assumption (Eble et al., 1987). After budding, the luminal loop and most likely as 
well the C terminus, are located on the surface of the virion. M protein has a 
similar transmembrane topology, exposing the preS2 domain to the ER lumen. In 
addition to the partial glycosylation site in the S domain, the preS2 domain 
contains an N-glycosylation site (Stibbe and Gerlich, 1983).  
L protein forms two isomers: In the ER membrane, the preS domains are 
displayed on the cytosolic side (i-preS conformation; see fig. 4). They are not 
glycosylated at two potential sites, but post-translationally myristoylated at a 
myristoylation site located in the preS1 region. A post-translational change of the 
topology in approx. half of the L proteins leads to the exposure of the preS 
domains on the luminal side (e-preS conformation). As a result, virions carry two 
isomers of L (Bruss et al., 1994). The mechanism of this process is unknown. 
However, binding of cytosolic and luminal chaperones to the preS1 domain has 
been shown, indicating an involvement of these proteins (Prange et al., 1999; 
Lambert and Prange, 2003; Cho et al., 2003).  
Due to the formation of two isoforms, L can fulfil several functions: The i-preS 
conformation activates different promoter elements and is thought to be important 
for contacting the nucleocapsid (Hildt et al., 1996; Bruss, 1997; Le Pogam and 
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Shih, 2002). The e-preS conformation participates in receptor binding on the    
host-cell surface (Gripon et al., 2005). The myristoylation of the preS1 region has 
been shown to be essential for infectivity (Gripon et al., 1995). 
 
 
Fig. 4: Transmembrane topology of HBV surface proteins.  
S traverses the ER membrane with signal 1 and signal 2 (green boxes) and probably with two 
additional hydrophobic domains (orange boxes), exposing N- and C terminus to the ER lumen. The 
luminal loop is partially glycosylated ((G)). M has a similar topology, with an additional glycosylation 
site (G) at the preS2 domain (light blue). L is further prolonged (preS1 domain; dark blue) and 
present in two isoforms: The preS1-preS2 domain locates first in the cytosol (i-preS1), in 50% of 
the L proteins the preS1-preS2 domain is later transferred to the luminal side of the ER (e-preS1). 
In the virion, 50% of the L proteins carry the preS1-preS2 domain outside. Asterisks indicate 
potential glycosylation sites, myr indicates the myristoylation site. (Adopted from Bruss, 2007). 
 
During insertion into the ER membrane, the surface proteins obtain asparagine-
linked high-mannose oligosaccharide chains. The importance of N-linked 
glycosylation processes for proper protein folding has been shown for many 
glycoproteins, as well as for HBV secretion (Helenius, 1994). Metha et al. (1997) 
demonstrated that M protein accumulates in the lysosome, if α-glycosidase based 
glycosylation is inhibited. As a result, SVPs containing S and L protein are 
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secreted, but no virions. This indicates different glycosylation mechanisms for the 
different surface proteins and emphasises the significance of this process for HBV.        
The glycosylated protein monomers form homo- and hetero-dimers between S, M 
and L. Responsible for this are cystein residues in the luminal loop of the S 
domain, which crosslink the proteins by building disulfide bridges (Wunderlich and 
Bruss, 1996). Crosslinking into higher oligomers occurs in cisternae of the ER, 
which belong to the ERGIC (Huovila et al., 1992).  
In the oligomerisation process, host proteins are efficiently excluded from the lipid 
bilayer. Furthermore, a re-organisation of the host lipids in the membrane is 
assumed. After budding into the intermediate-compartment lumen, the aggregates 
lack a typical unit membrane structure and exhibit lower lipid contents than 
conventional lipid membranes (Gavilanes et al., 1982). Since the information 
required for assembly is located in the S sequence, not only virions bud into the 
ER cisternae, but also empty envelopes, the SVPs. In comparison to the virions, L 
protein is underrepresented in spherical SVPs. In fact, the ratio of L to S protein 
seems to determine the particle form, since a higher proportion of L results in the 
formation of filaments (Heermann et al., 1984). A high L content of the particles 
has been shown to inhibit secretion (Persing et al., 1986). This phenomenon can 
be explained by a retention sequence at the N terminus of the preS1 domain, 
which can override the secretory elements in the S domain (Kuroki et al., 1989; 
Prange et al., 1991). In over-expression experiments, it became clear that L 
inhibits the secretion of S and M in a dose dependent fashion (Chisari et al., 1986; 
Persing et al., 1986). The over-accumulation of surface proteins in the ER can 
lead to cell stress and cell death (Chisari and Ferrari, 1995b). Affected cells 
develop specific cytopathic and morphologic characteristics. These so-called 
ground glass hepatocytes can be observed in livers of HBV infected mice and are 
sometimes found in human biopsies of HBV-infected livers (Nakamoto et al., 
1997).  
Virions and SVPs traverse the secretory pathway before they are exocytosed. In 
the golgi the carbohydrates are converted to a endoglycosidase H-resistant form 
(Patzer et al., 1984). The now mature viral and subviral particles are secreted from 
the cell.    
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1.1.6 Therapeutic approaches. 
 
Since 1980, prophylaxis by vaccination against HBV is possible and represents an 
effective method to avoid HBV infection and its consequences. For HBV infection, 
however, there is no treatment available to date which eradicates the virus.       
Life-long therapy is therefore necessary, accompanied with an increasing risk of 
the development of drug-resistant mutants.  
Patients with acute hepatitis B are treated symptomatically, if indicated. For 
chronic hepatitis, there are two different therapeutic approaches, both of which aim 
at controlling infectivity and progression of liver disease. 
Interferon α (IFN-α), a type 1 interferon, is most currently used. Interferons belong 
to the cytokine family, are natural mediators of the immune system with regulatory 
functions, and they are basically synthesised by leucocytes. IFN-α acts on 
different levels on the viral infection: It displays a direct antiviral effect, has 
antifibriotic and antiproliferative properties, and stimulates the immune system by 
activating the T-cell response. Since interferon treatment has constitutional and 
neuropsychiatric side effects, such as anaemia, thrombocytopenia, neuropenia 
and depression, its applicability is limited.  
An alternative approach is the application of nucleoside- and nucleotide 
analogues. These so-termed antivirals interfere with viral replication and by that 
block the formation of new virions (Marcellin et al., 2003; Asmuth et al., 2004). A 
commonly used antiviral is Lamivudin, a 2`-3`-dideoxy-cytosine analogue. It 
displays low cytotoxicity and does not interfere with the host DNA synthesis, and is 
therefore well tolerated.  
These treatments help to moderate the disease but cannot not dissolve infection. 
For that, an elimination of the infected hepatocytes would be necessary, because 
they contain the cccDNA, which is the template for virion synthesis. For patients 
with HBV-related hepatocellular carcinoma or liver failure, the only option is to 
undergo partial hepatectomy or liver transplantation. Simultaneous application of 
antivirals and anti-HBV surface antigen improves graft re-infection rates and graft 
survival.       
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1.1.7 Fluorescent labelling of viruses and viral proteins. 
 
Fluorescent labelling of viral proteins and viruses, or virus-like particles, provides a 
powerful tool for investigating unexplored aspects in viral life cycles. Direct 
visualisation enables the real-time microscopic tracking of viral proteins or virions 
in the context of a living cell. Therefore, it can provide an insight into virus-host cell 
interactions. Furthermore, it allows co-localisation studies, for instance with cellular 
compartments or proteins.   
Nucleic acids can be labelled with either unspecific intercalating dyes, such as    
4’,6-Diamidin-2’-phenylindol-dihydrochlorid (DAPI), or by incorporation of 
fluorescent 2'-deoxyuridine-5'-triphosphates. This strategy is advantageous to 
microscopically follow enveloped virus particles inside the cell, after the envelope 
has been released. Prerequisite for this approach is a large genome of the virus. 
Labelling of the outer envelope protein with lipophilic dyes, which laterally diffuse 
into membranes, has successfully been performed with the influenza virus 
(Lakadamyali et al., 2003).  
A novel technique has currently been reported by Arhel et al. (2006), using the  
bis-arsenical fluorescein derivate FlAsH. This very small molecule binds with high 
affinity to a six aa tetracysteine tag and is therefore very specific. By introducing 
this tag into the protein sequence, theoretically every protein can be targeted.     
A common approach is the genetic incorporation of fluorophores, such as green 
fluorescent protein (GFP) or red fluorescent protein (RFP). This method has led to 
important breakthroughs in understanding of the behaviour of many viruses, such 
as adenovirus (Ad; Suomalainen et al., 1999), adeno-associated virus 
(Seisenberger et al., 2001) and simian virus 40 (Pelkmans et al., 2001).  Insertion 
of GFP into the Gag protein of HIV allowed studying the trafficking of this protein, 
as well as production of infectious virions (Müller, 2004). Campbell et al. (2007) 
double-labelled HIV-1 with two fluorophores. This permitted the discrimination 
between unspecific endocytosed virions from those that have entered the host cell 
via the infection pathway.  
GFP is a well characterised, spontaneously fluorescing protein isolated from the 
pacific jellyfish Aequoria victoria (Morin and Hastings, 1971; Ogawa et al., 1995). It 
is a widely used marker for gene expression monitoring and protein localisation. 
Another, relatively new fluorophore is the monomeric RFP (mRFP), derived from 
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the red fluorescent protein dsRed isolated from the disc anemone Discosoma sp.. 
dsRed has the disadvantage of forming tetramers and therefore being very large. 
This problem has been overcome with the development of the monomeric form 
(Shaner et al., 2004).    
Despite many successful studies with labelled viruses, one has to be aware that 
living systems are sensitive and prone to error if modifications are inserted. 
Careful analyses are necessary to ensure that the modification is tolerated and 
does not change the characteristic properties of the natural virus or protein.  
 
Described in this study is the fluorescent labelling of hepatitis B virus surface 
proteins with GFP and mRFP.   
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1.2 The immune system. 
 
Creatures are permanently in close contact with their environment and many 
different micro-organisms. To defend the body from such diverse infectious 
invaders as viruses, bacteria, fungi or multi-cellular parasites, a highly developed 
and complex system is necessary. But the seeking and killing of pathogens, 
together with the ability to differentiate between self and non-self, is not the only 
function of the immune system. Infected cells have to be recognised and removed, 
as well as degenerated or damaged cells, which are prone to develop malignant 
tumours.   
Immune cells derive from one common precursor, the haematopoietic stem cells in 
the bone marrow. They give rise to all types of blood cells. Myeloid progenitors are 
the precursors of macrophages, granulocytes, mast cells and most dendritic cells 
(DC). Lymphoid progenitors develop into lymphocytes, which further differentiate 
into two cell types. One population differentiates in the bone marrow (B) and is 
therefore designated as B lymphocytes. The second population differentiates in 
the thymus (T) into so-called T lymphocytes (Janeway et al., 2004).  
The immune system is divided into two systems. The phylogenetic older system is 
innate and displays the initial, antigen non-specific response of the body to a 
broad range of antigens. It comprises a number of different cell types, e.g. 
phagocytic cells, natural killer (NK) and natural killer T (NKT) cells, as well as 
molecules.   
The phylogenetic younger, adaptive immune system is acquired and refers to 
antigen-specific defence mechanisms. The establishment of an adaptive immune 
response, which takes several days, aims at the specific removal of one particular 
antigen. Through repeated exposure to the same pathogen, the adaptive immune 
response improves and in many cases confers lifelong protective immunity. On the 
one hand, cellular immunity is involved, mediated by T cells, and on the other 
hand, humoral immunity, mediated by antibodies and cytokines.  
Typically, effective immunity to a pathogen requires both the rapid but unspecific 
innate, as well as the later occurring pathogen-specific adaptive immune 
response.             
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1.2.1 Innate immunity. 
 
The innate immune system provides a first line of defence against most          
micro-organisms. Furthermore, it plays a crucial role in stimulation of the adaptive 
immune response and control of infections during the first days, until adaptive 
immunity is established.  
The innate immunity relies on the recognition of highly conserved structures,      
so-called pathogen-associated molecular patterns (PAMP). These are present in 
micro-organisms, but not in eukaryotic cells (Kawai and Akira, 2006). Innate 
immunity includes a cellular compartment and a soluble component, the 
complement system. The latter comprises a number of different plasma proteins, 
which activate proteolytic processes on microbial surfaces. This contributes to 
inflammation and induces pathogen uptake by macrophages and neutrophils 
(Janeway et al., 2004). This initial inflammation, induced by the innate immune 
system is crucial for the activation of the adaptive immune system (Janeway        
et al., 2004).   
Pattern recognition receptors (PRR) that tag the different PAMPs are expressed 
by a variety of immune and non-immune cells. PRRs are present mostly on the 
plasma membrane, but also intracellularly (Medzhitov, 2001). Toll-like receptors 
(TLR) represent probably the most important family of PRRs. Their name is 
traceable to the Toll protein of drosophila, which possesses striking functional 
homologies to the TLRs in mammalians (Rock et al., 1998).     
The cellular component of the innate immune system consists of a variety of cell 
types. If phagocytic cells, e.g. macrophages or DCs, bind a PAMP, a signalling 
cascade is prompted. The cells get activated and internalisation of the pathogen is 
triggered. Furthermore, the secretion of cytokines and chemokines is induced. 
These proteins mediate cellular communication, attract cells from the blood stream 
to the site of recognition and initiate a local inflammation process (Janeway et al., 
2004). Furthermore, cytokines are responsible for the onset of the acute-phase 
response, a process taking place in the liver. Hepatocytes secrete acute-phase 
proteins, such as C-reactive protein, which are able to bind pathogens and 
stimulate the complement system (Janeway et al., 2004).  
DCs play a pivotal role in the activation of the adaptive immune system, further 
described in chapter 1.2.3. Another cell type involved in innate immunity is         
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NK cells. They are responsible for the recognition of abnormal cells, for example 
tumour cells or cells containing intracellular pathogens (Trinchieri, 1989; Biron et 
al., 1999). NKT cells express NK-cell and T-cell markers and mediate direct 
cytotoxicity (Bendelac et al., 1995). Furthermore, they are producers of high 
amounts of IFNγ, a type 1 interferon known to inhibit the replication of HBV and 
other viruses (Guidotti et al., 1999; Pavic et al., 1993; Franco et al., 1997). 
The defence mechanism of the innate immune system is rapid and effective. 
However, it is restricted to invaders that can be recognised by the germ-line 
encoded PRRs. Since micro-organisms evolve more rapidly then their hosts, some 
of them developed protective strategies to prevent recognition. This constraint has 
been overcome by the adaptive immune response.        
 
  
1.2.2 Adaptive immunity. 
 
The concept of adaptive immunity is to adapt to one specific invader. Key 
mediators for the humoral and cellular branch of the adaptive immune response 
are B and T lymphocytes, respectively. They recognise antigen structures present 
on pathogens, but not on own cells, as foreign. Lymphocytes, carrying the receptor 
against a specific antigen can promote a specific response against it. This includes 
cell proliferation and differentiation into specialised effector cells. This adaptation 
process takes four to seven days and is responsible for the delay between 
infection and adaptive immune response (Janeway and Medzhitov, 2002). 
Activation of specialised antigen presenting cells (APC) is a prerequisite for 
induction of the adaptive immune response. In this respect, dendritic cells 
represent the most potent cell population. Their role will be discussed in detail in 
the next chapter.  
The B-cell mediated humoral immune response relies on antibody production and 
acts on extracellular, circulating antigens, such as pathogens and foreign proteins. 
Naïve B lymphocytes, circulating in the blood, bear antigen receptors of a 
particular specificity on their surface, termed membrane-standing immunoglobulin 
(IgM) or B-cell receptor (BCR). All individual cells differ in this specificity (Janeway 
et al., 2004). The body therefore has a broad diverse lymphocyte receptor 
repertoire at command, enabling it to react to virtually any existing antigen. 
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However, the number of cells able to bind to a given antigen is very small. A 
mechanism known as clonal selection ascertains the expansion of lymphocytes, 
as soon as their specific antigen receptors fit to an invaded pathogen (Janeway et 
al., 2004). Receptor-antigen interaction is the first signal for the receptor-carrying 
B cell to get activated. Importantly, a second signal, provided by T cells, is 
necessary to induce the activation process. A large population of cells with the 
same receptor specificity is build up through clonal expansion. The original 
membrane-standing BCR is secreted in the form of antibodies. Their functions are 
firstly the neutralisation of pathogens or their often toxic products by specific 
binding. As a result, their access to potential target cells is blocked. Secondly, 
bound antibodies serve as a marker for phagocytic cells, which recognise the 
constant region of the antibodies and ingest antibody-covered pathogens. This 
type of antibody binding is referred to as opsonisation (Janeway et al., 2004). 
Thirdly, antibodies activate the complement system. 
After removal of the antigen, most effector cells undergo apoptosis (Banchereau et 
al., 1994). However, a small population of effector cells persist. They traverse an 
immunoglobulin-isotype change from IgM to IgG and develop into memory B cells. 
These long-living cells circulate within the lymphoid organs and mediate lifelong 
immunity (Liu et al., 1991).       
The high diversity of antigen receptors is based on a genetic mechanism called 
somatic recombination. BCRs consist of a heavy and a light chain, each containing 
a constant and a variable region. The genes encoding the variable regions are 
inherited as sets of gene segments. These segments are joined by DNA 
recombination, building genes encoding the variable regions of both chains.  
These genes are unique in every lymphocyte (Janeway et al., 2004). Furthermore, 
somatic hyper-mutation during the immune response leads to additional variation 
in the already rearranged genes, often resulting in improved antibody-antigen 
binding (Weigert et al., 1970; Michael et al., 2002). To ensure that the generated 
antigen receptors are useful, not directed against the host-self, and that 
lymphocyte-cell numbers remain relatively constant, further mechanisms are in 
need. Lymphocyte survival is regulated by signals from their antigen receptors, 
delivered by cells in the lymphoid organs. A positive selection process guarantees 
that only those cells survive, which receive survival signals (Linette and 
Korsmeyer, 1994). A negative selection for cells strongly reacting with              
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self-antigens prevents autoimmunity by purging off receptors recognising           
self-peptides (Mannie, 1991; Laufer et al., 1996). In lymphocytes not receiving 
survival signals, as well as in those lymphocytes strongly reacting with               
self-antigens, apoptosis is induced.  
The cellular component of the adaptive immune response is directed against 
intracellular antigens. It requires antigen processing and presentation from 
infected or transformed body cells, the latter presenting tumour-specific antigens. 
T lymphocytes are the main effectors of the cellular immune response. One 
differentiates two types of T cells, based on their surface co-receptors, so called 
clusters of differentiation (CD). CD4 and CD8 determine the interaction of the       
T cell with the antigen presentation complexes (MHC, major histocompatibility 
complex) MHC I and MHC II on APCs (Woodland and Dutton, 2003). MHC I is 
expressed on every nuclear cell and presents intracellular antigens. MHC II is 
present only on professional APCs and carries phagocytosed antigens of 
extracellular pathogens. An exception displays a mechanism known as cross-
presentation. In this case, internalised extracellular antigens are transferred to the 
MHC I pathway (Bevan, 1976).  
CD4 positive (CD4+) T cells bind antigens presented on MHC II molecules. They 
are divided into the helper-cell and regulatory-cell subsets. T helper cells (TH) are 
further differentiated into TH1 and TH2 subsets, carrying out different functions, 
particularly in the defence against bacteria. While TH1 cells activate macrophages 
and promote phagocytic activities, thus driving the immune response in the 
direction of cytotoxicity, TH2 cells foster the humoral immune response by B-cell 
activation to produce neutralising antibodies (Ridge et al., 1998; Sigal et al., 1999). 
The importance for instance of HBV-specific CD4+ T cells in the defence against 
HBV is due to the induction and maintenance of CD8+ T-cell responses and the 
activation of B cells (Rehermann, 2003).  
CD8 positive (CD8+) T cells are referred to as cytotoxic T lymphocytes (CTL) and 
recognise antigens in the MHC I context. Their task is to kill infected cells. In case 
of an HBV infection, CTLs specific for different HBV epitopes remove infected 
hepatocytes directly by lysis. However, they seem to control infection as well at a 
non-cytolytic level (Maini et al., 2000).   
A small subpopulation of CD4+ and CD8+ T cells, termed regulatory T cells (Treg), 
exercise control functions of the adaptive immune response, for example in the 
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regulation of immuno-inflammatory effects during viral infections (Suvas et al., 
2004). They are characterised by the expression of the surface markers CD25 and 
forkhead box protein 3 (FoxP3; Raimondi et al., 2007).                      
The activation of naïve T lymphocytes takes place in the thymus, basically via the 
same mechanism as described for B cells. T cell receptors (TCR) differ from 
BCRs in their structure. Nevertheless, their diversity is also obtained by somatic 
gene recombination and controlled by positive and negative selection processes. 
Antigens taken up by APCs are processed, loaded on MHC I or MHC II molecules, 
and displayed at the cell surface. The clonal selection ensures that only those       
T cells bearing a specific TCR for the given antigen, and which bind the          
MHC-antigen complex presented by an APC together with co-stimulatory signals, 
are activated. A large population of antigen-specific T cells is build up via clonal 
expansion. After removal of the antigen, the death of most effector T cells is 
induced by the absence of stimuli from their specific antigen. A small population of 
memory T cells is retained, which is very sensitive to re-stimulation by its antigen 
and able to react very fast (Janeway et al., 2004).  
   
 
1.2.3 Dendritic cells. 
 
Dendritic cells are the key antigen presenting cells. They play a cardinal role in 
innate and adaptive immunity, especially in T-lymphocyte activation and 
differentiation (Banchereau and Steinman, 1998). The origin of DCs is elusive, but 
at least two DC precursor populations are proposed, the myeloid and plasmacytoid 
progenitors. However, some DC subsets may derive from a third origin 
(Banchereau et al., 2000). The DC precursors develop into immature DCs (imDC) 
and migrate to peripheral tissues. They persist there for a variable length of time. 
ImDCs are phagocytic cells continually taking up extracellular material via 
pinocytosis. In addition to this receptor-independent uptake mechanism, they 
engulf pathogens via phagocytosis and receptor-mediated endocytosis. ImDCs 
express many different types of PRRs, such as C-type lectins, mannose receptors 
and TLRs. Besides the high expression level of PRRs, imDCs are characterised 
by low expression levels of MHC and co-stimulatory molecules. Small amounts of 
synthesised MHC II molecules are mainly sequestered in endosomes and 
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lysosomes (Cella et al., 1997). ImDCs do not interact with lymphocytes or secrete 
cytokines and chemokines (Janeway et al., 2004). Morphologically, imDCs can be 
distinguished from mature DCs (matDC) by means of the lack of dendrites. These 
are typical for matDCs. The main differences between immature and mature DCs 
are listed in fig.5   
 
 
Fig. 5: Main characteristics of immature and mature dendritic cells. 
 
Pathogens ingested by imDCs are intracellular degraded. Activated by pathogen 
uptake, a signalling cascade is induced, which leads to a change in the       
protein-expression patterns. The expression of MHC and co-stimulatory molecules 
is highly up-regulated (Banchereau et al., 2000). Along with the transition, PRRs 
and antigen uptake are down-regulated (Garret et al., 2000). Functional MHC II 
peptide-antigen complexes are generated and accumulate at the cell surface, 
clustered with co-stimulatory molecules (Turley et al., 2000). In this condition, the 
cells are designated as mature. They are endowed with the ability to effectively 
present antigens, activate naïve T cells and stimulate the innate and adaptive 
immune system via cytokine secretion (Banchereau et al., 2000). Remodelling of 
the chemokine-receptor profile facilitates homing to lymphoid organs (Chan et al., 
1999). Subsequently, the matDCs migrate to the lymph nodes, where they provide 
the naïve T cells with two signals crucial for activation: The first signal is antigen 
specific and results from binding of the TCR to the antigen, presented by a MHC 
molecule on the DC surface. The second signal is provided by co-stimulatory 
molecules, such as CD80 and CD86, also present on the DC surface. The role of 
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DCs in regulating T-cell responses is well documented (Banchereau et al., 2000): 
The density of peptides presented at the surface, the types of co-stimulatory 
molecules expressed, and cytokines secreted by matDCs upon stimulation with 
the different types of signals, drive naïve T-cell development into a certain 
direction. CD4+ T-cell differentiation into TH1 cell is induced by DC IL-12 and IFN 
type 1 production (Lanzavecchia and Sallusto, 2001; Eisenbarth et al., 2003). In 
response to extracellular pathogens, DCs mediate CD4+ T-cell development into 
TH2 cells (Moser and Murphy, 2000; Sher et al., 2003). CD8+ T cells become 
effector CTLs or, upon co-stimulation with TH cells, memory T cells (Janssen et al., 
2003; Shedlock and Shen, 2003).  
An important characteristic of DCs is the ability to cross-present antigens. The 
classical MHC I pathway provides for the presentation of endogenous antigens to 
CD8+ T cells, for instance in virus-infected cells. In contrast, exogenous antigens 
are presented via the MHC II pathway, activating CD4+ T cells. This phenomenon 
is known as MHC restriction. Viral proteins expressed in the cytoplasm are 
subjected to the MHC I pathway and presented to CTLs. However, since not all 
viruses infect DCs, there must be alternative ways to transfer antigens to the    
MHC I pathway: DCs can receptor-mediated internalise infected or maligned 
apoptotic cells and cross-present their endogenous antigens on MHC I molecules 
to CTLs (Albert et al., 1998). This is likely to occur via a pathway directly 
transferring the internalised antigens to the ER, where they are loaded on MHC I 
molecules (Ackermann et al., 2005). Also antigens that are not expected to gain 
access to the cytoplasm are presented on MHC I molecules via an exogenous 
pathway. Little is known about this process, but DCs seem to allow the egress of 
internalised antigens from endocytic organelles into the cytosol          
(Kovacsovics-Bankowski et al., 1995; Rodriguez et al., 1999). From there, the 
antigens enter the conventional MHC I pathway and are presented on MHC I 
instead of MHC II molecules. So far, DCs and to a lesser extend macrophages, 
are the only cell types known to be capable of breaking MHC restriction 
(Banchereau et al., 2000).      
The main pathway by which DCs get activated, mature and provide all necessary 
signals to naïve T cells, is PAMP recognition via PRRs. They are therefore 
regarded as the key cell type coupling PRR-mediated innate immune recognition 
to the initiation of an adaptive immune response.  
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DCs play a dual role in the immune system. On the one hand, they respond to 
foreign antigen stimulation such that T-cell activation occurs. On the other hand, it 
is presumed that they play a role in induction and regulation of immune-tolerance 
(Steinman et al., 2003). This is an important feature to avoid immune responses 
against self, and against antigens permanently present, for instance in the 
respiratory or digestive tracts (Vermealen et al., 2001). Resident tissue DCs take 
up self-antigens or permanently present environmental antigens via phagocytosis 
or macropinocytosis. After a certain time they traverse to lymphoid tissues, 
although not being activated by infection. Since they lack co-stimulatory molecules 
on their surface, these cells do not activate T cells, but induce tolerance to the 
antigen (Steinman et al., 2003). This mechanism is presumably a safeguard 
against autoimmunity and chronic inflammation (Banchereau and Steinman, 
1998). A specific T-cell population, the Tregs, controls the maintenance of         
self-tolerance (Gershon et al., 1974; Baecher-Allan et al., 2004). This has to be 
accomplished by a mechanism not interfering with pathogen-specific protective 
immune response. Pasare and Medzhitov (2003) hypothesised a scenario based 
on two different control mechanisms: Firstly, upon TLR activation DCs must 
express co-stimulatory molecules. Secondly, DCs must produce IL-6. The IL-6, in 
turn, affects T cells in a way that makes them resistant to suppression by Tregs.  
In vivo observations in mice of Yang et al. (2004) also hint in this direction.  
Multiple DC subsets have been identified so far. However, their function in immune 
defence remains to be unravelled. Researches in humans and mice demonstrated 
that the immune system comprises of many DC subpopulations with distinct            
gene-expression patterns, PRR profiles and anatomical locations. This suggests a 
specialisation of the different subsets to interact with different types of pathogens 
and to induce distinct effector cells (Banchereau et al., 2000; Ito et al., 2005). In 
the following, the focus lies on DC subsets continuously circulating in peripheral 
blood, as well as on resident hepatic DCs.  
Monocytes make up for a large percentage of the peripheral blood mononuclear 
cells (PBMC). They differentiate either into tissue macrophages or myeloid 
dendritic cells (mDC). The expression of a variety of TLRs enables them to 
recognise a wide range of pathogens in the blood and peripheral tissue (Kadowaki 
et al., 2001a). In vitro differentiation of monocytes isolated from peripheral blood is 
a tool commonly used to obtain dendritic cells. The advantages over the direct 
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isolation of DCs are on the one hand the straight forward protocol, and on the 
other hand the high cell number, which can be obtained from a relatively small 
amount of peripheral blood. Isolated monocytes can be differentiated into 
immature monocyte-derived DCs (moDC) by addition of granulocyte-macrophage 
colony stimulating factor (GM-CSF) plus interleukin-4 (IL-4). By addition of 
lipopolysaccharide (LPS) and tumor necrosis factor α (TNF-α), mature moDCs 
can be generated (Sallusto and Lanzavecchia, 1994). However, Osugi et al. 
(2002) demonstrated that in vitro generated moDCs differ from blood DCs in 
several aspects. Therefore their behaviour does not always reflect the situation in 
peripheral blood DCs.  
The major DC precursors in vivo are myeloid and plasmacytoid DCs (mDC, pDC) 
(Liu et al., 2001). mDCs are characterised by the absence of surface lineage 
markers and the presence of blood dendritic cell antigen 1 (BDCA1) and CD11c 
(Ito et al., 2002). They make up approx. 1 to 2% of PBMCs and are characterised 
by a strong expression of TLRs 1, 2, 3 and 5, mainly recognising bacterial 
components, except for TLR 3, which binds viral ds RNA (Kadowaki et al., 2001a). 
Upon stimulation, they produce pro-inflammatory cytokines, such as TNF-α, IL-6, 
IL-12 as well as IFN-α and β (Kadowaki et al., 2001a and 2001b; Ito et al., 2002).  
pDCs constitute a very small population of 0.5 to 1% of PBMCs. They are 
characterised by the markers BDCA2, BDCA4 and CD123 (Colonna et al., 2004). 
A very important feature of pDCs is their role in antiviral defence. During viral 
infection, pDCs are recruited to the inflamed lymph nodes. They are the main 
source of type 1 IFNs, which inhibit viral replication and thus have a strong 
antiviral effect (Cella et al., 1999; Siegal et al., 1999). IFNs are therefore used for 
the treatment for instance of chronic HBV infection. The ability of pDCs to 
efficiently recognise viruses is at least partially due to the expression of TLRs 7 
and 9, which are specific for ss RNA and ds DNA viruses, respectively (Kadowaki 
et al., 2001a; Lund et al., 2003; Diebold et al., 2004; Heil et al., 2004). In vitro 
experiments have revealed that pDCs can induce TH1 differentiation, and activate 
B cells to secrete antibodies (Cella et al., 2000; Jego et al., 2003). Furthermore, 
the induction of mDC maturation by HIV-infected pDCs has been demonstrated 
(Fonteneau et al., 2004). The ability to induce Tregs is suggested (Gilliet and Liu, 
2002). Taken together, these data indicate a major function of pDCs in the 
immune response against viruses.  
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Resident DCs are present in low numbers in the liver, but expand upon stimulation 
(Thomson et al., 1999). However, after stimulation the hepatic DC populations still 
exhibit imDC phenotype, expressing low levels of MHC II, CD80 and CD86. It is 
suggested that these cells induce tolerance rather then activate naïve T cells 
(Thomson and Lu, 1999a and 1999b). Recent studies demonstrated that they are 
less efficient in activating naïve T cells compared to other organ resident DC 
populations (Goddard et al., 2004; de Creus et al., 2005).  
 
 
1.2.4 HBV-specific immune response. 
 
HBV-infected patients are usually detected only after the onset of clinical 
symptoms, which occurs two to six months after infection. Therefore, the early 
events of the HBV-specific immune response are difficult to study in natural human 
infection. Most data have been obtained in mouse, woodchuck and chimpanzee 
models (Guidotti et al., 1996; Guidotti et al., 1999; Wang et al., 2003; Wieland et 
al., 2004). The progression of an acute self-limiting and a chronic HBV infection 
differ in several aspects. Fig. 6 schematically depicts the characteristics of both.  
For approx. four weeks post primary infection, HBV remains quiescent, with low 
amounts of 102 to 104 HBV genome equivalents per ml blood in the circulation 
(Rehermann and Nascimbeni, 2005). HBsAg and HBeAg come up about four 
weeks after exposure, followed by antibodies against the viral core protein        
(anti HBc). By this time viremia is established, characterised by viral titers of 109 to 
1010 virus particles per ml blood (Ribeiro et al., 2002). Serum levels of                   
alanin-aminotransferases (ALT) rise between weeks eight and twelve. These 
enzymes are released by apoptotic hepatocytes and serve as markers for liver 
injury. In 90% of the cases, acute infection is cleared after ten to fifteen weeks. 
IgG-type antibodies against HBcAg, HBsAg and HBeAg mediate a lifelong 
protective immunity against HBV (Rehermann and Nascimbeni, 2005). Despite the 
clearance, low levels of viral replication can be detected for decades in the 
patients. Trace amounts of persisting virus might contribute to maintaining 
immunity against HBV in recovered patients, since antigen-specific humoral and 
cellular immune responses control the virus (Rehermann et al., 1996). Conversely, 
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the persisting virus may as well be responsible for chronic infection in some 
individuals (Rehermann and Nascimbeni, 2005).       
Compared to many human viruses, such as HIV, CMV and HCV, which display a 
fast viral spread and subsequent rapid activation of innate immunity, the kinetics of 
HBV infection appear to be unconventional (Bertoletti and Gehring, 2006). The 
cause of the delayed appearance of HBV DNA and proteins is unclear. One could 
speculate that HBV initially infects only a few hepatocytes with a slow doubling 
time, or that HBV does not reach the liver immediately after infection (Bertoletti 
and Gehring, 2006).   
 
 
Fig. 6: Course of acute self-limited and chronic HBV infection (from: Rehermann and 
Nascimbeni, 2005). 
 
Chronic hepatitis B is a heterogeneous disease with variable courses and severity 
(Ganem and Prince, 2004). In contrast to an acute infection, the chronic 
progression is characterised by a lack of anti HBs-specific IgGs and a late and 
weak or missing antibody response to HBeAg. Virus load is variably high but 
persistent, and often HBeAg is detectable for years after the primary exposure 
(Ganem and Schneider, 2001). Hepatic flares with irregularly increasing and 
decreasing ALT levels can be detected in approx. 2% of patients, mostly in 
correlation with changes in therapy (Mels et al., 1994). Spontaneous recovery of 
T-cell reactivity during flares, as well as under lamivudine therapy, followed by viral 
clearance, has been observed (Rossol et al., 1997; Boni et al., 2001).     
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In general, it has become clear that the course of HBV infection depends mostly 
on the adaptive T-cell response of the host (Wieland et al., 2004). Cytotoxic T cells 
are responsible for the clearance of the infection as well as for liver injury (Thimme 
et al., 2003). In the case of a persistent liver inflammation, which is typical for 
chronic HBV carriers, DNA damage due to massive regenerative processes 
promotes HCC formation (Chisari and Ferrari, 1995b). A quantitative difference in 
virus-specific CTL numbers between chronic and acute infection has been 
demonstrated, correlating with virus control, but not with liver damage (Maini et al., 
2000). Virus-specific T-cell response is weak or undetectable in chronic carriers 
(Ferrari et al., 1990; Rehermann et al., 1995b). The CTLs infiltrating the liver are, 
contrary to the acute outcome, virus non-specific or directed against sub-dominant 
epitopes. They contribute to liver damage (Webster et al., 2004). An HBV-specific 
TH -cell response is mostly absent (Ferrari et al., 1990).  
Some factors that could explain the impairment of the immune response in chronic 
HBV infection have been suggested. One candidate escape mechanism is the 
development of mutated virus. However, HBV mutants are not common in acute 
infection, as well as in chronic infection, and typically remain in low abundance 
(Rehermann et al., 1995a; Whalley et al., 2004). Another possibility is the 
involvement of HBeAg, which is secreted in large amounts during viral replication. 
Its tolerising effect has been shown in mice (Milich and Liang, 2003; Chen et       
al., 2005a). This might account for the low levels of core-specific T-cell responses. 
A role in chronicity has also been proposed for the SVPs produced in up to        
104-fold excess over virions (Rehermann and Nascimbeni, 2005). The effects of 
Tregs have not yet been fully elucidated (Maloy and Powrie, 2001). However, a 
role in chronicity of several virus infections, e.g. with HCV or HIV has been 
proposed (Sugimoto et al., 2003; Kinter et al., 2007). Therefore, inhibition of    
HBV-specific T-cell function in chronic HBV by Tregs may be considered. 
Furthermore, the immunological features of the liver may support immuno-
tolerance in chronic HBV infection: The hepatic environment is known to be 
tolerogenic. Presentation of exogenous antigen to T cells by liver endothelial cells 
induces specific T-cell tolerance (Limmer et al., 2000). Further on, hepatocytes 
require a very high antigen concentration to stimulate CTLs, due to a low 
expression level of MHC I. This implies that pathogens infecting the liver are less 
likely recognised. However, these data are currently under debate (Janeway et al., 
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2004; Chen et al., 2005b). Data concerning CTL priming in the liver in animal 
models are controversial. Crispe et al. (2000) and Bowen et al. (2004) reported 
apoptosis of activated CD8+ T cells and tolerance induction in CD8+ T cells in the 
liver, respectively. Inconsistent with this, in other studies the rapid activation of 
naïve and effector CD8+ T cells within the liver of mice has been observed 
(Isogawa et al., 2005; Klein and Crispe, 2006). 
The existence of HBV in extra-hepatic sites has been described, possibly 
contributing to low-level HBV persistence (Ganem and Schneider, 2001). An 
infection of immune cells by HBV might be the reason for an impaired immune 
response in chronic hepatitis B carriers. DCs, being crucial for T-cell priming, 
appear interesting in this context. Functional impairment of these cells could 
explain the B-cell and T-cell hypo-responsiveness in chronic HBV-infected 
patients. Furthermore, it is known for many chronic viral infections, such as HCV, 
HIV and vaccinia virus infection that DC function is impaired (Kanto et al., 1999; 
Auffermann-Gretzinger et al., 2001; Bain et al., 2001; Knight et al., 1993; Donaghy 
et al., 2003; Engelmayer et al., 1999). Evidence for DC dysfunction in chronic HBV 
infected patients also exists, but is controversially discussed. While Beckebaum et 
al. (2003) found functional deficits in moDCs upon contact with HBV this result 
was not confirmed in a study by Tavakoli et al. (2004). With regard to the question 
whether total DC numbers are reduced in chronic HBV infection, the data are 
contrary as well (Beckebaum et al., 2002; van der Molen et al., 2004; Duan et al., 
2004). Some investigators reported the presence of HBV-DNA in DC lysates, 
detected by polymerase chain reaction (PCR). This finding was generally 
interpreted as an indication for infection of DCs with HBV (Beckebaum et al., 2002; 
Tavakoli et al., 2004; Zheng et al., 2004). However, since phagocytosed viruses 
are also detected with this method, the DNA did not necessarily originate from 
replicating virus, as shown by Köck et al. (1996). Merely the proof of an 
established cccDNA pool in these cells would allow the conclusion that DCs are 
productively infected (Ganem and Schneider, 2001). Thus, the possibility of a 
direct infection of DCs with HBV in chronic patients remains to be determined.  
  
The following study addressed the question whether immature or mature moDCs 
can be infected with HBV in cell culture and whether viral antigens are expressed. 
Advantage was taken from HBV-based vectors, which allow dissecting the early 
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steps of HBV infection (Protzer et al., 1999). Luciferase expression under the CMV 
promoter or an HBV-specific promoter, after uptake and nuclear transport, enables 
a distinction between unspecific viral uptake and infection (Untergasser and 
Protzer, 2004). Furthermore, the formation of nuclear HBV-cccDNA after 
incubation with wild-type HBV was investigated in moDCs with an optimised PCR 
technique. In order to investigate HBV-antigen expression adenoviral vectors 
carrying a complete HBV genome, as well as a GFP reporter-cassette, were used 
to efficiently bring the HBV genome into the cells (Sprinzl et al., 2001). To verify 
the results in the in vivo situation, mDCs and pDCs from highly viremic chronic 
carriers were tested ex vivo for HBV infection via PCR.     
 
 
 
 
 
 
 
2. (I) Dendritic cells take up viral antigens but do not support        
the early steps of Hepatitis B virus infection 
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2.1 Results I 
 
In chronic HBV carriers, dendritic cells (DC) are functionally impaired. A reason 
for this might be the infection of DCs by HBV. In this study, it was analysed in 
an in vitro system whether monocyte derived DCs (moDC) support the different 
steps of HBV infection: Virus uptake, nuclear transport of the genome, and 
replication. To address the question whether moDCs are capable of HBV 
antigen production and progeny virus formation, HBV genomes were artificially 
introduced into the cells with an adenoviral vector system. Taking advantage 
from HB viral vectors expressing Renilla luciferase either under a non–liver-
specific promoter or under a HBV promoter, genome delivery into the nucleus 
was analysed using a luciferase detection assay. Furthermore, moDCs were 
incubated with wild-type HBV and investigated by quantitative real-time PCR for 
the presence of the different viral DNA forms: the rcDNA, which is present only 
in virions in the cytosol, and the cccDNA, which is only present inside the 
nucleus of an infected cell. To verify the observation in the in vivo situation, 
myeloid (mDC) and plasmacytoid (pDC) DCs from chronic HBV carriers were 
investigated ex vivo. Quantitative real-time PCR was used for the detection of 
rcDNA and cccDNA in the cells, and with electron microscopy the cells were 
further analysed for the presence of viral and subviral particles. 
 
 
2.1.1 HBV antigen expression and replication in moDCs.  
 
Monocyte derived dendritic cells (moDC) are a commonly used model for 
immature and mature peripheral blood DCs. Monocytes were isolated from 
buffy coats or fresh peripheral blood and in vitro differentiated into immature 
moDCs using IL-4 and GM-CSF. Upon further stimulation with LPS, TNF-α and 
PGE2 mature moDCs were obtained. To determine the maturation status, the 
cells were examined for the expression levels of HLA-DR, CD80, CD86 and 
CD83. These proteins are typical surface markers of matured moDCs.  
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Fig. 7: Flow cytometry analysis of the maturation status of moDCs.  
In the upper panel the percentage of moDCs expressing the surface markers HLA-DR, CD80, 
CD86 and CD83 before in vitro differentiation (immature moDCs) are shown. The lower panel 
depicts the percentages of moDCs expressing the markers after in vitro differentiation (mature 
moDCs). 
 
Fig. 7 shows an example of the flow cytometry data of a moDC preparation 
before and after in vitro maturation. Flow cytometry revealed a significant       
up-regulation of the surface markers in mature moDCs in comparison to 
immature moDCs. Only 25.39% of immature moDCs expressed HLA-DR, while 
98.44% of mature moDCs were positive for the marker. CD80 was expressed in 
21.52% of immature moDCs and 92.67% of mature moDCs. While 0.39% and 
1.89% of immature moDCs appeared positive for CD86 and CD83 respectively, 
these markers were expressed by 90% and 92.88% of cells after differentiation. 
The results of the flow cytometry analyses for all moDCs are summarised in   
tab. 1.  
 
Tab. 1: Summary of flow cytometry analyses of moDCs. 
The data represent the median percentages of cells, staining positive for the surface markers 
HLA-DR, CD80, CD86 and CD83 before (immature moDCs) and after (mature moDCs) in vitro 
differentiation.  
 
 
 
 
 
 
Marker            Immature moDCs         Mature moDCs 
 
HLA-DR 21.6% ± 5.2% 92.2% ± 3.4% 
CD80 32.5% ± 9.9% 90.5% ± 8.4% 
CD86 3.1% ± 1.9% 88.0 ± 4.0% 
CD83 4.4% ± 4.7% 96.6 ± 2.6% 
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It demonstrates that the change in the expression pattern of the analysed 
surface markers after the maturation protocol was generally observed in all 
experiments. This shows that the in vitro differentiation of immature moDCs into 
mature moDCs was successful. 
 
          
2.1.1.1 Transduction of moDCs with AdG-HBV1.3.  
 
In order to study whether immature and mature moDCs express hepatitis B viral 
antigens under HBV-specific promoters, an adenoviral vector system was 
chosen.  
In contrast to the use of wtHBV, this allowed to exclusively analyse the 
expression of the viral antigens: it is known that DCs are susceptible for 
adenovirus infection, which includes virus uptake and genome transfer into the 
nucleus. Therefore, additional effects such as a block in virus entry or genome 
delivery into the nucleus, which would impair the antigen expression, could be 
ruled out. The vector AdG-HBV1.3 is based on the adenovirus type 5 and 
contains a 1.3-fold HBV over-length genome (Fig. 8).  
 
 
Fig. 8: Schematic depiction of the adenoviral vector AdG-HBV1.3 
The insert, consisting of the 1.3-fold HBV over-length genome (grey bar) and the GFP reporter 
cassette (green bar), is placed in the E1A/E1B region of the adenovirus genome. The E1A/E1B 
region and the E3 gene of the adenoviral genome are deleted. 
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The over length is necessary, because the hepatitis B viral circular genome is 
organised in overlapping ORFs. In addition to the HBV genome, a GFP reporter 
cassette is integrated in the adenoviral vector under CMV promoter control. 
AdG-HBV1.3 has been shown to efficiently initiate HBV antigen expression in 
primary human hepatocytes (PHH; Fig. 10a). Due to the deletions of the 
E1A/E1B region and the E3 gene, the adenovirus vector is infectious but 
replication deficient. Since all HBV genes are expressed from the vector, HBV 
replication is possible and the vector can be used to induce HBV replication. An 
overview over the transduction of a PHH with adenoviral vectors is provided in 
fig. 9. 
 
 
Fig. 9: Transduction of a hepatocyte with AdG-HBV1.3 
The adenoviral vector, containing the HBV 1.3 over-length genome (blue) and the GFP reporter 
cassette (green), enters the cell. The transgenes are delivered to the nucleus and GFP RNA 
(green serpentine line) and the HBV RNAs (blue serpentine lines) are built. GFP proteins (green 
stars) accumulate in the cell. HBV capsids assemble and after reverse transcription of the 
encapsidated pgRNA, they are either exported (progeny HBV) or re-imported into the nucleus. 
A cccDNA pool can be established. SVPs form and bud out of the cell. The progeny virus can 
either re-infect the cell or infect other cells.   
 
To investigate the expression of HBV antigens in moDCs, the AdG-HBV1.3 
stock was first titrated on a PHH culture (Fig. 10a, left panel). A multiplicity of 
infection (moi) of 1 virus particle per cell (vp/cell) led to a transduction rate of 
approx. 65%. With a moi of 3 vp/cell, more than 90% of the PHHs were 
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transduced, as monitored microscopically by GFP expression. Transduction of 
the PHHs with a moi of 10 vp/cell did not increase the percentage of            
GFP-positive cells. In the PHH culture, 10% of the cells remained 
untransduced. These were most probably non-parenchymal liver cells, which 
make up for 5-15% in PHH cultures, and are not susceptible for adenovirus  
type 5 infections. Mock-transduced PHHs served as negative control.  
 
 
Fig. 10: Transduction of PHHs, immature and mature moDCs with AdG-HBV1.3.  
The results for immature and mature moDCs reflect the median values and standard deviations 
of data obtained from moDCs of three different donors. Left panels: Flow cytometry analysis of 
GFP positive PHHs (a), immature moDCs (b) or mature moDCs (c) after transduction with the 
indicated mois of AdG-HBV1.3. Middle panel: ELISA for HBsAg in the supernatant of 
transduced PHHs (a), immature moDCs (b) or mature moDCs (c) at the indicated mois. Right 
panel: ELISA for HBeAg in the supernatant of transduced PHH (a), immature moDCs (b) or 
mature moDCs (c) at the indicated mois. S/Co = Signal/Control; S/N = Signal/Noise. 
 
To obtain similar transduction rates with AdG-HBV1.3 in moDCs, the cells were 
incubated with mois of 1, 10, 30, 100, 300, 1000 and 3000 vp/cell. The gene 
transfer efficiency was determined using flow cytometry, sorting for GFP-
expressing cells. The results for the titration of AdG-HBV1.3 on immature and 
mature moDCs are depicted in fig. 10b and c (left panels), respectively. A moi of 
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1000 vp/cell was required to reach a transduction rate of 80% for both immature 
and mature moDCs. The amount of secreted HBsAg and HBeAg in the medium 
of the transduced cells was examined at day four post transduction by ELISA. 
The results are presented in fig. 10 (middle and right panels). The transduced 
PHHs secreted high amounts of HBsAg and HBeAg. The secretion correlated 
with the amount of transduced cells, and reached the highest level after 
transduction with a moi of 10 vp/cell. For the immature and mature moDCs, low 
amounts of HBsAg and only trace amounts of HBeAg could be detected, 
correlating with the amount of transduced cells. Compared to 80% transduced 
PHHs, the secretion of HBsAg was reduced 4.3-fold in 80% transduced 
immature moDCs, and 1.6-fold in 80% transduced mature moDCs. HBeAg 
expression, which is controlled by a liver-specific promoter, was 17-fold lower 
for immature moDCs and 24.6-fold for mature moDCs. Summarising, moDCs 
were only to a slight extend able to express HBV antigens, even though the 
transduction rate with the adenoviral vector was 80%. 
The expression level of HBsAg was higher than the expression level of HBeAg, 
possibly due to the liver specificity of the precore/core promoter. The maturation 
state of the moDCs seemed to play a minor role in the ability of HBV antigen 
expression. However, in comparison, HBsAg was higher expressed in moDCs 
in the matured status, while HBeAg was higher expressed in moDCs with 
immature status.  
The expression of HBsAg and HBeAg is known to depend on the presence of 
the transcription factors HNF1 and HNF4. The two forms of HNF1, HNF1-α and 
HNF1-β, enhance the transcription from the preS1 promoter, which gives rise to 
the HBsAg. HNF4 is necessary for effective transcription from the precore/core 
promoter, leading to HBeAg expression. In order to investigate whether moDCs 
express HNF1 and HNF4, Western blotting of cellular lysates with antibodies 
against HNF1 and HNF4 was performed. The hepatocellular carcinoma cell line 
HepG2 served as a positive control. To control the amount of blotted protein, 
the house keeping protein β-actin was stained on the blot. Fig. 11 shows the 
Western blots for HNF1 and HNF4. Both proteins were clearly detected in 
HepG2 cells. The 92 kDa band represents HNF1-α, the 61 kDa band results 
from HNF1-β, which was expressed in lower levels. Neither in immature moDCs 
nor in mature moDCs could HNF1 be detected. The same held true for HNF4: 
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The 56 kDa protein was present in HepG2 cells, but not in immature and mature 
moDCs.  
 
Fig. 11: Western blot analysis of transcription factors required for HBV gene expression.  
Mature and immature moDCs of two different donors and, as positive control, HepG2 cell lysate 
were analysed for HNF1 and HNF4 expression. Analysis for β-actin was added to control 
loading of equal protein amounts. 
 
Although the low expression levels of HBsAg and HBeAg implied that HBV 
replication did not occur in moDCs, the culture media of immature and mature 
moDCs transduced with AdG-HBV1.3 were assayed for HBV progeny-virus 
formation. Therefore, the media were subjected to caesium chloride density 
gradient centrifugation, followed by dot blot analysis. The density gradient 
centrifugation allows separating free HBV DNA, DNA-containing capsids and 
intact enveloped HBV virions, as they sediment in different density fractions. 
The density fractions were collected and dot blotted on a nylon membrane.  
 
           
Fig. 12: Dot blot analysis of supernatants of AdG-HBV1.3 transduced PHHs and moDCs.       
A HBV-DNA standard with concentrations from 1000 pg to 8 pg was added to the blot to be able 
to quantify the amount of HBV DNA in the samples. The supernatant of AdG-HBV1.3 
transduced PHHs served as positive control for progeny virus formation. 
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The dot blot was probed with a 32P-labelled HBV-specific DNA. In the culture 
medium of AdG-HBV1.3-transduced PHHs, which was added as positive 
control, HBV progeny virus was detected in large amounts. Conversely, no 
progeny virus could be found in the media of immature and mature moDCs after 
transduction with AdG-HBV1.3 (Fig. 12). 
   
 
2.1.1.2 Transduction of moDCs with rHBV.  
 
To address the question whether or not the early steps of HBV infection are 
supported by moDCs, recombinant HBV-based vectors (rHBV) were used. The 
vectors rHBV-rLuc and rHBV-CMV-rLuc express renilla luciferase under the            
HBV-specific preS2/S promoter or the CMV promoter, respectively. The vectors 
are schematically depicted in fig. 14a. Because all HBV genes are knocked out 
by the introduction of stop codons (C, P, L, M, X -), the vectors are replication 
deficient. Only luciferase can be expressed, as soon as entry and transport of 
the genome into the nucleus have occurred. Fig. 13 schematically depicts the 
transduction of a hepatocyte with rHBV.  
With this system at hand, it was possible to distinguish between the different 
steps of early HBV infection:  
Firstly, rHBV cannot enter the cells, or is unable to transfer the genome to the 
nucleus. In this case, no luciferase would be detected after transduction with 
rHBV-CMV-rLuc or rHBV-rLuc. 
Secondly, rHBV enters the cell and delivers the genome into the nucleus, but 
gene expression from HBV-specific promoters is not supported. In this case, 
luciferase expression would be detected only after transduction with           
rHBV-CMV-rLuc, which expresses luciferase under the HBV-independent CMV 
promoter. Transduction with rHBV-rLuc would not give rise to luciferase 
expression.  
Thirdly, rHBV enters the cell, delivers the genome into the nucleus, and       
HBV-specific promoters are active. In this case, luciferase would be expressed 
from both the rHBV-CMV-rLuc and the rHBV-rLuc vector construct.  
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Fig. 13: Transduction of a hepatocyte with rHBV. 
HBV-based vectors enter via HBV-specific receptors and uncoat. The HBV rc genome 
containing the luciferase transgene is transferred to the nucleus. cccDNA is formed and 
transcription from the respective promoter (the HBV-specific preS/S promoter in case of     
rHBV-rLuc and the CMV promoter in case of rHBV-CMV-rLuc) leads to luciferase expression 
and accumulation in the transduced cell. HBV genes cannot be transcribed because of the 
introduced stop codons.   
 
The experiment was performed in the following way: Every measurement was 
repeated three times. The cells were transduced with a moi of 100 vp/cell in the 
absence or presence of neutralising anti-HBs antibodies (nAb; Hepatect, Biotest 
Pharma). Mock-transduced cells served as negative control. At day four post 
transduction, 106 cells were lysed and assayed for luciferase expression. The 
measured relative light units (RLU) were normalised to the total protein content 
of the lysates. As a positive control for the vectors, transduced PHHs were 
used. A transduction efficiency of approx. 5% of PHHs was usually reached, 
when using a moi of 100 vp/cell. Despite this low amount of transduced cells, 
luciferase expression 200-fold above background was measured after 
transduction of PHHs with rHBV-CMV-rLuc and rHBV-rLuc. As illustrated in    
fig. 14b, the presence of neutralising antibodies during transduction completely 
abrogated luciferase expression by blocking the specific uptake of rHBV 
particles. The RLU measured in rHBV-transduced cells in the presence of 
neutralising antibodies are comparable to those obtained from mock-transduced 
PHHs.  
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Fig. 14: Transduction of PHHs and moDCs with recombinant HBV expressing luciferase. 
(a) Schematic depiction of the constructs rHBV-rLuc and rHBV-CMV-rLuc. (b-f) Transduction of 
PHHs (b), immature moDCs (c, e) and mature moDCs (d, f) with the indicated rHBV at a           
moi of 100 vp/cell in the absence or presence of neutralising antibodies (nAb).     
 
To obtain representative results for the transduction of immature and mature 
moDCs, cells from three different donors A, B and C were used in independent 
experiments. Fig. 14c and d show the results for immature (c) and mature (d) 
moDCs, transduced with the vector rHBV-rLuc. The first set of three bars 
indicates the median values and standard deviations measured with immature 
(c) and mature (d) moDCs after transduction with rHBV-rLuc. The second set of 
three bars represents the results obtained after transduction in the presence of 
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neutralising antibodies. The RLU measured in mock-transduced cells of donor 
A, B and C (last three bars, Fig. 14c and d) served as negative control. 
Comparing the results from immature rHBV-rLuc-transduced moDCs, 
performed in absence or presence of neutralising antibodies with               
mock-transduced cells (Fig. 14c), it becomes obvious that luciferase was not 
expressed in the moDCs. Thereby, no difference was observed between the 
cells from the different donors A, B and C. Transduction of mature moDCs with 
the vector rHBV-rLuc (Fig. 14d) revealed the same result. No luciferase 
expression could be detected, independent of the absence or presence of 
neutralising antibodies.    
To examine whether the inability of immature and mature moDCs to express 
luciferase was a matter of the HBV-specific promoter, moDCs were transduced 
with the vector rHBV-CMV-rLuc. In this vector, the luciferase gene is controlled 
by the CMV promoter. Nevertheless, in this experiment luciferase expression 
was undetectable, independent of the presence or absence of neutralising 
antibodies and maturation state of the moDCs (Fig. 14e, f). The RLU measured 
for immature and mature moDCs were at mock-control level for the cells from all 
three donors.  
    
Tab. 2: Quantitative PCR analysis of HBV DNA forms in DNA extracted from moDCs 
incubated with rHBV. 
  Sample                                           rcDNA copies/103cells       cccDNA copies/103cells   
+ rHBV-rLuc 48.3 ± 9.7 - 
+ rHBV-rLuc + nAb 62.0 ± 19.6 -  
Immature 
moDCs 
mock < 0.5 - 
+ rHBV-rLuc 29.3 ± 8.3 - 
+ rHBV-rLuc + nAb 17.8 ± 4.6 -  
Mature  
moDCs 
mock < 0.5 - 
 
To dissect between a block in the uptake of rHBV into moDCs and a block in 
nuclear transfer of the genome, the immature and mature moDCs transduced 
with rHBV-rLuc were analysed by quantitative real-time PCR, as described in 
2.1.1.3. PCR results revealed that rcDNA was present in immature and mature 
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moDCs, independent of the presence of neutralising antibodies (nAb; Tab. 2). 
This indicates that rHBV was taken up by moDCs, but was unable to transfer 
the genome into the nucleus. Furthermore, the internalisation was probably 
unspecific, e.g. by phagocytosis or macropinocytosis, because anti-HBs 
antibodies did not block the uptake. 
 
 
2.1.1.3 Infection of moDCs with wtHBV.  
 
To exclude firstly that wtHBV behaves differently from recombinant HBV and 
secondly that luciferase expression or detection was problematic, moDCs were 
incubated with wtHBV at a moi of 100 vp/cell. After 18 h, the inoculum was 
removed and the cells were extensively washed and trypsinised, in order to 
remove attached virus. Cells were further cultivated for 24 h, before DNA was 
prepared from the cell lysates. Using specific quantitative Light Cycler™      
real-time PCR, the cellular DNA was assayed for the presence of HBV rcDNA 
and HBV cccDNA. The binding sites of the primers within the HBV genome are 
delineated in fig. 15. The primers designed for rcDNA detection ((+) 1745 and    
(-) 1844) bind a sequence within the S region, giving rise to a 99 bp product. 
This part is double stranded in both the rc and the cccDNA form of the HBV 
genome and can therefore be amplified from both DNA forms. Since rcDNA is 
usually present in more than 100-fold excess in comparison to cccDNA, the 
amount of amplificates resulting from binding to cccDNA is insignificant. The 
primers used for cccDNA detection span the single-stranded region, the nick 
and the gap of the rc genome, and therefore do not amplify the rcDNA form.               
Primer (+) 2760 binds close to the direct repeat and primer (-) 156 binds in the 
region of the gap, which is single stranded in the rcDNA. In the cccDNA form 
the gap is filled, and the nick and the attached viral polymerase are removed. 
Only then amplification of the 580 bp product of the cccDNA PCR occurs.    
Three independent infection experiments were performed with immature and 
mature moDCs in the absence or presence of neutralising antibodies (nAb).              
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Fig. 15: Location of the primers used for ccc (red arrows) and rcDNA (blue arrows) PCR. 
 
Mock-infected moDCs served as negative control, PHHs infected with wtHBV 
were used as positive control in the PCR reactions (Tab. 3; Fig. 16). The 
detection limits were averaged at 0.2 copies/103 cells for rcDNA, and                 
1 copy/103 cells for cccDNA. The results are summarised in tab. 3, the PCR 
products obtained from mature moDCs are shown on an agarose gel in fig. 16.  
 
Tab. 3: Quantitative PCR analysis of HBV DNA forms in DNA extracted from moDCs 
incubated with wtHBV. 
  Sample                                            rcDNA copies/103cells        cccDNA copies/103cells  
+ HBV 6.68 ±  9.7 - 
+ HBV + nAb 3.9 ± 3.8 -  
Immature 
moDCs 
mock < 0.5 - 
+ HBV 2.94 ± 2.0 - 
+ HBV + nAb < 0.5 -  
Mature  
moDCs 
mock < 0.5 - 
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Between 0 and 20 copies/103 cells of rcDNA could be found in immature 
moDCs. The presence of neutralising antibodies during the incubation with 
wtHBV had no major influence on the uptake. 
The lysates of mature moDCs were also positive for rcDNA, with 1 to                  
6 copies/103 cells. The presence of neutralising antibodies (nAb; Hepatect, 
Biotest Pharma) during the incubation with wtHBV reduced the uptake of viral 
particles into mature moDCs or directed the particles to rapid degradation. A 
weak band, observed in the third lane of mature moDCs incubated with HBV 
plus neutralising antibodies (Fig. 16) was likely due to a minimal contamination, 
as the crossing point (CP) for this sample was > 40, which is below the 
detection limit of < 0.2 copies/ 103 cells. 
 
 
Fig. 16: Agarose gel of the PCR analysis of mature moDCs subjected to wtHBV. 
In vitro matured moDCs were incubated with wtHBV (+HBV), or wtHBV plus neutralising 
antibodies (+HBV +nAb) at mois of 100 vp/cell. Uninfected cells (mock) and HBV-infected PHHs 
(+) served as controls. M = DNA size marker.   
 
In contrast, the cccDNA PCR was negative in immature and mature moDCs 
after incubation with wtHBV, irrespective of the presence or absence of 
neutralising antibodies. This indicates that no HBV genomes were imported into 
the nucleus. 
These results show that low amounts of HBV particles were taken up by 
moDCs. However, a nuclear transcription template was not established, 
indicating that either the uncoating or the delivery of the genome into the 
nucleus was blocked.    
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2.1.2 Analysis of blood derived dendritic cells from high viremic chronic 
hepatitis B patients. 
 
In HBe-positive chronic HBV carriers, the blood-circulating DCs are exposed to 
high amounts of virus. To investigate whether these DCs take up HBV viral or 
subviral particles, and whether they are infected with HBV, myeloid DCs 
(mDCs) and plasmacytoid DCs (pDCs) were isolated from chronic HBV carriers. 
Four patients with mild to moderate hepatitis and high titers of HBsAg and 
HBeAg were selected. The ALT levels of the patients ranged from the upper 
normal limit to 6-fold elevation. The viremia and the calculated HBV input per 
cell for each patient are summarised in tab. 4. The DCs were isolated from 
peripheral blood by MACS in two rounds of positive selection. To control the 
purity of the obtained cell populations, they were subjected to flow cytometry 
analyses. The cells were stained for characteristic surface markers. For mDCs, 
the marker BDCA-1 was used (Fig. 17a), pDCs were stained for CD123 and 
BDCA-2 (Fig. 17b). Generally, cell purities of 76% to 96% were obtained for 
both cell populations. Fig. 17 gives an example for a characteristic staining of 
mDCs and pDCs.  
 
 
Fig. 17: Characteristic flow cytometry analysis of isolated (a) mDCs and (b) pDCs. 
 
Using quantitative real-time PCR, mDCs and pDCs were investigated for the 
presence of HBV rcDNA and cccDNA. The presence of cccDNA would indicate 
nuclear transport and thus infection of the DCs. The exclusive existence of 
rcDNA would argue for an uptake of virions by the DCs, specific or unspecific, 
without nuclear transport and thus without infection.  
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Tab. 4: Quantitative PCR analysis of HBV DNA forms in DNA extracted from blood-
circulating mDCs and pDCs of chronic HBV carriers and in vitro HBV infected PHHs.     
Sample    HBV viremia     Cell type       HBV input       rcDNA copies       cccDNA copies
                   /ml blood                                   /cell                 /103 cells                /103 cells       
1 8.2 x 107 
mDCs 
pDCs 
5460 
8200 
11.6 
- 
- 
- 
2 7.9 x 107 
mDCs 
pDCs 
5260 
7900 
- 
- 
- 
- 
3 2.6 x 109 
mDCs 
pDCs 
173300 
260000 
- 
6.2 
- 
- 
4 4.8 x 108 
mDCs 
pDCs 
32000 
48000 
- 
- 
- 
- 
5 - PHHs 100 3600 230 
     
 
DNA from PHHs, in vitro infected with HBV at a moi of 100 vp/cell, was used as 
positive control for rcDNA and cccDNA. As a negative control for cccDNA 
served DNA isolated from the patients own sera, as well as DNA isolated from 
the serum of a HBV-infected chimpanzee with a viral titer of 1.25 x 108 HBV 
copies/ml blood. Tab. 4 outlines the PCR results.  
 
 
Fig. 18: Agarose gel of the PCR analysis of blood-circulating DCs from patient 1. DNA 
from sera of an HBV-infected chimpanzee and patient 1 served as negative control for cccDNA, 
DNA from HBV-infected PHHs served as positive control for cccDNA and rcDNA. 
 
In mDCs and pDCs from only one patient each, low amounts of 11.6 and            
6.2 rcDNA copies/103 cells were detected, respectively. The PHH DNA, serving 
as positive control, contained 3600 rcDNA copies/103 cells. No cccDNA was 
present in DCs from the chronic infected patients and the negative controls. In 
the positive control, 230 cccDNA copies/103 PHHs were detected by real-time 
PCR (Tab. 4; Fig. 18). The PCR products were subjected to agarose gel 
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electrophoresis. In fig. 18, the PCR products obtained from cells of patient 1 are 
visualised (mDCs, pDCs). The sera of the HBV-infected chimpanzee and of 
patient 1 were clearly positive for rcDNA. The cccDNA form is not present in 
free virions. Accordingly, the sera were negative for cccDNA. The in vitro 
infected PHHs contained both the nuclear ccc form of the HBV genome and the 
genomic rc form of the virions. This result clearly shows that blood-derived 
mDCs and pDCs of highly viremic carriers barely take up HBV particles and do 
not support the HBV replication cycle.   
To further analyse whether blood-circulating mDCs and pDCs in chronically 
HBV infected patients take up viral or subviral particles, transmission electron 
microscopy was performed with freshly isolated mDCs and pDCs. In fig. 19, an 
mDCs is depicted. In the cell, endocytic vesicles containing few subviral 
particles were observed. Neither virions nor free capsids were detected in the 
cytoplasm or at the nuclear membranes of the cells. pDCs appeared negative 
for HBV viral or subviral particles.  
 
 
Fig. 19: Transmission electron microscopy of ultra-thin 50 nm sections of an mDC. The 
red arrow points at an endocytic vesicle containing three SVPs. 
 
Quantitative real-time PCR of other peripheral blood-cell populations revealed 
that B cells were positive for rcDNA in three of the four analysed patients, with 
copy numbers per 103 cells of 10, 14.6 and 19.3, respectively.                      
Enriched T-lymphocyte fractions of two patients contained 132.8 and 68 copies 
rcDNA/103 cells, respectively, and 4 copies rcDNA/103 cells were detected       
in monocytes of one patient. cccDNA was not detected in any of these cells     
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(Tab. 5). This indicates that HBV-particle uptake into the cells occurred, but that 
an HBV infection was not established.    
 
Tab. 5: Quantitative PCR analysis of HBV DNA forms in DNA extracted from B cells (B), 
enriched T-cell fractions (T) and monocytes (M) of chronic HBV carriers. 
Sample        HBV viremia        Cell type             rcDNA copies                  cccDNA copies 
                    /ml blood                                           /103 cells                          /103 cells     
1 8.2 x 107 
B 
T 
M 
19.3 
132.8 
- 
- 
- 
- 
2 7.9 x 107 
B 
T 
M 
- 
- 
- 
- 
- 
- 
3 2.6 x 109 
B 
T 
M 
10 
68 
- 
- 
- 
- 
4 4.8 x 108 
B 
T 
M 
14.6 
- 
4 
- 
- 
- 
 
To summarise, the PCR data, as well as the EM analyses, reveal that mDCs 
and pDCs of high viremic chronic HBV carriers were not infected with HBV to a 
significant proportion; neither were B cells, monocytes and enriched                 
T-lymphocyte fractions of chronic HBV carriers. However, low amounts of VPs 
and SVPs seemed to be taken up by DCs and may be presented as antigen to 
T cells.  
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2.2 Discussion I 
 
Dendritic cells are the most potent antigen-presenting cells, and therefore play 
an important role in the immune system. They induce antigen-specific cellular 
and humoral immune responses by presenting internalised antigens to T and   
B lymphocytes. In chronic HBV carriers, DC dysfunctions and impaired T-cell 
responses have been reported: Decreased DC numbers, reduced maturation 
and T-cell stimulatory capacity of mDCs, as well as reduced IFN-α production of 
pDCs (Beckebaum et al., 2002; van der Molen et al., 2004; Duan et al., 2004). 
Numbers of virus-specific CTLs are decreased and a virus-specific T-cell 
response is barely detectable (Rehermann et al., 1995b; Maini et al., 2000).  
For various viruses, it has been shown that DC infection, causing an impairment 
of DC function, is a potent strategy to circumvent a virus-specific immune 
response. In HIV-infected patients for example, DCs display a reduced capacity 
to stimulate allogeneic lymphocytes (Knight et al., 1993). A similar correlation 
was found for vacciniavirus infection (Engelmeyer et al., 1999). Here, the 
maturation of DCs seems to be inhibited upon infection. A recent study of 
Wertheimer et al., (2007) provided evidence for an influence of HCV protein 
expression on DCs. The protein expression profile of the DCs changed, 
particularly with respect to chemokines, when HCV proteins were expressed in 
the DCs. Furthermore, DC dysfunction was found to correlate with an impaired   
HCV-specific CD4+ T-cell response in chronic carriers (Della Bella et al., 2007).   
As the impairment of DC and T-cell function in chronic HBV-infected patients 
might be caused by HBV infection of DCs, the different steps of HBV infection 
were analysed in blood DCs. The question, at which level HBV might affect DC 
functionality, was addressed.  
Although low-level expression of HBsAg and HBeAg was possible in moDCs, 
no infection with HBV was detected. The results were confirmed in the in vivo 
situation by ex vivo analysis of mDCs and pDCs from high viremic HBV carriers, 
using quantitative real-time PCR and electron microscopy. Therefore, it can be 
excluded that HBV infects blood DCs at a frequency sufficient to explain the 
impairment of the virus-specific T-cell response in chronic HBV carriers. 
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2.2.1 HBV antigen expression and replication in moDCs.  
 
2.2.1.1 Transduction of moDCs with AdG-HBV1.3. 
 
In order to test whether DCs are able to express HBV antigens, the HBV 
genome was artificially introduced in moDCs via an adenoviral vector. HBsAg 
expression, and to a higher extent HBeAg expression, were reduced in moDCs 
compared to similarly AdG-HBV1.3-transduced PHHs. No progeny virus was 
formed. A possible explanation for the very low expression level of HBeAg could 
be the high liver specificity of the precore/core promoter, which is responsible 
for HBeAg and core expression (Honigwachs et al., 1989; Ganem and 
Schneider, 2001). Liver-enriched nuclear factors, important for transcription 
from the precore/core promoter as well as transcription of the pre-genomic 
RNA, are missing in moDCs (Tong and McLachlan, 2001 and 2002). The 
reduction of HBsAg expression in moDCs, compared to PHHs, was less strong, 
presumably because the preS2/S promoter shows only limited liver specificity 
and is constitutively active in a wide range of cells (Siddiqui et al., 1986; Faktor 
et al., 1988; Zhou and Yen, 1990). The reduction in HBsAg expression 
compared to PHHs may therefore be due to differences in the promoter activity. 
Alternatively, cccDNA, which serves as an additional transcription template in 
PHHs, might not be present in moDCs (Ganem and Schneider, 2001; Ganem 
and Prince, 2004). The inability to produce progeny virus may be based on a 
lack of the nuclear transcription factors HNF1 and HNF4. Western blot analysis 
of immature and mature moDC lysates showed that these factors were not 
expressed by moDCs. HNF1 and HNF4 are essential for the transcription from 
the preS1 promoter, and for the transcription of the HBV pre-genomic RNA, 
respectively (Courtois et al., 1988; Honigwachs et al., 1989; Raney et al., 1997). 
The differences in the expression-level reduction between immature and mature 
moDCs of HBsAg and HBeAg could be explained by a re-modelled         
protein-expression pattern in moDCs after maturation (Banchereau et al., 2000; 
Garret et al., 2000). While immature moDCs primarily express proteins 
necessary for antigen uptake, upon maturation they up-regulate MHC and       
co-stimulatory molecule expression. This change in the protein expression 
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pattern during the maturation process may result in an increased expression of 
HBsAg and a decreased expression of HBeAg.  
 
 
2.2.1.2 Transduction of moDCs with rHBV.  
 
To investigate whether moDCs can be infected with HBV, HBV-based vectors 
(rHBV) were used. These vectors express luciferase, either under the          
HBV-specific preS2/S promoter (rHBV-rLuc) or the non-liver specific CMV 
promoter (rHBV-CMV-rLuc). They mimic the early steps of HBV infection, these 
being entry, uncoating, and transport of the genome into the nucleus (Klöcker et 
al., 2000; Untergasser and Protzer, 2004). rHBV transduction can be completely 
blocked with neutralising antibodies, as shown in the positive control with PHHs 
(Schulze-Bergkamen et al., 2003).  
The luciferase system is very sensitive, with an estimated detection limit of        
1 positive cell/104 moDCs. Using this assay, HBV infection of permissive cells 
can be specifically and sensitively detected. However, luciferase expression 
was not detected after incubation with rHBV-rLuc or rHBV-CMV-rLuc, neither in 
immature nor in mature moDC. Both the CMV promoter and the preS2/S 
promoter are active in moDCs. This was shown in the AdG-HBV1.3 transduced 
moDCs, which expressed GFP under the CMV promoter and HBsAg under the 
preS2/S promoter. Therefore, the lack of luciferase expression after 
transduction with rHBV suggests that the rHBV genome was not delivered to 
the nucleus. This can either be due to a block of entry into the cells, or to a 
block of uncoating and nuclear transfer of the genome. Despite the high 
sensitivity of the luciferase assay, a transduction rate below 1:10-4 cannot be 
excluded. However, it is unlikely that infection of DCs with HBV at such low 
levels can cause DC dysfunction.         
To elucidate whether rHBV entered the cells, an optimised quantitative real-time 
PCR was used, which allowed a distinction between rcDNA and cccDNA. These 
DNA forms are present in cells after HBV infection as well as after rHBV 
transduction. The fact that immature and mature moDCs contained rcDNA after 
transduction with rHBV-rLuc suggests that moDCs internalised rHBV. However, 
since the cells were extensively washed but not trypsinised, virions which stuck 
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to the cell surface possibly gave rise at least to some of the rc copies detected 
in the cell lysates. The nuclear cccDNA form was not present in the cells. The 
presence of rcDNA but not cccDNA suggests that the block leading to the 
inability to express luciferase was probably not located in the uptake 
mechanism, but rather in the uncoating or DNA-delivery step. The 
internalisation seemed to be an unspecific process, e.g. phagocytosis or 
macropinocytosis, because anti-HBs antibodies, blocking the specific HBV 
uptake into hepatocytes, did not have this effect in moDCs. The copy numbers 
of rcDNA found in immature moDCs were the same when incubated only with 
rHBV and when incubated with rHBV in the presence of neutralising antibodies. 
Since immature DCs are specialised for antigen uptake, they phagocytose large 
amounts of opsonised antigens (Banchereau et al., 2000; Janeway et al., 2004). 
rHBV uptake was slightly reduced in mature moDCs compared to immature 
cells, and in the presence of antibodies the amount was further shortened. This 
was expected, as mature DCs primarily present internalised antigen, whilst 
uptake activity is down-regulated (Banchereau et al., 2000; Garret et al., 2000).   
 
 
2.2.1.3 Infection of moDCs with wtHBV.  
 
To exclude that wtHBV behaves differently to rHBV, moDCs were incubated 
with wtHBV. Quantitative real-time PCR was used to analyse immature and 
mature moDCs for the presence of rcDNA and cccDNA. cccDNA was found 
neither in immature nor in mature moDCs, despite an estimated detection limit 
of 1 copy/103 cells. These data coincide with the results obtained with moDCs 
incubated with the luciferase expressing rHBV (2.2.1.2). In this case, luciferase 
expression could not be detected with the luciferase assay, and cccDNA could 
not be found using quantitative real-time PCR analysis. After incubation with 
wtHBV, moDCs were not infected with HBV, or at the most with a very low 
frequency below the detection limit of 1:10-3. However, the presence of minor 
amounts of rcDNA in immature, and to a lesser extent in mature, moDCs 
demonstrates that wtHBV uptake was possible. The lack of cccDNA formation, 
plus the fact that the uptake was independent of the presence of neutralising 
antibodies, emphasises an unspecific uptake mechanism for wtHBV. This 
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resembles the PCR data of the aforementioned experiment performed with 
rHBV. However, the copy numbers of rcDNA per cell differed. moDC lysates of 
cells incubated with rHBV revealed 5- to 10-fold higher amounts of virus DNA, 
compared to moDCs incubated with wtHBV. This discrepancy may be due to 
the extensive trypsinisation and washing performed with moDCs after 
incubation with wtHBV, but not with cells incubated with rHBV. Therefore, the 
additional copies may have stemmed from rHBV attached to the cell surface, 
whereas most of the wtHBV attached to the moDCs have probably been 
removed by the trypsinisation and washing procedure. Furthermore, differences 
in the production method of rHBV and wtHBV may be the cause for the 
differences in the rcDNA amount between moDCs incubated with rHBV, and 
moDCs incubated with wtHBV: rHBV were produced in serum-free medium via 
transfection of HuH7 cells. In contrast, wtHBV were produced by the 
HepG2.2.15 cell line in the presence of FCS. Therefore, rHBV particles did not 
carry serum proteins on their surface, whilst wtHBV produced by HepG2.2.15 
cells were most likely covered with serum proteins bound to the surface. The 
phenomenon that serum proteins bind to the virus surface in vivo and in vitro 
has been described several times (Khelifa and Mo, 1987; Heermann et            
al., 1988; Krone et al., 1990). These differences in the virus surface 
characteristics may contribute to variability in the uptake mechanism or 
efficiency. Furthermore, the two cell lines may differ in their glycosylation 
machinery, leading to altered glycosylation patterns of the HBV surface 
proteins. Since it is known that protein glycosylation patterns influence the 
uptake into APCs by scavenger receptors, this may be an alternative reason, 
why rHBV was internalised to a higher extent than wtHBV (Vlassara et            
al., 1985).                    
 
 
2.2.2 Analysis of blood derived dendritic cells from high viremic chronic 
hepatitis B patients. 
 
To verify the results obtained with moDCs in the physiological situation,       
blood-circulating DCs of four high viremic chronic HBV carriers were ex vivo 
studied for HBV infection. The main populations of circulating DCs are myeloid 
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and plasmacytoid DCs (Banchereau, 2000). A very important feature of the 
latter is their role in antiviral defence. They are the main source of type 1 IFN, 
which can inhibit viral replication, and thus have a strong antiviral effect (Cella 
et al., 1999; Siegal et al., 1999). In the four chronic HBV carriers, mDCs and 
pDCs have been exposed to up to 2.6 x 105 virions per cell. Nevertheless, no 
cccDNA could be detected in mDCs and pDCs of all carriers with quantitative 
real-time PCR. This argues against an infection of these cells with HBV. 
Cytoplasmic rcDNA was found in low amounts in mDCs of patient 1 and pDCs 
of patient 3, indicating that HBV is taken up by mDCs and pDCs to a very low 
extent, as is the case in moDCs. However, mDCs and pDCs were exposed to a 
much higher amount of viral particles. Uptake of HBV by mDCs and pDCs 
appeared to be a rare event in chronic HBV carriers. rcDNA was not detectable 
in three of the four investigated mDC and pDC samples, respectively, despite a 
detection limit of 0.2 copies/103 cells. In agreement with the molecular analyses, 
electron microscopy revealed that HBV capsids or complete virions were not 
present in the cytoplasm, or at the nuclear membrane of mDCs and pDCs. Only 
SVPs were found in low amounts in endocytic vesicles of mDCs. Once more, 
this indicates an unspecific uptake mechanism of HBV VPs and SVPs. 
However, the observation that the internalisation of HBV was such a rare event 
is unexpected, as blood-circulating mDCs and pDCs display an immature 
phenotype and usually internalise high amounts of pathogens. One reason 
could be that HBV VPs and SVPs are covered by serum proteins and therefore 
might less easily be detected as foreign (Krone et al., 1989).  
To conclude, mDCs and pDCs of high viremic chronic HBV carriers were not 
infected with HBV to a sufficient amount to explain the DC dysfunction in these 
patients. Furthermore, the DCs rarely internalised HBV VPs and SVPs.      
In B cells, monocytes and enriched T-cell fractions, quantitative real-time PCR 
revealed low amounts of HBV rcDNA, while all cells were negative for cccDNA. 
This suggests that these cells were also not infected with HBV.   
In previous studies, possible HBV infections were mostly analysed using PCR 
or PCR in situ hybridisation, which only detects the rc form of HBV DNA 
(Beckebaum et al., 2002; Arima et al., 2003; Tavakoli et al., 2004). Thereby, a 
differentiation between input virus, or unspecifically up-taken virions, and 
cccDNA formation is hardly possible. Nuclear entry of viral DNA is a 
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prerequisite for successful HBV infection of a cell and results in the formation of 
cccDNA, which serves as a transcription template for HBV RNAs (Ganem and 
Schneider, 2001; Ganem and Prince, 2004). This also holds true for HBV-based 
vectors, where cccDNA is formed from the rHBV genome to express the 
transgene. Therefore, only the specific detection of cccDNA is an indication for 
infection. The detection of rcDNA merely implies the presence of virions, either 
bound to cells, inside endocytic or lysosomal vesicles, or free in the cytoplasm 
(Köck et al., 1996).     
In the study of Beckebaum et al. (2002), HBV DNA was found in pDCs of 
chronic HBV carriers and complete HBV particles were observed in cytoplasmic 
vesicles of mDCs by electron microscopy. This result was interpreted as an 
indication for HBV infection of DCs, which might cause DC dysfunction in 
chronic HBV carriers. However, the fact that many enveloped virus particles 
were detected in vesicles, whereas no free capsids were present in the 
cytoplasm, argues for uptake of these virions by phagocytosis, rather than for 
infection. The latter would require the release of capsids into the cytoplasm, 
which transport the viral genome to the nucleus. Köck et al. (1996) used a PCR 
assay that amplifies cccDNA more efficiently than rcDNA, to test whether HBV 
infects PBMCs. They found no evidence that PBMCs can be infected with HBV 
and concluded that adsorbed virus might explain the detection of HBV DNA or 
RNA by PCR. Contrary to this, in other publications the existence of HBV DNA 
in PBMCs was interpreted as HBV infection, which could interfere with PBMC 
function in virus-specific immunity (Stoll-Becker et al., 1997; Trippler et           
al., 1999). However, the data presented in this project and the investigation of 
others exclude an infection of blood-circulating DCs as well as monocytes,      
B-cells and enriched T-cell fractions, to an extent sufficient to cause DC 
dysfunction and impairment of a virus-specific immune response.  
The assumption that an infection of DCs with HBV is not the reason for the 
impairment of DCs and T-cell function raises the question whether or not the 
presence of rcDNA in the DCs influences their functionality. Van der Molen et 
al. (2004) performed functional studies, which did not reveal any correlation 
between the amount of HBV DNA present in mDCs and their suppressed 
allostimulatory capacity. Furthermore, they found no link between the amount of 
HBV DNA and the capacity of mDCs to express CD80 or CD86 during in vitro 
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maturation. Although the amount of HBV DNA, associated with pDCs seemed 
to be higher than that associated with mDCs, they did not show an altered 
allostimulatory capacity. Thus, the amount of HBV DNA associated with DCs 
did not correlate with a certain functional impairment. A similar observation was 
published by Tavakoli et al. (2004). They investigated immature and mature 
moDCs of chronic HBV carriers. Contrary to the investigations with HCV of 
Wertheimer et al. (2007), the amount of HBV DNA and antigen expression 
detected in the moDCs was not in line with a loss of the allostimulatory capacity 
of these cells. Thus, there seems to be no correlation between the amounts of 
rcDNA present in the DCs, and their impaired immune response to HBV.  
Considering the data from this study and the literature, one can hypothesise 
that the contact with HBV antigens, in particular SVPs, which circulate in vast 
amounts in the blood during infection, may alter the antiviral immune response. 
Evidence for an influence of high antigen levels on the immune system comes 
from different studies: In the mouse lymphocytic choriomeningitis virus model, a 
gradual loss of T-cell function was demonstrated. This so called T-cell 
exhaustion was caused by a high viral load (Fuller et al., 2003; Wherry et al., 
2003). First, the IL-2 production was impaired, followed by a loss of cytotoxicity 
and a lack in TNF-α secretion. Finally, the INF-γ production was impaired. This 
functional inactivation then promoted further viral persistence. Whether the 
exhaustion was induced by the antigen contact itself, e.g. by repeated TCR 
triggering with presented antigens, or indirect, e.g. by cytokine deprivation, is 
currently not understood. However, fluxes in the viral load appeared to partially 
restore at least some T-cell functions (Fuller and Zajac, 2003).        
The question whether or not a high HBV load influences cell numbers and 
functionality on the DC level was recently addressed by Van der Molen et al. 
(2006). A reduction of the virus load was found to correlate with a substantial 
increase of mDC but not pDC numbers, to a level comparable to that of 
uninfected healthy controls. The allostimulatory capacity of isolated and in vitro 
matured mDCs increased significantly. A highly reduced number of DCs could 
explain the low number of virus-specific T cells, characteristic for chronic HBV 
infection. Coincidentally, it has been reported that the level of HBV replication in 
the liver, and thus the amount of circulating VPs and SVPs, influences the 
profile of the virus-specific cytotoxic T-cell response during chronic infection 
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(Webster et al., 2004). A study of Maini et al. (2000), points as well in this 
direction. They proposed that a quantitative difference in virus-specific CTL 
numbers between chronic and acute infection, correlated with virus control. 
Furthermore, it was demonstrated by others that the CD4+ and CD8+ T-cell 
response increased after lamivudine-induced reduction of the virus load (Boni et 
al., 1998 and 2003). In theory, a mechanism such as the following could explain 
the spontaneous recovery of chronic patients, sometimes observed after 
lamivudine therapy: If the immune system is unable to control the virus in the 
early phase of infection, high viral titers are reached in the blood. Vast antigen 
exposure leads to an impairment of DCs, followed by T-cell exhaustion. If the 
virus load can be efficiently reduced by an antiviral therapy, the immune system 
can recover, and a restored T-cell response might then be strong enough to 
control the remaining virus (Rossol et al., 1997; Boni et al., 2001). 
In the context of the influence of frequent antigen encounter, Stoop et al. (2005 
and 2007) highlighted the role of Tregs. There is evidence that these cells 
contribute to the hypo-responsiveness of the immune response against HCV, 
HIV and CMV (Sugimoto et al., 2003; Aandahl et al., 2004; Cabrera et al., 
2004). In HBV infection, CD4+CD25+FoxP3+ Tregs have been shown to impair 
the immune response in chronic carriers by immuno-suppression of            
HBV-specific CD8+ T cells (Franzese et al., 2005; Stoop et al., 2005). 
Furthermore, CD4+CD25+FoxP3+ Tregs are present in increased numbers in 
peripheral blood of chronic HBV carriers, possibly correlating with the virus load 
(Xu et al., 2006). Frequent antigen encounter for a long period of time, as is the 
situation in chronic carriers with high viral load, has been suggested to stimulate 
Treg (Taams et al., 2002). This was confirmed by Stoop et al. (2007), who 
found a simultaneous decrease in CD4+CD25+FoxP3+ Treg numbers and virus 
load after adevovir treatment of chronic carriers. At the same time, they 
observed an increased immune response to HBcAg. The authors hypothesised 
a self-maintaining regulatory loop between Tregs and DCs, which might 
contribute to HBV persistence: Immature DCs can induce Tregs, and increased 
Treg numbers can inhibit DC maturation, leading to a decreased stimulatory 
capacity of T cells (Shevach, 2002; Min et al., 2003; Misra et al., 2004). 
Alternatively, alterations in the microenvironment of lymphoid organs during 
HBV infection could contribute to DC and T-cell dysfunction in chronic carriers. 
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Rehermann et al. (1995b) found that trace quantities of HBV DNA and RNA can 
persist in the serum and in PBMCs in resolved acute HBV-infected persons. 
The fact that HBV persistence was not due to an impaired immune response, 
suggests an immunologically privileged site of persistence, where HBV cannot 
be reached by CTLs. On the one hand, this persistence may result in the 
ongoing antigen-specific humoral and cellular immune response, observed after 
recovered acute infection (Rehermann et al., 1996). On the other hand, the 
persisting virus may also be responsible for the chronic disease (Rehermann 
and Nascimbeni, 2005).     
Since the liver is the primary site of viral replication and therefore the site where 
an immune response against the virus is expected to be initiated, possible 
alterations in the liver must also be considered. First of all, the immunological 
features of the liver seem to support immuno-tolerance in chronic HBV infection: 
The hepatic environment is known to be tolerogenic, containing intrahepatic    
T-cell populations, and high numbers of APCs, such as liver DCs, Kupffer cells 
and liver sinusoidal endothelial cells (Crispe, 2003). Presentation of exogenous 
antigens to T cells, by liver sinusoidal endothelial cells, has been shown to 
induce specific T-cell tolerance (Limmer et al., 2000). This mechanism could 
also contribute to HBV-specific tolerance. Furthermore, an infection of liver DCs 
with HBV cannot be excluded, as DC populations are very heterogeneous. The 
situation in blood DCs may not reflect liver-DC behaviour, with respect to 
functional impairment and the ability to be infected with HBV. Unfortunately, the 
isolation of liver DCs is not yet established, and intrahepatic immunological 
events are difficult to study. The few studies performed in this field revealed 
differences between intrahepatic and circulating virus-specific CD8+ T cells, 
concerning phenotype, frequency and activation status in chronic HBV and HCV 
infections, as well as in acute HBV infection (Bertoletti et al., 1997; Maini et al., 
2000; Sprengers et al., 2006).  
An interesting feature of the antigen-presenting cells in the liver is the 
constitutive expression of the programmed death 1 molecule ligand 1 (PD1-L1) 
in Kupffer cells, liver sinusoidal endothelial cells and stellate cells (Iwai et al., 
2003; Chen et al., 2006). In hepatocytes, PD1-L1 expression is regulated in an 
IFN-α- and IFN-γ-dependent manner (Mühlbauer et al., 2006). Its receptor, the 
PD1 molecule, is an inhibitory receptor of the CD28 co-stimulatory family and is 
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expressed by myeloid cells, B cells and T cells (Ishida et al., 1992; Chen, 2004; 
Greenwald et al., 2005). PD1 signalling upon interaction with PD1-L1 after liver 
infiltration of T cells is a major mechanism to inhibit virus-specific T cells: The 
antiviral effector functions of the T cells are impaired, and the T cells undergo 
apoptosis (Iwai et al., 2003; Dong et al., 2004). In a HBV mouse model, 
Isogawa et al. (2005) already demonstrated that virus-specific CD8+ T cells 
transferred into HBV transgenic mice, simultaneously up-regulated the PD1 
expression and lost their IFN-γ production capacity. In chronically HBV-infected 
patients, Geng et al. (2006) found that the PD1-L1 expression in CD14+ 
monocytes was increased in comparison to healthy controls. PD1-L1 
expression positively correlated with serum levels of IL-10, which is an 
immunosuppressive cytokine produced by different types of T cells, and 
monocytes (Accapezzato et al., 2005; Dikopoulos et al., 2005; Trinchieri 2007). 
Studies performed in acute and chronic hepatitis C revealed an involvement of 
the PD1-PD-L1 pathway as well in this disease: Urbani et al. (2006) 
demonstrated an up-regulation of PD1 levels in HCV-specific CD8+ T cells upon 
acute HCV infection, followed by a decline as soon as the infection cleared. In 
contrast, T cells of chronic HCV-infected patients displayed constantly high 
levels of PD1, together with an exhausted and functionally impaired phenotype. 
These cells were frequently found in the liver. In an in vitro experiment, the 
proliferative capacity of the exhausted cells increased upon a blockade of the 
PD1-PD-L1 interaction (Urbani et al., 2006; Radziewicz et al., 2007). 
Considering these data, together with the notion that IL-10 production correlated 
with PD1-L1 expression, a role in the development of chronic hepatitis B is 
possible. IL-10 is known to inhibit IFN-α production of APCs and can induce 
apoptosis of pDCs (Duramad et al., 2003; Dolganiuc et al., 2006).      
In addition to the PD1-PD1-L1 pathway, the immunoproteasome is a factor 
which might influence the immune response against HBV in the liver. It differs 
from the constitutive proteasome in quantitative and qualitative aspects of its 
proteolytic activity (Klötzel et al., 2001; Van den Eynde et al., 2001). In mice, it 
has been demonstrated that specific subunits of the immunoproteasome were 
necessary for the efficient processing and presentation of CD8+ T-cell epitopes 
(Fehling et al., 1994; Van Kaer et al. 1994; Chen et al., 2001). In LCMV-infected 
mice, replacement of the constitutive proteasomes by de novo assembly of 
                                                                                                                                   Discussion I 
 
 60
immunoproteasomes has been observed in the infected organ, the liver (Khan 
et al., 2001). The IFN-inducible catalytic and regulatory subunits of the 
immunoproteasome, LMP2, LMP7, MECL1 and PA28α/β, seem to play a role in 
the IFN-induced inhibition of HBV capsid assembly in hepatocytes (Wieland et 
al., 2000, 2003 and 2005). Furthermore, immunoproteasome activity was shown 
to be required for IFN-mediated HBV inhibition (Wieland et al., 2000; Robek et 
al., 2002). In HCV-infected chimpanzees, Shin et al. (2006) differentially 
analysed the role of the immunoproteasome in innate and adaptive immune 
response. They found that the antigen-processing machinery of virus-infected 
hepatocytes is already stimulated by virus-induced type I IFN, prior to T-cell 
infiltration of the liver. In HBV infection, however, an early IFN response was not 
detectable in the liver of chimpanzees, consistent with the finding that an 
increased expression of immunoproteasome subunits was induced only in later 
phases of infection (Wieland et al., 2004). In a study of Robek et al. (2007), an 
altered CD8+ T-cell response against the HBV envelope proteins and the 
polymerase protein was described for mice lacking the immunoproteasome 
subunit LMP7. Since the T-cell response differs between acute and chronic 
HBV infection in the multi-specificity of the epitopes, one could hypothesise a 
differential regulation of antigen processing in acute versus chronic infection. 
Professional APCs, which constitutively express the immunoproteasome, are 
responsible for the T-cell priming (Robek et al., 2007). Furthermore, the 
subunits LMP2 and LMP7, expressed in hepatocytes after IFN induction, might 
facilitate the recognition of infected hepatocytes (Sallusto and Lanzavecchia, 
1999; Morel et al., 2000; Khan et al., 2001).   
There is evidence that alteration of DC function in chronic HCV infection might 
not be caused by the infection of DCs but may be a consequence of liver 
disease progression (Barth et al., 2005). A similar mechanism is conceivable for 
chronic HBV infection, because the development of liver cirrhosis and 
hepatocellular carcinoma, due to persistent inflammation, is very common 
(WHO, 2007; Chisari and Ferrari, 1995b). However, it has been published in the 
aforementioned studies of Maini et al. (2000) and Webster et al. (2004) that 
differences in virus-specific CTL response between chronic and acute infection 
were independent of the liver disease.  
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To summarise, the mechanisms underlying the impaired immune response 
against HBV in chronic carriers remain to be elucidated. In this study it was 
proven by in vitro analyses using moDCs, as well as by ex vivo analyses of 
mDCs and pDCs, isolated from chronic HBV carriers, that an infection of                 
blood-circulating DCs is not the reason for the impairment of DC and T-cell 
function. The fact that chronic HBV patients do not exhibit a general 
immunological hypo-responsiveness speaks for a virus-specific defect, rather 
than a general allostimulatory deficit (Tavakoli et al., 2004). Furthermore, the 
recovery of chronic HBV patients, whether self-generated or after antiviral 
therapy, indicates that the mechanisms responsible for clearance can be 
spontaneously induced. To define the critical event, that allows HBV to affect 
the host immune system in a way that it can persist, would provide insight into 
the question as to why some patients recover from an acute hepatitis B, while 
others develop a chronic disease. Furthermore, it would help to establish an 
efficient treatment against chronic hepatitis B.         
The difficulties of these studies are, on the one hand, the heterogeneity of 
course and severity of the chronic disease in different patients, as well as the 
heterogeneity of the different DC and T-cell subsets. Furthermore, these cells 
are difficult to isolate in a sufficient purity. On the other hand the different 
compartments of the immune system are interconnected, so that the failure of 
one of them will have an impact on the whole system. Therefore, it will be 
difficult to define the determinant or determinants, which allow HBV persistence.  
     
 
 
 
 
 
 
 
 
3. (II) Generation and characterization of hepatitis B virus surface 
proteins fused to GFP and RFP 
 
 
                                                                                                                 Results II 
 62
3.1 Results II 
 
Many aspects of the HBV life cycle still remain unclear. To elucidate the 
different steps of virus entry and egress, the visualisation of viral (VP) and 
subviral (SVP) HBV particles is desired. Therefore, plasmids encoding the HBV 
small (S), middle (M) or large (L) surface protein fused to a green (GFP) or red 
(RFP) fluorescent protein were constructed. These fluorescent proteins could 
be used to observe not only the surface protein behaviour in cells, but also 
particle formation and release from the cells. Furthermore, if infectious 
fluorescent virus is built, the early steps of infection could be monitored. 
Prerequisite for using the fluorescent fusion proteins is that they display the 
same properties as their parental counterparts. Otherwise, results would hardly 
be conferrable on the natural situation in HBV infection. Therefore, the fusion 
proteins were analysed for their fluorescence and stability properties, and 
compared to the parental proteins with regard to their localisation in cellular 
compartments and the ability to form SVPs and VPs.   
 
 
3.1.1 Cloning of GFP- and RFP-fused HBV surface proteins.  
 
To generate fluorescent HBV surface proteins, the plasmid pCH S An-b-glob, 
encoding S under CMV promoter control was used as basis. The GFP and RFP 
genes were gained from the plasmids pCH GFP An-b-glob and RFP1_pRSETB, 
respectively. The fusion constructs and the resulting proteins are schematically 
depicted in fig.20. The plasmid shown in fig. 20a encodes the GFP-S fusion 
protein, with GFP N-terminally fused to S. Since current HBV surface-protein 
models propose a localisation of the N terminus in the ER lumen, upon budding 
of SVPs and VPs into the ER lumen the fluorescent domain should be located 
at the particle outside. In order to remove possible sterical problems which 
could influence the folding of GFP or S, an additional fusion protein based on 
GFP-S was designed. It carries a glycine spacer (sp) consisting of 12 
nucleotides between GFP and S. This fusion protein is designated GFP-sp-S 
(Fig. 20b).    
                                                                                                                 Results II 
 63
    
 
Fig. 20: Generated DNA constructs and the resulting fusion proteins.    
The HBV envelope proteins traverse the ER membrane with two transmembrane domains 
(green boxes) and probably with two additional hydrophobic domains (orange boxes), exposing 
N- and C terminus to the ER lumen. After budding, the termini are located at the outer surface 
of VPs and SVPs. All fusion proteins are under control of a CMV promoter (PCMV). a) GFP-S 
carries the GFP at the N terminus of S. b) GFP-sp-S is based on GFP-S with a spacer (sp; 
yellow box) consisting of four glycins integrated between GFP and S. c) S-GFP and S-RFP 
carry the fluorescent part at the C terminus of S. d) M-GFP and M-RFP base on S-GFP and     
S-RFP, respectively. They were extended by the preS2 domain (light blue). The ATG of S was 
exchanged to ACG. e) L-GFP and L-RFP are based on M-GFP and M-RFP, and were further 
extended by the preS1 domain (dark blue). Both ATGs from S and M were exchanged to ACG. 
(G) = partial glycosylation site; G = glycosylation site; i = immunodominant epitope; asterisks = 
potential glycosylation sites, Myr = myristoylation site. 
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Alternatively, the fluorescent protein was fused to the C terminus of S. Like the 
N-terminus, the C terminus of S is supposed to be located in the ER lumen, 
which is topologically equivalent to the VP and SVP surface. Therefore, the 
fused fluorescent protein, either GFP or RFP, is as well suggested to be placed 
at the surface of VPs and SVPs (Fig. 20c; S-GFP, S-RFP). For the generation 
of fluorescent M proteins carrying GFP or RFP at the C terminus (M-GFP;           
M-RFP), the preS2 region was introduced between CMV promoter and S of the 
plasmids S-GFP and S-RFP, respectively. The location of the fluorescent part of 
the fusion proteins was not changed by this modification. To abolish expression 
of S-GFP or S-RFP from these plasmids, the start codons of S were exchanged 
from ATG to ACG (Fig. 20d). The fusion proteins L-GFP and L-RFP were 
generated by introducing the preS1 sequence in front of the preS2 region of the 
plasmids M-GFP and M-RFP, respectively (Fig. 20e). Thereby, the translation 
initiation codons of M and S were replaced by ACGs. Therefore, only the L 
fusion proteins should be expressed from these plasmids. The correct 
introduction of the ACGs was controlled by sequencing of the generated 
plasmids.  
 
 
3.1.2 Fluorescence and stability of GFP- and RFP-fused HBV surface 
proteins.  
 
In a first step it was elucidated whether the fusion of GFP or RFP to the HBV 
surface proteins resulted in a fluorescent fusion protein. Therefore, S-GFP,   
GFP-S and GFP-sp-S were transiently transfected into HuH7 cells and fixed 
with 4% PFA 24 h later. After Dapi staining of the nuclei the cells were analysed 
using confocal fluorescence microscopy (FluoView1000, Olympus). Comparing 
S-GFP (Fig. 21a) with GFP-S (Fig. 21b), it becomes obvious that the fusion site 
had an impact on the protein formation. In case of S-GFP, the GFP was fused 
to the C terminus of S. This gave rise to a higher fluorescence compared to 
GFP-S, which carries the GFP at the N terminus of S. The introduction of the 
glycine spacer between GFP and S in the fusion protein GFP-S, which led to 
the new protein GFP-sp-S, did only slightly improve the fluorescence of the 
fusion protein (Fig. 21c).    
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Fig. 21: Confocal fluorescence microscopy of HuH7 cells transfected with a) S-GFP,          
b) GFP-S or c) GFP-sp-S.  
 
Western blotting and detection with a polyclonal anti-GFP antibody (rαcoreGFP, 
in-house production) of cellular lysates reveals that S-GFP transfected HuH7 
cells expressed an approx. 52 kDa protein which likely displays the fusion 
protein (Fig. 22). The 30 kDa band is most probably a fusion protein fragment, 
because solitary GFP, which could theoretically be expressed in low amount 
from the internal translation initiation site of the GFP gene, has a size of 28 kDa. 
 
 
Fig. 22: Western blotting of lysates of S-GFP or GFP-S transfected HuH7 cells. 
 
Conversely, in cells transfected with GFP-S, only two weak bands of approx.     
40 kDa and 80 kDa were detected, although the same amount of plasmid was 
transfected and similar protein amounts were loaded on the gel. Both protein 
bands neither corresponded to the intact fusion protein nor to solitary GFP. This 
implies rapid degradation of the GFP-S fusion protein, which would also explain 
the low fluorescence of the fusion protein in the fluorescence microscopic 
analysis. Another possibility is that translation of GFP-S was incomplete due to 
misfolding of the protein during the translation process. The 80 kDa band may 
indicate the formation of aggregates.  
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Because the N-terminal fusion of GFP to S seemed not suitable for the 
formation of a fluorescent fusion protein, the fusion of GFP to the middle (M) 
and large (L) surface proteins was executed only at the C terminus of the 
surface proteins. Protein expression of M-GFP and L-GFP was examined using 
confocal fluorescence microscopy as described. The results are presented in 
fig. 23. Comparable to S-GFP, M-GFP and L-GFP were brightly fluorescent, 
with the fluorescence distributed in cytosol and nuclei.   
 
 
Fig. 23: Confocal fluorescence microscopy of HuH7 transfected with a) M-GFP or              
b) L-GFP.  
 
The localisation of the fluorescence indicates either that GFP was expressed 
not only in the context of the fusion protein but also from its own internal 
translation initiation site, or that the fusion protein was instable.  
In order to further investigate the stability of the GFP fusion proteins, Western 
blotting of cellular lysates with a polyclonal antibody against GFP (rαcoreGFP, 
in-house production) and a polyclonal antibody recognising all HBV surface 
proteins (gαHBsAg, Abbott) was performed (Fig. 24). GFP transfected cells 
(GFP) and S transfected cells (S) served as the respective positive controls, 
untreated HuH7 cells (HuH-) were added as negative control. To be able to 
examine whether the presence of parental protein has an impact on the stability 
of the fusion proteins, these were transfected either alone or together with S. 
The same blot was first stained with the antibody against the HBV surface 
proteins, and after stripping analysed with the antibody against GFP.  
The faint 55 kDa band visible in the negative control (HuH-) is unspecific and 
present in all samples independent of the detection antibody. The GFP control 
sample (GFP) was negative after using the gαHBsAg antibody, but after 
incubation with the antibody directed against GFP, two protein bands were 
detected. The 28 kDa band stemmed from monomeric GFP. The presence of 
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the additional, approx. 55 kDa protein speaks for dimerisation of GFP, leading 
to 56 kDa GFP dimers. These are formed by wild type GFP in addition to the 
monomers. The S transfected control cells (S) expressed a 17 kDa band 
detected with gαHBsAg antibody. This band is a product of an internal 
translation initiation ATG within the S gene, and present in all samples            
co-transfected with S (S-GFP/S, M-GFP/S, L-GFP/S).     
 
 
Fig. 24: Western blot analysis of HuH7 cell lysates after transfection with GFP fusion 
proteins.   
 
In S-GFP transfected and S-GFP/S co-transfected cells a band of approx.       
52 kDa was detected with both the αHBs and the αGFP antibody and therefore 
most probably represents the fusion protein. A glycosylated form was not 
detected. The approx. 28 kDa band visible in the GFP blot represents solitary 
GFP. Bands of approx. 100 kDa and 130 kDa and a band of unknown size 
larger than 130 kDa were detected after co-transfection of SGFP and S. These 
bands might be protein oligomers. In the GFP blot of the S-GFP/S                   
co-transfected cells an approx. 24 kDa was detected in addition to the 28 kDa 
band present in both the S-GFP transfected cells and the S-GFP co-transfected 
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cells. The same band is visible in L-GFP and L-GFP/S transfected cells and 
presumably represents incomplete translated GFP or GFP fragment.  
Despite the fact that fluorescence microscopy analysis clearly demonstrated the 
expression of a fluorescent protein (Fig. 23a), the M-GFP fusion protein could 
not be detected by Western blotting. This was independent of co-transfection of 
S (M-GFP/S). As is the situation for the S-GFP and SGFP/S samples, the faint 
band of approx. 27 kDa hints at the low expression of solitary GFP. 
The approx. 72 kDa protein present in the cells after transfection of L-GFP and 
L-GFP/S was detected with both the αHBsAg and the αGFP antibody and 
corresponds to the fusion protein. The 52 kDa band present in both blots might 
be due to S-GFP expression from the L-GFP plasmid, or a degradation product. 
With the anti GFP antibody an additional 24 kDa protein was detected. This is 
possibly incompletely translated GFP, as well as the two bands of approx.       
17 kDa and 20 kDa detected only with the anti GFP antibody. The bands of 
approx. 100 kDa and 130 kDa and the large band of unknown size present in 
the S-GFP/S, L-GFP and L-GFP/S samples indicated the formation of 
oligomers.  
 
In order to obtain a red variant of the fluorescent surface proteins, RFP was 
fused to the C terminus of S, M and L. The expression of the fusion proteins 
was analysed as described before. All proteins were brightly fluorescent, with 
the fluorescence signal detectable predominantly in the cytosol, and little or no 
nuclear localisation (Fig. 25).  
 
 
Fig. 25: Confocal fluorescence microscopy of HuH7 cells transfected with RFP fusion 
plasmids. 
 
To confirm that the RFP fusion proteins are stable, a Western blot analysis was 
performed using a polyclonal antibody against all HBV surface proteins 
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(gαHBsAg, Abbott; Fig. 26). Due to the lack of an anti-RFP antibody, a parallel 
control for RFP expression could not be performed.  
As described also for the Western blot of the GFP fusion proteins, an unspecific   
55 kDa protein is visible in all samples. In addition, a second unspecific protein 
of approx. 33 kDa was detected. In cells expressing only S, the approx. 50 kDa 
band corresponded to S dimers. The disulphide bridges, which cross-link the 
dimers are often not completely destroyed by the denaturing conditions of the 
Western blot procedure. The unglycosylated and the glycosylated monomers 
were detected as 24 kDa and 27 kDa bands. Transfection of S-RFP led to the 
expression of a 52 kDa protein, likely representing S-RFP. Additionally, a 
double band of 24 kDa and 27 kDa indicates that solitary S was also expressed 
in both the unglycosylated and the glycosylated form. Alternatively, these bands 
may represent N-terminal proteolytic fragments of the fusion protein.  
 
 
Fig. 26: Western blot analysis of HuH7 cell lysates after transfection with RFP fusion 
proteins.   
 
Upon co-transfection of S-RFP and S, more S was built, as indicated by the 
strong 24 kDa and 27 kDa bands. Furthermore, an approx. 50 kDa band 
corresponding to the size of S dimers was present. As described before for      
M-GFP, in cells transfected with M-RFP the protein detection with an antibody 
against HBs was not possible, although a bright fluorescent protein was 
previously seen in fluorescence microscopy. This fluorescent protein did not 
exhibit the characteristic distribution of RFP, implying that the fluorescence was 
not due to expression of solitary RFP. However, only a faint 52 kDa protein was 
detected, which likely resulted from S-RFP expression from the M-RFP plasmid. 
If S was co-transfected, an approx. 50 kDa band indicated the presence of      
S-RFP or S dimers. However, S monomers were not present in a detectable 
amount in M-RFP/S transfected cells.   
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After transfection with L-RFP or L-RFP/S, the cells expressed a 72 kDa protein 
which likely corresponded to the fusion protein. Furthermore, a 52 kDa band 
was found, which might display S-RFP. Weak 24 and 27 kDa bands likely 
corresponded to the unglycosylated and glycosylated forms of S. If S was       
co-transfected to L-RFP, a double band of approx. 50 kDa was detected, which 
most likely stemmed from S dimers.       
 
To gain information on whether the fluorescence signal in cytosol and nucleus 
derives from the fusion proteins or from solitary GFP or RFP, cells transiently 
transfected with S-GFP or S-RFP were stained with a polyclonal antibody 
(rαHBvax, in-house production) against S and a secondary antibody coupled to 
Alexa 564 (gαr Alexa Fluor 564, Invitrogen) in case of S-GFP transfected cells.  
 
 
Fig. 27: Co-localisation analysis of S-GFP and S-RFP with an anti-S antibody.  
Confocal fluorescence microscopy of HuH7 cells transfected with a) S-GFP or b) S-RFP and 
stained for S protein.  
 
To investigate co-localisation of RFP with S, a secondary antibody coupled to 
Alexa 488 (gαr Alexa Fluor 488, Invitrogen) was chosen to visualise S. The 
staining should co-localise with the fluorescence derived from the fusion 
proteins, if these are intact. Analyses were performed using a laser scanning 
confocal microscope (FluoView1000, Olympus). With help of the co-localisation 
tool of the microscope software (CellP, Analysis GmbH), areas not positive for 
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both red and green signals at the same spot were extracted from the               
co-localising pixels. The latter display the areas in which the analysed proteins 
co-localise. The results are provided in fig. 27. Visualisation of the co-localising 
pixels revealed that only little green fluorescent signal in the cytosol was 
positive for both GFP and S (Fig. 27a, co-localising pixels). This implies that the 
green fluorescence in the nucleus and in parts as well in the cytosol of the       
S-GFP transfected cells was not due to the presence of intact fusion protein, but 
mostly caused by solitary GFP or fusion-protein fragments. This is consistent 
with the fact that the observed distribution of the fluorescence is characteristic 
for GFP but not for trans-membrane proteins such as the HBV surface proteins. 
On the contrary, most of the red fluorescence signals seen after S-RFP 
transfection appeared to stem from intact fusion protein. Most pixels were 
positive for red and green fluorescence, indicating the presence of both RFP 
and S at the same locus (Fig. 27b, co-localising pixels).       
In summary, the C-terminal fusion of GFP and RFP to the HBV surface proteins 
resulted in fluorescent proteins. In contrast to the RFP fusion proteins, most of 
the fluorescence of the GFP fusion proteins did not originate from the fusion 
proteins and was located in cytosol and nuclei. Western blotting of the S and    
L fusion proteins revealed that not only the fusion protein was present in the 
cells but also smaller protein fragments.  
 
 
3.1.3 Localisation of GFP- and RFP-fused HBV surface proteins. 
 
To gain information on the distribution of the fusion proteins in cells, their 
localisation in cellular compartments was investigated. Since the GFP fusion 
proteins appeared at least partially unstable in Western blot analysis and 
immuno-fluorescence data revealed that the fluorescence did mostly not 
originate from the fusion protein but rather from solitary GFP or fusion protein 
fragments, the following experiment concentrated on the RFP fusion proteins. 
The HBV surface proteins traverse from the ER into the golgi. Therefore, a 
localisation in these compartments could as well be expected for the fusion 
proteins, presuming that they still behave as their HBV parental counterparts. 
Co-localisation analyses were performed using a laser scanning confocal 
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microscope (FluoView1000, Olympus) as described in 3.1.2. HuH7 cells 
transfected with a plasmid encoding S (pCH S An-b-glob) were used as positive 
control. Due to the lack of anti-M and anti-L antibodies suitable for immuno-
fluorescence staining, these wild type controls could not be performed. To 
exclude that RFP per se is located in the ER, RFP (pCH RFP An-b-glob) 
transfected cells were analysed. The cells were fixed with 4% PFA and stained 
24 h post transfection with a monoclonal antibody for the ER membrane protein 
calnexin (mαcalnexin, Santa Cruz Biotech). A secondary antibody coupled to 
Alexa Fluor 488 (gαm Alexa Fluor 488, Invitrogen) visualised the ER.  
 
 
Fig. 28: Co-localisation analysis of S and RFP with the ER marker calnexin.  
Confocal fluorescence microscopy of HuH7 cells transfected with a) S or b) RFP. The right 
panel (co-localising pixels) shows the pixels positive for green and red fluorescence.  
 
S was stained with a polyclonal antibody against the HBV vaccine (rαHBvax,   
in-house production) and an Alexa Fluor 568 coupled secondary antibody      
(gαr Alexa Fluor 568, Invitrogen). S appeared to partially localise in the 
perinuclear region of the ER (Fig. 28a). On the contrary, RFP was mostly 
present in the nuclei with only low amounts in the cytosol. Fig. 28b 
demonstrates that RFP was not distributed in the ER, since no co-localising 
areas were detected. 
The next step was to clarify whether the fusion proteins were partially 
distributed in the ER and whether the presence of other HBV proteins 
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influenced their localisation. The S-RFP encoding plasmid was transfected into 
HuH7 cells either alone (S-RFP, Fig. 29a) or together with equal amounts of                   
pCH S An-b-glob encoding S (S-RFP/S, Fig. 29b).  
 
 
Fig. 29: Co-localisation analysis of RFP fusion proteins with the ER marker calnexin.  
Confocal fluorescence microscopy of HuH7 cells transfected with a) S-RFP, b) S-RFP plus S,  
c) M-RFP, d) L-RFP or e) L-RFP plus HBV L-. The right panel (co-localising pixels) shows the 
pixels positive for both green and red fluorescence.  
 
In both cases pixels with co-localising red and green fluorescence could be 
detected, demonstrating a partial localisation of the S-RFP fusion protein in the 
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ER. The presence of S did not influence this distribution. The investigation of   
M-RFP proves that this protein was as well partially distributed in the ER       
(Fig. 29c). L-RFP also showed a partial co-localisation with the ER, independent 
of the presence or absence of the other HBV proteins, provided by the            
co-transfected plasmid HBV L-. This plasmid encodes all HBV proteins except 
for L (Fig. 29d, 29e).  
The HBV surface proteins are known to oligomerise and bud into the ER as 
spherical or filamentous SVPs, and, in presence of the other HBV proteins, as 
well as VPs. From the ER the particles are transported to the golgi, before they 
are exocytosed. Therefore, in the following co-localisation with the golgi marker 
golgi matrix protein 130 (GM130) was investigated. A monoclonal antibody 
against GM130 (mαGM130, BD Pharmingen) was used together with an Alexa 
Fluor 488 coupled secondary antibody (gαm Alexa Fluor 488, Invitrogen) to 
stain the golgi apparatus.  
 
 
Fig. 30: Co-localisation analysis of S and RFP with the golgi marker GM130.  
Confocal fluorescence microscopy of HuH7 cells transfected with a) S or b) RFP. The right 
panel (co-localising pixels) shows the pixels positive for green and red fluorescence.  
 
As positive control, S was transfected into HuH7 cells and stained after 48 h 
with the aforementioned antibodies directed against S and GM130, respectively. 
To exclude that RFP per se localises within the golgi, RFP transfected cells 
were analysed in parallel. 
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Fig. 30 depicts the results of the control stains. S was present in the whole cell, 
with a clear distribution in the golgi. RFP could be seen predominantly in the 
nucleus, but as well in the cytosol. It did not co-localise with the golgi marker 
GM130.  
 
 
Fig. 31: Co-localisation analysis of RFP fusion proteins with the golgi marker GM130.  
Confocal fluorescence microscopy of HuH7 cells transfected with a) S-RFP, b) S-RFP plus S,  
c) M-RFP, d) L-RFP or e) L-RFP plus HBV L-. The right panel (co-localising pixels) shows the 
pixels positive for green and red fluorescence.    
 
For S-RFP and S-RFP co-transfected with S, a localisation in the golgi could be 
demonstrated (Fig. 31a and b). A difference in the distribution due to the 
                                                                                                                 Results II 
 76
presence of S was not observed. M-RFP also exhibited a clear localisation in 
the golgi (Fig. 31c). The analysis of L-RFP and L-RFP co-transfected with the 
plasmid pCH HBV L- revealed that the presence of the other HBV proteins did 
not influence the partial localisation of L-RFP in the golgi (Fig. 31d and e).  
In summary, all RFP-fused HBV envelope proteins partially co-localised with the 
ER marker calnexin and with the golgi marker GM130, resembling the 
behaviour of the wild type S protein. The distribution was unaffected by           
co-transfection of wt S in case of S-RFP or HBV L- in case of L-RFP.    
 
 
3.1.4 Formation of SVP containing GFP- or RFP-fused HBV surface 
proteins. 
 
SVPs are present in vast amount in the blood of HBV infected persons. In cell 
culture infection or transfection experiments, SVPs are secreted in 100- to       
10000-fold excess to VPs. They can be produced solely from S, which harbours 
the self assembly properties necessary for SVP formation. To investigate 
whether the S fusion proteins still exhibit this characteristic, supernatants of 
cells transfected either with S-RFP or S-GFP alone or together with equal 
vector amounts for S expression were collected after four days. Fluorescence 
microscopy analysis previously confirmed that the transfected cells expressed 
the fluorescent proteins. The supernatants of untransfected cells served as 
negative control   (Fig. 32; HuH). As positive controls, the supernatant of cells 
transfected only with the parental S protein (Fig. 32, S) or with a plasmid 
encoding all HBV proteins and able to initiate HBV replication (Fig. 32, HBV1.1) 
was used. To isolate the SVPs from the supernatants, an immuno-precipitation 
(IP) was performed using sepharose G beads and a polyclonal antibody 
(rαHBvax, in-house production) directed against S. The precipitate was 
analysed by Western blot using another polyclonal antibody (gαHBsAg, Abbott) 
directly coupled to horseradish peroxidase. As depicted in fig. 32, cells 
transfected with HBV1.1 (left panel) secreted a high amount of SVPs containing 
all types of HBV envelope proteins in their different glycosylation forms. Cells 
transfected with S (right panel) secreted SVPs consisting of both unglycosylated 
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and glycosylated S. The transfection of S-GFP and S-RFP did not give rise to a 
detectable amount of SVPs in the supernatant. 
 
Fig. 32: Western blot analysis of cell supernatant immuno-precipitates for the presence 
of SVPs after transfection with S-GFP or S-RFP.  
 
Only if the parental S protein was co-transfected with S-GFP and S-RFP, weak 
bands revealed that small amounts of SVPs were present in the supernatants. 
These SVPs did not contain any S-GFP or S-RFP, as the detected protein 
bands had the size of the wild type S.  
This experiment shows that the S fusion proteins were not capable of SVP 
formation. 
 
 
3.1.5 Formation of VPs containing RFP-fused HBV surface proteins. 
 
Although the inability to form SVPs implies that particle formation in general was 
impaired, it was investigated whether the fluorescent HBV envelope fusion 
proteins were capable of progeny virus production. Therefore, HuH7 cells were 
transiently co-transfected with HBV1.1 and the fusion proteins in different ratios. 
Four days post transfection, the supernatant was concentrated using centrifugal 
devices, and transferred to caesium chloride density ultracentrifugation. This 
allows the separation of free HBV DNA, DNA-containing capsids and intact 
enveloped virions by their sedimentation in different density fractions. The 
collected density fractions were dot blotted on a nylon membrane and 
hybridised with a 32P-labelled HBV DNA probe. Fig. 33 depicts an example for 
the virus production in cells transfected with 1 part S-RFP DNA plus 1, 10 or 
100 parts HBV1.1 DNA. In the supernatant of the positive control, HuH7 cells 
transfected with plasmid HBV1.1, viral DNA was detected, as well as low 
amounts of DNA-containing unenveloped capsids, and virions (Fig. 33, 
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HBV1.1). Conversely, if fusion construct plasmids were co-transfected with 
HBV1.1, the capability of virus formation appeared to be impaired. Only HBV 
DNA, but no DNA-containing capsids and intact virions were detected. The 
same held true, if the DNA ratios for the transfection were changed, for example 
to a 10:1 or 100:1 ratio of fusion construct DNA to wtHBV DNA or if M-RFP or  
L-RFP were co-transfected to wtHBV DNA. Only in rare cases traces of DNA-
containing capsids and virions could be detected. If the supernatant of cells    
co-transfected with fusion construct DNA and wtHBV DNA was concentrated 
and transferred to PHHs, no infection of PHHs could be detected. This indicates 
that even if small amounts of virus were produced in the HuH7 cells after 
transfection, this virus was not infectious or the amount was too minor to initiate 
infection in PHHs. Possibly, the fusion proteins even impair virus maturation.  
 
 
Fig. 33: Dot Blot analysis of supernatants of HuH7 cells co-transfected with fusion 
protein DNA and wtHBV DNA. S-RFP and wt HBV were co-transfected into HuH7 cells in a 
ratio of 1 part fusion protein DNA and 1 (1:1), 10 (1:10) or 100 (1:100) parts HBV DNA. HuH7 
cells transfected with the HBV encoding plasmid (HBV) served as positive control.   
 
In summary, different GFP and RFP fused HBV surface proteins were 
generated. The N-terminal fusion of GFP did not give rise to a strong 
fluorescent protein. The C-terminal fusion of GFP and RFP resulted in 
fluorescent proteins well detectable in fluorescence microscopy. In contrast to 
the RFP fusion protein however, most of the fluorescence detected in GFP 
fusion protein transfected cells did not originate from the fusion proteins but 
rather from solitary GFP or protein fragments. RFP fusion proteins partially 
localised in the ER and golgi, as observed for the parental HBV surface 
proteins. However, they were not capable of SVP or VP formation, and even 
impaired the capacity of the parental surface proteins co-expressed.       
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3.2 Discussion II 
 
Fluorescent labelling of viral proteins and viruses, or virus-like particles, has 
been shown to provide a powerful tool for investigating unexplored aspects in 
viral life cycles. A commonly used technique is the genetic incorporation of 
fluorophores into virus proteins. The insertion of GFP into the Gag protein of 
HIV for instance allowed studying the trafficking of this protein, as well as 
production of infectious virions (Müller et al., 2004). In case of adeno-associated 
virus, Lux et al. (2005) were able to directly monitor the cytosolic and nuclear 
trafficking with GFP-tagged virus particles.  
Since many aspects of the HBV life cycle still remain unclear, the visualisation 
of viral (VP) and subviral (SVP) HBV particles is a promising approach to 
elucidate different steps of virus entry and egress. It has already been reported 
by Lambert et al. (2004) that the fusion of GFP at the N but not the C terminus 
of S gave rise to a fluorescent fusion protein, which was incorporated into 
envelopes and secreted as fluorescent subviral and viral particles. It was 
described that the fluorescent virions were able to attach to liver cells, indicating 
that the fusion of GFP to the HBV surface protein is a promising approach. 
Therefore, GFP or RFP fused HBV surface proteins were constructed and 
analysed for their fluorescence and stability properties. To assay whether the 
fusion altered the characteristic properties of the HBV surface proteins, they 
were compared to the parental proteins with regard to their localisation in 
cellular compartments and the ability to form subviral and viral particles. In 
contrast however to the above mentioned study (Lambert et al., 2004), the GFP 
fused proteins did not co-localise with the parental proteins within the cell, 
suggesting a change in the protein characteristics. The RFP fusion proteins 
clearly co-localised with the parental proteins. But although they behaved 
similar to the parental proteins with regard to their distribution in the ER and 
golgi compartment, neither of them contributed to the formation of SVP or VP.   
Thus, the GFP and RFP fusion to HBV surface proteins characterised in this 
work were not suitable to generate fluorescent HBV particles. The main 
impediment was most probably misfolding of the fusion proteins. The bulky GFP 
and RFP domains seem to have topological and sterical effects, affecting 
stability, correct integration into the ER membrane or assembly and secretion of 
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properly formed particles. Labelling with small fluorescent molecules can 
minimise or overcome these problems and therefore perhaps provides a better 
strategy. 
 
 
3.2.1 N-terminal fusion of GFP to the small HBV surface protein.  
 
In order to test whether the constructed GFP and RFP fusion proteins were 
fluorescent, they were transiently transfected into HuH7 cells and the 
fluorescence was monitored by confocal fluorescence microscopy. S-GFP could 
clearly be detected in the cells as a bright fluorescence distributed in the cytosol 
and nucleus. In contrast, constructs carrying the GFP at the N terminus of S, 
designated GFP-S and GFP-sp-S, were hardly detectable. To elucidate whether 
this was due to protein instability or whether the fusion protein was stably 
expressed but only weakly fluorescent, the constructs were compared in 
Western blot analysis. While S-GFP was expressed, GFP-S was not detected 
as intact protein. Although comparable amounts of DNA and total protein were 
used for transfection and Western blotting, respectively, only very low amounts 
of a protein fragment reacting with the anti-HBs antibody were detectable. From 
this, it can be inferred that the N-terminal fusion of GFP to S led to an unstable 
protein, which was degraded in the cells. It has already been shown that the     
N terminus of S is very sensitive to alterations (Eble et al., 1986 and 1987; 
Bruss and Ganem, 1991): Upon addition of a 100 aa sequence derived from 
alpha globin, the correct translocation of the N terminus into the ER was 
impaired. However, this mutant was still integrated in the ER membrane and 
entered the secretory pathway, as shown by the detection of a glycosylated and 
an unglycosylated form of this mutant (Bruss and Ganem, 1991). In case of 
GFP-S, not only 100 aa but rather 238 aa of a bulky protein were fused to the N 
terminus of S. This seemed to have even more deleterious effects: Neither 
could the intact fusion protein be detected in Western blotting, nor was a bright 
fluorescence visible after transfection into HuH7 cells. This hints at rapid 
degradation. Translocation of the N terminus of the surface proteins across the 
ER membrane occurs co-translational and is mediated by a topogenic signalling 
sequence, designated signal 1, at the N terminus of the proteins (Eble et al., 
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1987). Upon N-terminal fusion of GFP, this signal sequence is now internal and 
might not any longer be accessible to the interactions with the signal 
recognition particle (SRP) mediating translocation of the ribosome to the ER 
(Rothman and Lodish, 1977; Walter and Blöbel, 1981, Keenan et al., 2001). 
Alternatively, later steps of the translocation process might be impaired, such as 
the binding of the SRP-ribosome complex to the ER translocon. The latter is a 
channel which conducts secretory proteins across the ER membrane and is 
also used by membrane proteins (Rapoport et al., 2004; van den Berg et al., 
2004; von Heijne, 2006). It has been evidenced that the second hydrophobic 
domain of the HBV surface proteins, designated signal 2, is sufficient to 
translocate the C terminus to the ER lumen and anchor the protein in the ER 
membrane. However, without a functional signal 1, the N terminus cannot be 
translocated and remains in the cytosol. This conformation hampers the 
formation of SVPs (Eble et al., 1987; Bruss and Ganem, 1991). In contrast to 
GFP-S, the mutants lacking a functional signal 1 analysed by Bruss and Ganem 
(1991) were stable. This indicates that GFP-S was not integrated into the ER 
membrane. Possibly, the folding of the GFP prevented the membrane 
integration. It has been shown that the folding of sequences N terminal to a 
signal sequence can sterically prevent this (Denzer et al., 1995). Lambert et al. 
(2004) reported the functional incorporation of GFP N-terminally fused to S into 
subviral particles. However, since they did not add an N-terminal signal 
sequence, their data are in contrast to the results presented here as well as by 
others (Bruss and Ganem, 1991). Although it has been published that the N 
terminus of S tolerates the addition of 84 foreign residues, it can be doubted 
that the addition of 238 aa of a bulky protein leads to correct integration into the 
ER membrane (Michel et al., 1988; Prange et al., 1995).  
Assuming that GFP-S was not targeted to the ER membrane, it was translated 
in the cytosol. This would result in a misfolded protein, which is degraded most 
probably by the ubiquitin-proteasome system, as described for cytosolic and ER 
import-incompetent proteins (Kostova and Wolf, 2003; Park et al., 2007).  
The introduction of a four aa glycin spacer between GFP and S slightly 
improved the fluorescence of GFP. This may be explained by a facilitative 
folding of the protein, which might have an impact on the degradation time. It 
has recently been reported that one of the multiple types of proteasomes, the 
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26S proteasome, is not capable of unfolding the compactly folded GFP moiety 
of some fusion proteins (Liu et al., 2003).  
One possibility to overcome the wrong localisation of GFP-S might be the fusion 
of an additional ER localisation sequence at the very N terminus, in front of the 
GFP. This would probably restore the membrane topology, as described by 
Bruss and Ganem (1991) for the above mentioned S fusion protein carrying 
sequences from alpha globin at its N terminus. After fusion of a signal sequence 
to the N terminus this protein was not only synthesised into the ER membrane 
in the correct topology, but was also competent to form secreted SVPs.                 
 
 
3.2.2 C-terminal fusion of GFP and RFP to the HBV surface proteins.  
 
3.2.2.1 The GFP fusion proteins S-GFP, M-GFP and L-GFP. 
 
The C-terminal fusion of GFP or RFP to the HBV surface proteins S, M and L 
resulted in brightly fluorescent proteins, as shown by confocal immuno-
fluorescence analyses. However, in case of the GFP fusion proteins the 
fluorescence was distributed in the cytosol as well as nucleus. The                  
co-localisation study performed with S-GFP and S demonstrated that most of 
the cytosolic fluorescence and none of the nuclear fluorescence stemmed from 
the intact fusion proteins. Due to the high signal to noise ratio caused by the 
strong green auto-fluorescence of the HuH7 cells, the degree of co-localisation 
might be higher as the pictures indicate. Nevertheless, the fluorescence in the 
nucleus can only be explained by solitary GFP, which is known to be distributed 
in the cytoplasm and diffuses also into the nucleus (Cubitt et al., 1995; Yang et 
al., 1996). It is unlikely that the fusion of GFP changes the original trans-
membranous localisation pattern of the HBV surface proteins towards a 
cytoplasmic and nuclear distribution (Kahaner et al., 1995; Marshall et al., 1995; 
Yang et al., 1996). Because the translation initiation ATG of GFP has not been 
changed in the GFP fusion constructs, the expression of GFP from these 
plasmids is theoretically possible. However, since the promoter is 226, 281 or 
400 aa distal from the ATG in S-GFP, M-GFP and L-GFP, respectively, and is 
not embedded in a Kozak sequence, this should be a rare event occurring by 
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leaky scanning of the ribosome (Kozak, 1987, 1989 and 1991). That solitary 
GFP was expressed in low amounts from the fusion protein constructs was 
shown by the Western blotting of cellular lysates. However, in case of S-GFP, 
the expression level of the fusion protein was higher than that of GFP, as 
indicated by the difference in band strength. This does not fit together with the 
co-localisation study, which revealed a major presence of solitary GFP. A 
brighter fluorescence of GFP in comparison to S-GFP may contribute to the 
contradictory results: The fluorescence of the fusion protein would be masked 
by the GFP fluorescence and fall under the threshold limit set for the               
co-localisation. In this case, S-GFP would only be stained red, while the green 
fluorescence of the GFP domain would be extracted together with the 
background in the co-localisation analysis. This would explain why, despite the 
low rate of co-localisation, the S staining revealed a well detectable amount of S 
in the cells. Furthermore, solitary S was rarely detected in Western blot analysis 
of lysates of S-GFP transfected cells. This emphasises the hypothesis that      
S-GFP might not be brightly fluorescent.  
It is known that the fluorescence of GFP depends on the correct folding of the 
fluorophore (Ward and Bokman, 1982; Cody et al., 1993). The mechanism 
underlying the cyclisation of the three C-terminal aa involved in fluorophore 
formation is yet unknown (Zacharias and Tsien, 2006). Although many 
examples for brightly fluorescent GFP fusion proteins have been published, 
among them also membrane proteins, it cannot be ruled out that an interaction 
with the HBV surface proteins impairs the proper folding of the imidazolone ring 
which forms the fluorophor (Cubitt et al., 1995; Olsen et al., 1995; Marshall et 
al., 1995; Moores et al., 1996; Yang et al., 1996). Alternatively, the incomplete 
synthesis or degradation of the fusion protein, leading to proteins consisting 
only of S or S carrying a small amount of GFP could be the reason for the 
minimal co-localisation. However, the Western blot results, which did not show 
expression of solitary S or protein fragments, argue against this hypothesis.      
M-GFP, which appeared as a brightly fluorescent protein in the microscopic 
analysis, was not detectable by Western blot under denaturing conditions. One 
can speculate that incomplete denaturation led to a folding which masked the 
epitopes of M and GFP. However, as both the anti HBsAg and the anti GFP 
antibody are polyclonal, this is unlikely, especially because S-GFP and L-GFP, 
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being treated equally and carrying partially the same epitopes, were recognised 
by both antibodies. Only a faint band of 28 kDa revealed low level GFP 
expression from the M-GFP plasmid. Upon sequencing it was ascertained that 
the translation initiation codon of S, was ATG instead of ACG as expected. One 
would therefore assume that S-GFP was also expressed from the M-GFP 
plasmid in low level. However, this was not confirmed by Western blotting. The 
translation initiation site of M is weak in the context of wild type HBV. However, 
the transfer of the translation site into the optimal surrounding of a Kozak 
sequence leads to the strong expression of M and a minor expression of S 
(Sheu and Lo, 1992). As this was performed by construction of the fusion 
protein plasmids, a weak translation initiation could be ruled out. Although it is 
known that M behaves like S with respect to trans-membrane topology and SVP 
formation, differences might exist contributing to the controverse picture 
obtained by Western blotting. Metha et al. (1997) found evidence for different 
glycosylation mechanisms for the different surface proteins, indicating that 
structural differences exist. In spite of many attempts to detect M-GFP in 
Western blot by using higher DNA amounts for transfection or different 
antibodies, the result could not be improved.    
Western blot analysis of L-GFP gave rise to a number of bands, indicating that 
not only the fusion protein was expressed from the plasmid. Sequencing of the 
plasmid revealed that the translation initiation ATG of S was present instead of 
ACG. The exchanged translation initiation site of M was unaltered. This 
explained the 52 kDa band detected with the anti HBsAg and anti GFP 
antibodies, which was due to S-GFP expression. A slightly smaller protein, 
which was also detected with both antibodies, might be explained to the 
expression of a smaller transcript from a translation start within S, contributing 
to a protein of approx. 45 kDa. Another possibility is the partial glycosylation of 
S-GFP, which would also explain the double band. However, since S-GFP 
appeared only in one form when expressed from the S-GFP plasmid, this was 
unlikely. The 33 kDa band may have been due to incomplete translation of        
L-GFP or represents a product of incomplete proteolytic degradation. Whether 
the 28 kDa band found in both blots represents the same protein fragment or 
expression of solitary S and solitary GFP cannot be concluded due to 
comparable protein sizes of GFP and S. However, the small proteins in the GFP 
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blot indicate degradation. The presence of the wt S protein did not stabilise the 
GFP fusion proteins, as the same protein fragments were present in the cells 
after co-transfection.  
The results of immuno-fluorescence and Western blot analyses implicate that 
the GFP fusion proteins were at least initially incorporated into a membrane. 
Otherwise, they should rapidly degrade. Many different approaches were used 
in order to confirm this hypothesis. However, the data obtained were 
contradictory, and left this question open.  
Nevertheless, it was tested whether the fusion proteins were capable of subviral 
particle formation. Immuno-precipitation of SVPs from supernatants of 
transfected cells revealed that particle formation was inhibited. The fact that low 
amounts of SVP were built from wild type S upon co-transfection indicated that 
the insertion of GFP resulted in an inablility of the S domain to assemble to 
SVPs. The secretion of wild type SVPs, however, was reduced but not blocked 
by S-GFP. The possible reasons for this effect, which has also been observed 
with S-RFP, are discussed in detail in the next chapter (3.2.2).        
To summarise, the GFP fusion proteins were unstable and dysfunctional with 
regard to SVP formation. This resulted most probably from misfolding or 
incorrect membrane topology. It has been published for different viral proteins 
that the incorporation of GFP can lead to a disruption of viral functions and has 
an impact on replication (Heinzinger et al., 1994; Engelmann et al., 1995; Petit 
et al., 2001). The formation of GFP and possibly also GFP fusion protein dimers 
was indicated by the Western blot results of GFP, S-GFP and L-GFP. It is a 
general problem of the type 1 GFP used for generating the fusion proteins. 
Three N-terminal aa are responsible for dimerisation of Aequorea derived GFP, 
which can occur in living cell at relatively low concentrations (Zacharias and 
Tsien, 2006). Changing the hydrophobic aa to positively charged residues 
inhibits dimerisation by preventing the formation of the hydrophobic contacts 
and hydrophilic interactions responsible for dimer formation (Zacharias et al., 
2002). It is obvious that dimerisation of the GFP part of the fusion proteins, 
which occurs in a head to tail fashion, interferes with the formation of the correct 
topology of the surface proteins and their dimerisation properties necessary for 
particle formation (Wunderlich and Bruss, 1996; Zacharias and Tsien, 2006).  
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Due to the instable expression, the high fluorescence background and the 
inability to secrete SVPs, the GFP fusion proteins were not suitable to trace the 
HBV surface proteins and were therefore not further analysed.  
 
 
3.2.2.2 The RFP fusion proteins S-RFP, M-RFP and L-RFP. 
 
The C-terminal fusion of RFP to the HBV surface proteins S, M and L resulted 
in brightly fluorescent stable proteins with a cytosolic distribution, as shown by 
confocal fluorescence microscopy. This was emphasised by the high degree of 
co-localsation between the RFP and S, proving that RFP was mostly expressed 
fused to S as an intact hybrid protein. However, Western blot analysis revealed 
that unglycosylated and glycosylated S was also expressed from plasmids       
S-RFP and L-RFP. Although M-RFP transfected cells displayed a bright 
fluorescent protein, M-RFP was undetectable by Western blotting. Because the 
fluorescent protein was not distributed in the nucleus, it can be excluded that 
the observed fluorescence derived from RFP expression. Like for M-GFP, 
sequencing of the M-RFP plasmid also revealed that the ATG of S was not 
mutated and gave rise to an additional translation start codon. This explains the 
expression of S-RFP observed in the Western blot of the M-RFP samples. The 
co-transfection of S did not stabilise M-RFP steady state levels. Only S dimers 
were found, monomers were probably present in an amount not detected with 
the anti HBsAg antibody. The reason why M-RFP and also M-GFP could not be 
detected by Western blotting although a fluorescent protein was clearly 
expressed in the cells remained obscure. In case of L-RFP, the corresponding 
band of 72 kDa was present in the transfected cells. Furthermore, they also built 
a protein of approx. 52 kDa. Because the introduced mutations of the M and S 
start codons were still intact, as controlled by sequencing, this might be due to 
protein expression from an internal start codon located within the S gene. The 
internal translation initiation can be observed with wild type S and was 
hypothesised also for L-GFP. Whether the RFP fusion proteins are expressed in 
the different glycosylation forms known for S, M and L cannot be concluded 
from this blot. Due to the lack of an anti RFP antibody recognising the fusion 
proteins, a differentiation between the expression of S-RFP fusion proteins     
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(52 and 55 kDa) and S dimers (48 and 54 kDa), was impossible by this method 
(Lawenza et al., 2006; Sole et al., 2007).        
The HBV surface proteins are synthesised directly at the ER membrane and 
further transported to the golgi, before they are secreted (Ganem and 
Schneider, 2001). Therefore, it was investigated whether the RFP fusion 
proteins co-localised with ER and golgi markers. Confocal fluorescence 
microscopy clearly showed that the RFP fusion proteins were partially localised 
in the ER and golgi, and displayed a pattern comparable to wt S. In contrast, 
RFP was not located in the respective compartments. This strongly supports the 
assumption that the RFP fusion proteins were integrated into the ER membrane 
and further transported to the golgi. A difference in the distribution was not 
observed upon co-transfection of S or HBV L-. However, since the Western blot 
showed the expression of S from the fusion protein plasmids, S was probably 
present also in the cells transfected only with the fusion protein plasmid. Thus, 
an influence of the wt proteins on the fusion protein distribution cannot be ruled 
out.  
The arising question was now whether the RFP fusion proteins, which were 
obviously localised in the ER and further transported to the golgi, were capable 
of particle formation. Immuno-precipitation experiments performed with 
supernatants of S-RFP and S-GFP transfected cells demonstrated that the 
fusion proteins were incapable of SVP formation, independent on the presence 
of wt S: Only moderate amounts of SVPs were secreted after co-transfection of 
S. These SVPs contained only the wild type protein, as shown by Western blot. 
Limitations of the approach due to improper antibody binding to the fusion 
proteins can be excluded. The capture antibody used for precipitation had 
proven to recognise non-denatured S-RFP in the immuno-fluorescence 
experiments. The detection antibody was previously used for the Western blot 
analysis of the fusion proteins. This leads to the conclusion that the S fusion 
proteins lost the self assembly properties of S or that assembled particles could 
not be secreted. The dysfunction of S-RFP and S-GFP did not inhibit the 
assembly and secretion of wild type SVP, which were detected at least in 
moderate amount.  
A reason for the inability to form SVPs is probably an interaction of the bulky 
RFP or GFP domain with the second hydrophilic loop of S, which is located in 
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the ER lumen. This could interfere with the different processing steps necessary 
for assembly and secretion: Firstly, glycosylation might be inhibited for instance 
due to sterical hindrances or general changes in the topology of S. It has been 
shown that the N-linked glycosylation processes, which take place in the ER 
and golgi, are important for proper membrane protein folding and HBV particle 
secretion (Helenius, 1994; Metha et al., 1997). Therefore, an impact on the 
fusion protein folding and the ability to enter the secretory pathway can be 
suggested. Lu et al. (1997) described that in glucosidase-inhibited cells the HBV 
surface proteins were dysfunctional. In contrast however to other glycoproteins, 
they were not rapidly degraded but were found in ER, golgi and lysosomes 
more than 20 h after synthesis (Moore and Spiro, 1993; Kearse et al., 1994). 
The authors suggested that the membrane proteins trafficked in the cells as 
lipoprotein particles rather than as single proteins. This scenario would go 
together with the fact that the fusion proteins co-localised with ER and golgi 
markers. Secondly, dimerisation could be impaired by topological changes or 
sterically masking the cystein residues in the luminal loop of the S domain, 
which crosslink the proteins by building disulfide bridges (Wunderlich and 
Bruss, 1996). Thirdly, the interaction with the chaperones BiP and calnexin in 
the ER lumen, which are known to bind to S and support its maturation, might 
be disturbed by the presence of the large RFP or GFP domain (Xu et al., 1997; 
Cho et al., 2003; Bruss, 2007). Fourthly, the cystein residues located in the 
cytosolic loop between signal 1 and signal 2 seem to be required for subviral 
particle formation, as shown by Wunderlich and Bruss (1996). Although it is 
unlikely that the topology of the cytoplasmic loop was changed upon the fusion, 
an effect on the overall protein structure which could concern also the 
cytoplasmic domain must be considered. A sterical hindrance caused by the 
RFP or GFP domain may also be responsible for the reduced capacity of S to 
form particles. The SVPs are very densely packed structures with a                 
re-organised bilayer structure and low lipid content (Gavilanes et al., 1982; 
Ganem and Schneider, 2001). The mechanisms involved in membrane            
re-organisation and budding are unclear, but one can speculate that a changed 
topology of a certain percentage of S or the presence of large protein domains 
in the ER lumen interfere with these processes (Bruss, 2007). Impairment of the 
different steps of S maturation would result in the retention of the proteins in the 
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membrane. The stuck proteins would most probably be subjected to the 
lysosomal degradation pathway, which is in agreement with the co-localisation 
observed with the ER and golgi markers (Lu et al.1997, Mehta et al., 1997). 
Another possibility is that not particle formation but rather the secretion is 
impaired. Budded SVPs traverse the golgi, where the carbohydrates are 
converted to an endoglycosidase H-resistant form (Patzer et al., 1984). The 
now mature viral and subviral particles are secreted from the cell. As mutational 
analyses performed by Bruss and Ganem (1991) hint at a direct or indirect 
involvement of the C terminus of S in budding or intracellular vesicle transport, 
an impact of the RFP fusion on these later steps of SVP production has to be 
considered.  
It has already been described for other modified S proteins that assembly or 
transport of these proteins was impaired (Delpeyroux et al., 1987; Michel et al., 
1988; Bruss and Ganem, 1991; Prange et al., 1992 and 1995; Netter et al., 
2001; Lambert et al., 2004). The attempts to generate HBV surface protein 
chimera mostly derived from the idea to use the highly immunogenic SVPs as 
carriers for foreign antigens, so as to develop new potent vaccines. The foreign 
sequences were usually introduced into the first or second hydrophilic loop 
rather than at the termini. Delpeyroux et al. (1986) generated SVPs presenting 
the poliovirus neutralisation epitope, which elicited a strong immune response 
against poliovirus in mice. The immune response against HBsAg was only 
minor. Other examples are the creation of an HBsAg vaccine vector presenting 
HCV epitopes or the modification of M and S in order to induce a stronger 
immune response against the preS regions (Prange et al., 1995; Netter et al., 
2001). In the latter case the preS domains were fused to the N- or the               
C terminus of S and M. The fusion of 42 aa to the termini allowed secretion of 
SVPs, whereas the extension of the insert sequence was tolerated only at the N 
terminus. Immune responses were induced by some constructs against the 
introduced sequences, while production of antibodies against S, which 
represents the major immunogenic epitope, was negligible. This demonstrates 
that already the introduction of short sequences derived from the protein itself 
has an impact on the formation and secretion of the SVPs.  
Lambert et al. (2004) reported that the C-terminal fusion of GFP to S resulted in 
a dysfunctional fusion protein. They observed that the fusion protein, which was 
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secretion deficient, acted in a trans-dominant negative manner, inhibiting also 
the wild type S particle export. Inconsistent with this, the data presented here 
showed that the S-GFP fusion protein allowed the secretion of S. Since the ratio 
of fusion construct and S DNA used for co-transfection were the same in both 
experiments, this contradiction is difficult to explain. Lambert et al. (2004) 
suggested that misfolding of the S-GFP fusion protein was the reason for the 
inhibitory effect on the secretion of SVPs containing S-GFP, as well as the 
secretion of wild type SVPs. However, misfolding does not necessarily result in 
an inhibition of S particle formation, as observed in multiple repetitions of this 
experiment with the C-terminal fusion proteins S-GFP and S-RFP.          
Despite the inability to form SVPs, the fusion proteins were also examined for 
the formation of virions. Surprisingly, only very low amounts if any virions were 
secreted after co-transfection of the fusion proteins with wild type HBV. 
Unexpectedly, the presence of the fusion proteins had an inhibitory effect on the 
formation of wild type HBV particles. Since moderate amounts of wild type 
SVPs were secreted after co-transfection of the S fusion proteins with S, the 
secretion of VPs was also expected. Fluorescence of the cells confirmed 
successful transfection. Although the experiment was repeated several times 
with the different fusion proteins and different DNA ratios of fusion construct and 
wild type HBV, the results remained the same. This implies very drastic effects 
of the fused RFP domain on the process of VP formation. The aforementioned 
processes important for SVP formation also play a role in VP formation. In 
contrast to SVP formation however, which only requires S, the virion formation 
is more complex. At least two proteins, S and L have to be integrated in a 
certain ratio and order. M has been reported to be not required (Bruss and 
Ganem, 1991; Fernholz et al., 1991; Ueda et al., 1991). Furthermore, a correct 
topology of the surface proteins might be prerequisite for capsid binding to L. It 
can be hypothesised that the RFP fusion domain interferes with the correct 
arrangement of the surface proteins and the cellular lipids. Whether the lack of 
virion secretion was due to a block in the assembly steps, such as surface 
protein dimerisation and the interaction between surface proteins and core 
protein, or secretion has to be further analysed. However, since the constructed 
fusion proteins obviously were not capable of SVP and VP formation and the 
function could not be restored by the addition of wild type proteins, this was not 
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a successful strategy to generate fluorescent surface proteins. Firstly, the 
trafficking of these fusion proteins most probably does not mirror the behaviour 
of the wild type counterparts, and can therefore not be transferred to the 
situation of an HBV infection. Secondly, fluorescent SVPs and virions, which are 
desired to follow virus assembly and egress, were not formed.  
 
 
3.2.3 Perspective 
 
GFP or RFP fused HBV surface proteins were constructed with the aim to 
visualise trafficking of HBV surface proteins and assembly of viral particles in 
cells. Furthermore, the generation of fluorescent HBV subviral and viral particles 
was intended. This was hampered by the instability of the fusion proteins and 
the inability to form SVPs and VPs. This may be due to misfolding or sterical 
hindrance of protein-protein interactions by GFP or RFP, affecting correct 
integration into the ER membrane or the capability to build properly formed 
particles. The difference between GFP and RFP fusion proteins with regard to 
protein stability is surprising, because both are globular proteins of similar size. 
Possibly differences in their overall folding can explain this phenomenon. 
However, since the three dimensional structure of the monomeric form of RFP 
has not yet been elucidated, this remains speculative.  
The results presented in this study implicate that the addition of bulky 
sequences impairs the HBV surface protein structure and functionality. 
Therefore, this approach is not useful to visualise the different steps of HBV 
infection. The introduction of GFP or RFP changed the characteristics of the 
surface proteins in a way that they did not resemble the wild type proteins any 
more. Thus, the results obtained with the fusion surface proteins could not be 
transferred on the wild type surface proteins.  
The labelling with small fluorescent molecules may represent an alternative 
strategy. The recently developed tetracystein tag technology is especially 
promising. In this approach advantage is taken from the features of a non-
fluorescent, bisarsenic derivate of fluorescein, named FlAsH (Griffin et al., 1998; 
Martin et al., 2005). Besides the green fluorescent FlAsH, a red variant is 
available, designated ReAsH. The membrane-permeable reagent specifically 
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binds a tetracystein tag consisting of six aa integrated into the protein of choice. 
Since the tag is very small, the risc of an interference with wild type protein 
structures or activity is minimised. Upon covalent binding to the tag, the FlAsH 
is converted into a highly fluorescent form. First publications already provided 
promising results in elucidating the different steps of HIV trafficking in cells 
(Arhel et al., 2006; Turville et al., 2008). The incorporation of the tetracystein tag 
into the HBV surface proteins would most probably not influence the proteins, 
as it has been shown for the termini as well as for the hydrophilic loop, that 
small insertions are tolerated (Delpeyroux, 1986; Michel et al., 1988; Prange et 
al., 1995). This would allow tracking de novo-produced proteins, SVPs and VPs 
and probably as well virus production. Furthermore, labelling of the core or 
polymerase protein might also be possible, permitting for the specific monitoring 
of virions.  
The covalent binding of amino-reactive dyes represents an alternative method 
of virus labelling. However, as the dyes unspecifically incorporate into 
membranes by binding to amines, this approach is only useful for the labelling 
of purified SVPs and VPs. These can then be used to study the early steps of 
infection, such as virus uptake.     
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4. Material and Methods 
 
4.1 Material  
All solutions were prepared with deionised water from the Ultra Pure Water 
System Easy Pure UV/UF (Werner Reinstwassersysteme, Wilhelm Werner GmbH, 
Leverkusen, Germany).  
 
4.1.1 Chemicals 
Acidic acid     Roth, Karlsruhe, Germany 
Acryl amide     Sigma, Deisenhofen, Germany 
Agarose SeaKem LE   Cambrex Bio Science, Rockland, USA 
Ammonium acetate    Merck, Darmstadt, Germany 
Bromphenol blue    Merck, Darmstadt, Germany 
Caesium chloride   Roth, Karlsruhe, Germany 
Collagen      Serva, Heidelberg, Germany 
Developer G153 A + B   Agfa Geveart NV, Mortsel, Belgium 
1,4- Diazabicyclo[2,2,2]octane 98%  Sigma Aldrich Chemie GmbH, Steinheim,    
    (DABCO)   Germany 
4',6-Diamidino-2-phenylindol (DAPI) Molecular Probes, Inc, Eugene, USA 
Ethylenedinitrilotetraacedic acid Roth, Karlsruhe, Germany 
  (EDTA)      
Ethidium bromide    Merck, Darmstadt, Germany 
Ethanol      Roth, Karlsruhe, Germany 
Ficoll     Pan Biotech, Aidenbach, Germany 
Glycerol      Roth, Karlsruhe, Germany 
Hydrochloric acid    Roth, Karlsruhe, Germany 
Isopropanol     Roth, Karlsruhe, Germany 
Methanol      Roth, Karlsruhe, Germany 
Milk powder, low fat   Sigma, Deisenhofen, Germany 
Mowiol 4-88 reagent   Calbiochem, La Jolla, CA, USA   
Paraformaldehyde   Merck, Darmstadt, Germany 
Polybed 812 and epoxy resin  Polysciences, Warrington, PA, USA 
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Ponceau S     Roth, Karlsruhe, Germany 
Potassium     Roth, Karlsruhe, Germany 
Potassium acetate    Merck, Darmstadt, Germany 
Proteinase Inhibitor tablets  Roche Diagnostics, Mannheim, Germany 
Rapid Fixer G354   Agfa Geveart NV, Mortsel, Belgium 
Sodium acetate     Merck, Darmstadt, Germany 
Sodium chloride     Roth, Karlsruhe, Germany 
Sodium dihydrogenphosphate  Roth, Karlsruhe, Germany 
Sodium hydroxide    Roth, Karlsruhe, Germany 
Sucrose      Sigma, Deisenhofen, Germany 
Tetramethylethylendiamine (TEMED) Sigma, Deisenhofen, Germany 
Tris base     Roth, Karlsruhe, Germany 
Triton X-100     Roth, Karlsruhe, Germany 
Tween 20     Roth, Karlsruhe, Germany 
 
4.1.2 Cell culture 
4.1.2.1 Cell lines and primary cells 
HuH7   Human hepatoma cell line 
HepG2.2.15  Stably HBV producing hepatoma cell line (Sells et al., 1987) 
293 Human embryonic kidney cell line, stably producing adenovirus 
E1 Protein, ATCC no. CRL-1573 (Graham et al., 1977) 
PHH   Primary human hepatocytes, isolated from fresh liver specimen 
moDC   Monocyte derived dendritic cells, differentiated from blood  
   monocytes 
mDC   myeloid dendritic cells, isolated from fresh peripheral blood 
pDC   plasmacytoid dendritic cells, isolated from fresh peripheral blood 
 
 
 
 
 
 
  Material and Methods 
 95
4.1.2.2 Media and supplements 
Ampicillin      Sigma, Deisenhofen, Germany 
Collagenase Worthington Biochemical Corporation, 
  Lakewood, NJ, USA 
Dulbeccos MEM     Gibco, BRL, Eggenstein, Germany 
Dimethylsulfoxid (DMSO)   Merck, Darmstadt, Germany 
Ethyleneglycolbis (2-aminoethyl) Roth, Karlsruhe, Germany 
 -tetraacetic acid (EGTA) 
Fetal calf serum (FCS)    Biochrom AG, Berlin, Germany 
Gentamycin     Gibco BRL, Eggenstein, Germany 
Glutamine     Gibco, BRL, Eggenstein, Germany 
Granulocyte-macrophage colony R&D Systems, Wiesbaden, Germany 
  -stimulating factor (GM-CSF) 
HBSS     Gibco BRL, Eggenstein, Germany 
Heparin Liquemin N 25000   Roche, Mannheim, Germany 
HEPES      Gibco BRL, Eggenstein, Germany 
Hydrocortison     Sigma, Deisenhofen, Germany 
Inosine      Serva, Darmstadt, Germany 
Insulin      Serva, Darmstadt, Germany 
Interleukin-4 (IL-4)   R&D Systems, Wiesbaden, Germany 
Lipopolysaccharid (LPS)   Sigma, Deisenhofen, Germany 
   E.coli O26:B6   
Penicillin/ Streptomycin (P/S)  Biochrom AG, Berlin, Germany 
Sodium pyruvate    Gibco BRL, Eggenstein, Germany 
Non essential amino acids (NEAA) Biochrom AG, Berlin, Germany 
Polyethylenglycol (PEG) 6000  Serva Electrophoresis, Heidelberg, Germany 
Prostaglandin E2 (PGE2)  Sigma, Deisenhofen, Germany 
RPMI 1640    Gibco, BRL, Eggenstein, Germany 
Tumor necrosis factor-α (TNF-α) R&D Systems, Wiesbaden, Germany 
Williams Medium E    Gibco, BRL, Eggenstein, Germany 
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4.1.2.2.1 Primary human hepatocytes  
Preperfusion medium    HBSS, Ca/Mg-free  500 ml  
EGTA, 100 mM  2.5 ml  
Heparin, 5000 U/ml  1 ml 
  
Collagenase medium    Williams Medium E  250 ml 
Calcium chloride, 1 M 0.9 ml   
  Gentamycin, 10 mg/ml 2.5 ml  
Collagenase type IV 200 mg 
Wash medium     Williams Med E  500 ml  
      *Glutamine, 200 mM 5.6 ml   
*Glucose, 5%  6 ml  
 *Hepes, 1 M, pH 7.4 11.5 ml   
*P/S, 5000 U/ml  5.6 ml  
  (*Solutions were mixed and stored as premix at –20°C) 
 
PHH medium     Wash medium  500 ml  
Gentamycin, 10 mg/ml 5 ml   
          Hydrocortison             0.5 ml  
      Insulin    0.45 mg  
      DMSO    8.7 ml  
      Inosine, 82.5 mg/ml  2 ml   
 
4.1.2.2.2 Monocytes     
Monocyte medium   VLE RPMI    500 ml 
FCS    10% 
 
4.1.2.2.3 moDC  
Immature moDC medium  VLE RPMI    500 ml 
FCS    10% 
IL-4    10 ng/ml 
GM-CSF   10 ng/ml 
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Mature moDC medium   VLE RPMI   500 ml 
FCS    10% 
IL-4    10 ng/ml 
GM-CSF   10 ng/ml 
LPS    1 µg/ml 
TNF-α   50 ng/ml 
PGE2    50 ng/ml 
 
4.1.2.2.4 HuH7  
Cultivation medium   Dulbeccos MEM  500 ml  
      FCS                      50 ml 
Glutamine, 200 mM     5.5 ml  
 P/S, 5000 U/ml     5.5 ml   
NEAA, 100 x      5.5 ml   
 
Freezing medium    Dulbeccos MEM  500 ml  
      FCS                      20% 
      DMSO     10%  
 
4.1.2.2.5 HepG2.2.15  
Cultivation medium   Dulbeccos MEM  500 ml  
      FCS                      50 ml 
Glutamine, 200 mM     5.5 ml  
 P/S, 5000 U/ml     5.5 ml   
NEAA, 100 x      5.5 ml 
 
Virus production medium  PHH medium  250 ml 
Williams E medium  250 ml  
 FCS                      25 ml 
Glutamine, 200 mM     2.5 ml  
 P/S, 5000 U/ml     2.5 ml   
NEAA, 100 x      2.5 ml 
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4.1.2.2.6  293 cells  
Cultivation medium   Dulbeccos MEM  500 ml  
      FCS                      50 ml 
Glutamine, 200 mM     5.5 ml  
 P/S, 5000 U/ml     5.5 ml   
 
 
4.1.3 Bacteria culture 
 
4.1.3.1 Bacteria strains 
DH5α E. coli     Promega, Mannheim, Germany 
XL1blue E. coli     Stratagene, La Jolla, USA 
 
 
4.1.3.2 Media and supplements 
Agar  Becton Dickinson Microbiology Systems,   
          Sparks, USA 
Ampicillin      Sigma, Deisenhofen, Germany 
Geniticin (Neomycin; G418)   Invitrogen, Karlsruhe, Germany 
Sodium chloride     Roth, Karlsruhe, Germany 
Trypton oxide    Hampshire, England 
Yeast extracts   Becton Dickinson Microbiology Systems,   
  Sparks, USA 
 
LB medium, pH 7.0    Antibiotics   50 mg/ml 
      Natrium chloride   5 g/l  
  Yeast extracts   5 g/l  
  Trypton oxide  10 g/l 
 
LB agar  LB medium 
  Agar    15 g/l  
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4.1.4 Buffers and solutions 
 
4.1.4.1 Dot blot 
Denaturation solution    Natrium hydroxid  0.5 M 
      Natrium chloride  1 M 
           
Neutralisation solution   Tris, pH 7.4   0.5 M 
      Natrium chloride  3 M 
     
Hybridization buffer   SSC    6 x 
      Denhardts   5 x 
Salmon sperm DNA 10 µg/ml 
       
Wash buffer    SSC    1 x 
SDS    0.5% 
 
Denhardts solution     Ficoll 400    1% (w/v)   
Polyviynlpyrrolidon   1% (w/v)  
BSA     1% (w/v) 
 
SSC     Natrium chloride  3 M 
      Na3citrat x 2H2O  0.3 M   
  
 
4.1.4.2 Immunofluorescence 
Fixation solution  Paraformaldehyde  3.7%  
      PBS    1 x  
  
Saturation solution   Ammonium chloride 50 mM 
Permeabilisation buffer   Saponin   0.5% 
       PBS    1 x 
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Blocking solution    FCS    10% 
Saponin   0.1% 
PBS    1 x 
Antibody incubation buffer  Saponin   0.1% 
       PBS    1 x 
 
Mounting medium   Mowiol   2.4 g 
      Glycerol   12 g 
      Tris, pH 8.5   0.2 M 
      Dabco   50 mg 
 
 
4.1.4.3 Magnetic cell sorting 
MACS buffer     PBS     1 x 
HSA     0.5%   
  EDTA    2 mM   
                                                           (Degas and store at 4°C) 
 
4.1.4.4 Plasmid preparation, rapid boiling method 
STET buffer    Sucrose   8% (w/v) 
Triton X-100    0.1% (v/v) 
EDTA, pH 8.0  50 mM 
TrisCl, pH 8.0  50 mM 
 
Isopropanol/ Ammonium acetate  Isopropanol, 100%   75 ml 
Ammonuim acetate  19.27 g 
(Fill with ddH2O to 100 ml) 
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4.1.4.5 Western blot 
2 x Sample buffer    Tris HCl, pH 8.8   200 mM 
      EDTA         5 mM 
SDS         3% 
Bromphenol blue       0.1% 
Sucrose      10% 
β-Mercaptoethanol       1.7% 
 
10 x Running buffer, 1l  Glycine   144 g              
   Tris Base       30 g 
   SDS       10 g  
 
5 x Blotting buffer, 1l  Tris Base     15.15 g  
Gycine     72 g          
(Fill with ddH2O) 
 
1 x Usage buffer  Blot buffer   1 x 
     Methanol   1 x 
     H2O    3 x 
Blocking solution    Milk powder, non fat 0.5% 
      PBS    1x 
      Tween 20   0.05%  
 
Resolving gel, 12.5%   Acryl amide, 40%  6.25 ml 
Tris, 1.5 M, pH 8.8  5 ml 
H20    8.55 ml 
SDS, 10%   230 µl 
TEMED     20 µl 
APS, 10%   100 µl 
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Stacking gel, 5%    Acryl amide, 40%  0.375 ml 
Tris, 0.5 M, pH 6.8  1.2 ml 
H20    3.325 ml 
SDS, 10%   50 µl 
TEMED     4 µl 
APS, 10%    50 µl 
1. Antibody incubation buffer  Tween20   0.05% 
      PBS    1 x 
2. Antibody incubation buffer   Tween20   0.05% 
      PBS    1 x 
Milk powder, non fat 0.1% 
Wash buffer    Tween20   0.05 % 
      PBS    1 x 
Stripping buffer    Sodium hydroxide  0.2 M 
 
4.1.5 Antibodies  
4.1.5.1 Flow cytometry 
Mouse anti BDCA-2 (FITC)  Miltenyi, Bergisch Gladbach, Germany 
Mouse anti CD80 PE   BD Pharmingen, San Diego, CA, USA 
Mouse anti CD83  Immunotech, Marseille, France 
Mouse anti CD86   BD Pharmingen, San Diego, CA, USA 
Mouse anti CD123 FITC  Miltenyi, Bergisch Gladbach, Germany 
HLA-DR     BD Pharmingen, San Diego, CA, USA 
Streptavidin (PE)    BD Pharmingen, San Diego, CA, USA 
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4.1.5.2 Immunofluorescence 
 
4.1.5.2.1 Primary antibodies 
Mouse anti Calnexin    Santa Cruz Biotech., Santa Cruz, CA, USA 
Mouse anti Golgi matrix protein 130  BD Pharmingen, San Diego, CA, USA 
 (GM130)     
Goat anti Ras-like GTPase 6 (Rab6) Santa Cruz Biotech., Santa Cruz, CA, USA 
Rabbit anti HBvax  in-house production; polyclonal  
  antibody against the HBV vaccine 
Sheep anti preS1   gift from M. v. Roosmalen, BioMerieux,  
   Rotterdam; polyclonal antibody against the  
    preS1 region of the large surface protein  
 
4.1.5.2.2 Secondary antibodies 
Alexa Fluor 488 F(ab)2 fragment  Invitrogen, Karlsruhe, Germany 
  goat anti mouse IgG (H+L) 
Alexa Fluor 488 F(ab)2 fragment  Invitrogen, Karlsruhe, Germany 
  goat anti rabbit IgG (H+L) 
Alexa Fluor 488 F(ab)2 fragment  Invitrogen, Karlsruhe, Germany 
  rabbit anti goat IgG (H+L) 
Alexa Fluor 568 Invitrogen, Karlsruhe, Germany 
  goat anti mouse IgG (H+L) 
Alexa Fluor 568 F(ab)2 fragment  Invitrogen, Karlsruhe, Germany 
  goat anti rabbit IgG (H+L) 
Alexa Fluor 568   Invitrogen, Karlsruhe, Germany 
  rabbit anti goat IgG (H+L) 
Alexa Fluor 568 Invitrogen, Karlsruhe, Germany 
  donkey anti sheep IgG (H+L) 
Alexa Fluor 594 F(ab)2 fragment  Invitrogen, Karlsruhe, Germany 
  goat anti mouse IgG (H+L) 
Alexa Fluor 594 F(ab)2 fragment  Invitrogen, Karlsruhe, Germany 
  goat anti rabbit IgG (H+L) 
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4.1.5.3 Infection studies 
Hepatect®    human hepatitis B immunoglobulin, Biotest  
     Pharma GmbH, Dreieich, Germany 
 
4.1.5.4 Western blot  
 
4.1.5.4.1 Primary antibodies 
Goat anti HBsAg  Antibody from Murex HBsAg, Version 3,    
                                                              Abbott, Wiesbaden, Germany 
Mouse anti multidrug resistant  BD Pharmingen, San Diego, CA, USA 
  protein 2 (MRP2) 
Mouse anti heatshock protein 90  BD Pharmingen, San Diego, CA, USA 
  (HSP90) 
Mouse anti golgi matrix protein  BD Pharmingen, San Diego, CA, USA 
  (GM130) 
Rabbit anti β-actin  Sigma, St. Louis, MO, USA 
Rabbit anti hepatocyte nuclear  Santa Cruz Biotech., Santa Cruz, CA, USA 
factor (HNF) 1     
Rabbit anti hepatocyte nuclear  Santa Cruz Biotech., Santa Cruz, CA, USA          
factor (HNF) 4α        
Rabbit anti core/GFP  Combination of 2 mAbs from rabbit 
(Boehringer Mannheim); mAbs 10E11 and 
10F10 against epitopes aa8/20 and 
aa135/144 of the denatured core-protein 
 
 
4.1.5.4.2 Secondary antibodies 
Goat anti rabbit, HRP-conjugated Sigma, Deisenhofen, Germany  
Goat anti mouse, HRP-conjugated  Sigma, Deisenhofen, Germany 
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4.1.6 Enzymes 
Restriction endonucleases   Fermentas, St. Leon Rot, Germany 
T4-DNA Ligase     Roche Diagnostics, Mannheim, Germany 
Klenow Enzym     Roche Diagnostics, Mannheim, Germany 
Alkaline phosphatase    Roche Diagnostics, Mannheim, Germany 
Lysozyme 50 mg/ml   Novagen, Madison, USA 
RNaseA 10 mg/ml  Roche Diagnostics, Mannheim, Germany 
 
4.1.7 Kits 
 
4.1.7.1 Cell isolation 
BCAProteinTM Assay Kit  Pierce, Rockford, IL, USA 
BDCA-4 cell isolation kit      Miltenyi, Bergisch Gladbach, Germany 
CD1c cell isolation kit   Miltenyi, Bergisch Gladbach, Germany 
CD14 cell isolation kit   Miltenyi, Bergisch Gladbach, Germany 
CD19 cell isolation kit   Miltenyi, Bergisch Gladbach, Germany 
 
4.1.7.2 DNA amplification  
LC FastStart DNA MasterPlus  Roche Diagnostics, Mannheim, Germany  
  SYBR Green1 mix 
PCR DNA Amplification Kit   Roche Diagnostics, Mannheim, Germany 
PCR Purification Kit   Qiagen, Hilden, Germany 
 
4.1.7.3 DNA isolation 
MinElute PCR Purification Kit  Qiagen, Hilden, Germany 
QIAquick Gel Extraction Kit  Qiagen, Hilden, Germany 
QIAprep Maxiprep Kit   Qiagen, Hilden, Germany 
QIAprep Miniprep Kit  Qiagen, Hilden, Germany 
 
4.1.7.4 DNA labelling 
Rediprime DNA Labeling System Amersham, Buckinghamshire, England 
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4.1.7.5 ELISA 
Murex HBsAg Version 3  Abbott, Wiesbaden, Germany 
 
4.1.7.6 Luciferase detection 
Renilla Luciferase Assay System Promega GmbH, Mannheim, Germany 
 
4.1.7.7 Transfection 
FuGENE 6®    Roche Diagnostics, Mannheim, Germany 
 
4.1.7.8 Western blot detection 
ECL Western Blotting Detection Amersham, Buckinghamshire, England 
  Reagents   
Enhanced Chemiluminescence Pierce, Rockford, USA 
 
 
4.1.8 Nucleic acids 
 
4.1.8.1 Vectors 
 
pAdGH1.3  
Adenoviral vector for transduction of eukaryotic cell lines, containing a 1.3-fold 
HBV over length genome and a GFP reporter cassette under CMV promoter 
control (Sprinzl et al., 2001). 
 
rHBV-rLuc 
Recombinant HBV vector containing renilla luciferase as transgene under control 
of the HBV preS2/S promoter. All viral ORFs are knocked out, the gene encoding 
for the viral small envelope protein is replaced by a cDNA encoding renilla 
luciferase. The development of this type of recombinant HBV-based vectors is 
published in Protzer et al. (1999). 
 
rHBV-CMV-rLuc 
Based on rHBV-rluc, the HBV preS2/S-promoter is replaced by a CMV immediate 
early promoter/enhancer. 
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4.1.8.2 Plasmids 
 
000HBV 
Contains the wtHBV circularised genome.  
 
pCH -9/3091 
Contains a 1.3 over length HBV construct under the control of the CMV promoter 
(HBV nucleotides 3091-3182, 1-3182, 1-84). It was used to produce wtHBV (from 
R. Bartenschlager; Nassal et al., 1990). 
 
pCH 3142 
Helper plasmid for the rHBV production. The encapsidation signal is deleted (from 
R. Bartenschlager; Bartenschlager et al., 1990).  
 
pCH 1452 rLuc CPLX 
Transfer plasmid for the production of luciferase expressing rHBV vectors, with the 
luciferase gene under the control of the CMV promoter. It contains the complete 
HBV genome. The HBV S gene is replaced by the renilla luciferase gene under 
CMV promoter control. All HBV ORFs are deleted (from A. Untergasser).   
 
pCH luc 
Transfer plasmid for the production of luciferase expressing rHBV vectors, with the 
luciferase gene under the control of an HBV specific promoter. It contains the 
complete HBV genome. The HBV S gene is replaced by the renilla luciferase gene 
under S promoter control. All other HBV ORFs are deleted (from A. Untergasser).   
 
pCH GFP An-b-glob 
Contains the GFP gene under CMV promoter control, with poly-A side from the β-
globin gene. 
 
mRFP1_pRSETB 
Encodes the monomeric RFP (mRFP) under the T7 promoter (kindly provided by 
R. Tsien)    
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pCH S-Ag An-b-glob 
This plasmid contains the HBV S gene under the control of a CMV promoter. The 
poly-A side stems from the β-globin gene (from A. Untergasser).   
 
pCH GFP-S An-b-glob 
Generated from the plasmids pCH S-Ag An-b-glob and pCH GFP An-b-glob. It 
encodes the GFP gene N-terminally fused to the S gene.  
 
pCH GFP-sp-S An-b-glob 
Generated from the plasmid pCH GFP-S An-b-glob. It encodes the GFP gene N-
terminally fused to the S gene with a glycin spacer sequence of 12 aa inserted 
between GFP and S gene.  
 
pCH S-GFP An-b-glob 
Generated from the plasmids pCH S-Ag An-b-glob and pCH GFP An-b-glob. It 
encodes the GFP gene C-terminally fused to the S gene.  
 
pCH M-GFP An-b-glob 
Generated from the plasmids 000HBV and pCH S-GFP An-b-glob. It encodes the 
GFP gene C-terminally fused to the M gene. The ATG start codon for the S gene, 
which is present within the ORF of the M gene, was replaced by ACG.   
 
pCH L-GFP An-b-glob 
Generated from the plasmids 000HBV and pCH S-GFP An-b-glob. It encodes the 
GFP gene C-terminally fused to the L gene. The ATG start codons for the M and S 
genes, which are present within the ORF of the L gene, were replaced by ACG.   
 
pCH S-RFP An-b-glob 
It encodes the RFP gene C-terminally fused to the S gene. The mRFP gene was 
obtained from the mRFP1_pRSETB plasmid. After restriction of the mRFP PCR 
fragment and the plasmid pCH S-GFP An-b-glob with AccI and PaeI, the RFP was 
inserted into plasmid backbone of the pCH SGFP An-b-glob plasmid. The GFP 
was removed by the restriction. 
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pCH M-RFP An-b-glob 
It encodes the RFP gene C-terminally fused to the M gene. The mRFP gene was 
obtained from the mRFP1_pRSETB plasmid. After restriction of the mRFP PCR 
fragment and the plasmid pCH M-GFP An-b-glob with AccI and PaeI, the RFP was 
inserted into plasmid backbone of the pCH MGFP An-b-glob plasmid. The GFP 
was removed by the restriction. 
 
pCH L-RFP An-b-glob 
It encodes the RFP gene C-terminally fused to the L gene. The mRFP gene was 
obtained from the mRFP1_pRSETB plasmid. After restriction of the mRFP PCR 
fragment and the plasmid pCH L-GFP An-b-glob with AccI and PaeI, the RFP was 
inserted into plasmid backbone of the pCH L-GFP An-b-glob plasmid. The GFP 
was removed by the restriction. 
 
 
4.1.8.3 Oligonucleotides 
 
Amplification Primers 
S-GFP C-term fw  5´ TCTTTGGGTATACATTATGAGCAAGGGCGAG 3´ 
S-GFP C-term rev  5´ GCAAGCTGCATGCTCACTTGTACAGCTCG 3´ 
GFP-S N-term fw 5´ ACGATTAGTCGACATGAGCAAGGGCGAG 3´ 
GFP-S N-term rev  5´ GAATCGAGGTACCCTTGTACAGCTCGTCC 3´ 
GFP-S N-term sp fw 5´ TTCTGGAGGCGGAGGGTCCGGTAC 3´ 
GFP-S N-term sp rev 5´ CGGACCCTCCGCCTCCAGAAGGTAC 3´ 
L-GFP fw    5´ AGAACGGTACCATGGGGCAGAATCTTTCCAC 3´ 
L-GFP rev   5´ AGAACGGTACCATGCAGTGGAATTCCACAACC 3´ 
M-GFP fw   5´ CTCAGGCCACGCAGTGGAATTCCACAAC 3´ 
M-GFP rev  5´ GTTGTGGAATTCCACTGCGTGGCCTGAG 3´ 
RFP fw   5´ GCAAGCTGCATGCTTAGGCGCCGGTGGAGT 3´ 
RFP rev    5´ GCAAGCTGCATGCTTAGGCGCCGGTGGAGT 3´ 
 
Primers for quantitative real time PCR 
HBV1745 fw  5´ GGAGGGATACATAGAGGTTCCTTGA 3´ 
HBV1844 rev  5´ GTTGCCCGTTTGTCCTCTAATTC 3´ 
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HBVccc2760 fw   5´ GACTCTCTCGTCCCCTTCTC 3´ 
HBVccc156 rev  5´ ATGGTGAGGTGAACAATGCT 3´ 
 
  
4.1.9 Ladders  
 
4.1.9.1 DNA standards 
SmartLadder, 0.2-10 kb   Eurogentec, Liege, Belgium 
SmartLadder, 0.1-2 kb    Eurogentec, Liege, Belgium 
 
4.1.9.2 Protein standards 
Pre-stained Protein ladder   Invitrogen, Karlsruhe, Germany 
 
 
4.1.10 Expendable items 
Cell culture flasks    Nunc, Wiesbaden, Germany 
Cell culture dishes    Nunc, Wiesbaden, Germany 
Cell culture well plates    Nunc, Wiesbaden, Germany 
Centricon Plus-70, Biomax 100  Millipore Corp., Billerica, MA, USA 
Centrifuge vials, Falcon Becton Dickinson GmbH, Heidelberg, 
  Germany 
Chamber Slides LabTekII, RS Glass Nunc, Wiesbaden, Germany 
Cryo vials      Nunc, Wiesbaden, Germany 
Cuvettes      Sarstedt, Nümbrecht, Germany 
Freezing Container NalgeneTM  Nunc, Wiesbaden, Germany 
Hyperfilm ECL     GE Healthcare, Buckinghamshire, UK 
Pipette tipps     Starlab GmbH, Ahrensburg, Germany 
Pipetboy Swift Pet®   Abimed, Langenfeld, Germany 
Pipetts, single use   Sarstedt, Nümbrecht, Germany 
Reaction vials     Eppendorf, Hamburg, Germany 
Tissue paste Histoacryl®  Braun, Melsung, Germany 
Whatman 3MM   Biometra, Göttingen, Germany 
Ultra centrifuge-tubes, polyallomer Beranek Laborgeräte, Weinheim, Germany  
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4.1.11 Equipment 
Centrifuges:  
 Centrifuge 5417C / 5417R  Eppendorf, Hamburg, Germany 
 Megafuge 1.0 / 1.0 R   Heraeus Holding GmbH, Hanau, Germany 
Fraction recovery system  Beckman, München, Germany 
Biocycler Thermocycler T3 Biometra, Göttingen, Germany 
Blot chamber MiniProtean®3 Cell BIO-RAD Laboratories, Hercules, USA 
Dot blot apparatus Minifold I  Schleicher & Schuell, Dassel, Germany 
ELISA Reader MRX Revelation Dynex, Gaithersburg, USA 
Film processor Curix 60  Agfa Geveart NV, Mortsel, Belgium 
Flow cytometer FACSCanto™  BD Biosciences, Heidelberg, Germany 
Gel chambers     BIO-RAD Laboratories, Hercules, USA 
Heating block Thermomixer comfort Eppendorf, Hamburg, Germany 
Incubator      Heraeus Holding GmbH, Hanau, Germany 
Light Cycler System   Roche Diagnostics, Mannheim, Germany 
Luminometer   Berthold Technologies, Bad Wildbad,  
  Germany   
Microscopes 
  Fluorescence microscope IX81   Olympus, Hamburg, Germany 
  Confocal microscope    Olympus, Hamburg, Germany 
    FluoView1000  
Nylon membrane, positively charged Roche Diagnostics, Mannheim, Germany 
PVDF membrane    Amersham, Buckinghamshire, England 
pH-Meter      WTW, wissenschaftlich technische  
  Werkstätten 
Pipetboy Swift Pet®   Abimed, Langenfeld, Germany 
Phosphoimager, Molecular  BIO-RAD Laboratories, Hercules, USA 
  Imager FX 
Photometer Smart Spec 3000  BIO-RAD Laboratories, Hercules, USA 
Photo system for agarose gels  BIO-RAD Laboratories, Hercules, USA 
 Gel-doc 2000 
Power Supplies Pack300  BIO-RAD Laboratories, Hercules, USA 
Refrigerators and freezer   Liebherr, Lientz, Germany 
Rocking platform WT12   Biometra, Göttingen, Germany 
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Shaker      Innova 4230, New Brunswick Scientific, USA 
Sterile hood (cell cultur)   Heraeus Holding GmbH, Hanau, Germany 
UV-Oven GS Gene LinkerTM   BIO-RAD Laboratories, Hercules, USA 
Ultra centrifuges:     
   Sorvall RC 50 Plus    Kendro, Langenselbold, Germany 
   XL 70      Beckman, München, Germany 
 Scales Kern 440-47   Sartorius AG, Göttingen, Germany 
 
 
4.1.12 Software 
Autoradiography  Quantity One, 4.2.1, BIO-RAD Laboratories,    
    Hercules, USA 
Data processing     Windows 2000, MS Office 2000, Word and
      Excel, Microsoft, Redmont, USA 
Flow cytometry    FACSDiva™, BD Biosciences, Heidelberg, 
  Germany 
Fluorescence microscopy  Cell P, AnalySIS, Soft Imaging System     
   GmbH, Münster, Germany 
FV10-ASW, Version 1.6a 
Graphic programmes   Adobe Photoshop 5.5, Adobe, San Jose,     
   USA 
Power Point 2000, Microsoft, Redmont, USA 
Light Cycler   Probe Design Analysis and Rel Quant,     
   Roche Diagnostics, Mannheim, Germany 
Luminometer     Magellan Software, Tecan, Grödig, Austria 
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4.2 Methods 
All procedures were performed at room temperature, if not indicated otherwise. 
 
4.2.1. Cell culture 
All procedures were carried out under sterile conditions, using sterile solutions and 
equipments. All cells were cultivated in a humidified incubator at 37°C containing 
5% CO2.   
 
4.2.1.1 Calculation of cell numbers and cell viability   
To determine cell numbers, a Neubauer hemacytometer was used. The 
hemacytometer consists of a glass chamber, which is divided into four large 
squares, each consisting of 16 small squares. It holds a quartz coverslip exactly 
0.1 mm above the chamber floor. A homogenous cell suspension was filled in the 
hemacytometer by capillary action. In all four large squares the cells were counted 
and the cell number was calculated as follows:  
Cell number/ml = total cell number x dilution factor x 104 
                   4 
The cell viability was determined with trypan blue. Therefore, the cell suspension 
was mixed with an equal volume of trypan blue prior to counting. Trypan blue 
diffuses into cells. While living cells continuously remove the dye via pumps, it 
remains in the cytosol of dead cells. Therefore, dead cells appear blue and can be 
distinguished from living cells using light microscopy.       
 
4.2.1.2 Freezing and thawing of cells 
Cell pellets were re-suspended in freezing medium. 1 ml of cell solution with a 
density of approx. 1 to 3 x 106 cells was transferred to one cryo vial. The vials 
were slowly cooled to -80°C in a freezing container and then stored in liquid 
nitrogen. To re-cultivate frozen cells, they were quickly thawed and carefully       
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re-suspended in 10 ml cultivation medium. After centrifugation for 5 min at        
1200 rpm, the cells were re-suspended in cultivation medium.  
 
4.2.1.3 Cell lines 
The human hepatoma cell line HuH7 was maintained in complete DMEM medium. 
Passage was performed at a ratio of 1:5 when the cells were 100% confluent. 
HepG2.2.15 cell were cultivated in complete DMEM or, for virus production, in a 
1:1 mixture of PHH medium and complete Williams E medium. 293 cells were kept 
in complete DMEM and passaged at a ratio of 1:5 when 100% confluent.  
 
4.2.1.4 Primary cells  
 
Primary human hepatocytes 
PHH were isolated from fresh surgical liver specimen from patients undergoing 
partial hepatectomy. The procedure was approved by the local Ethics Committee, 
with obtained informed consent of the patients.  
The protocol based on a collagen perfusion established by Barry and Friend 
(1969), which was further developed into a two-step perfusion by Seglen (1976). 
The collagen perfusion with the additional pre-perfusion step using Ca2+- and 
Mg2+-free medium, followed by differential centrifugation, is standard for the 
isolation of primary human hepatocytes (Hsu, 1985; Berry, 1997; Schulze-
Bergkamen et al., 2003).    
The pre-perfusion, perfusion and the PHH medium were warmed to 37°C prior to 
the perfusion, and the wash medium was cooled to 4°C. Cell culture dishes were 
coated with collagen. For that purpose, the dishes were incubated with a 1:10 
diluted collagen solution (Serva, Heidelberg) for 30 min at 37°C. Afterwards the 
dishes were washed twice with ddH2O and air dried.       
The healthy liver tissue piece was placed on a kidney dish. A large branch of the 
port vein was canulated, and the canula was fixed with tissue paste (Histoacryl®, 
Braun, Melsung). The two-step collagenase perfusion started with 500 ml         
pre-perfusion medium, with a flow rate between 20 and 40 ml/min. At cut surfaces 
with high medium passage, the large vessels were occluded with tissue paste. The 
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medium was discarded after traversing the liver tissue. After 15 to 20 min, 
perfusion was continued with 250 ml perfusion medium containing freshly added 
collagenase type IV (Worthington, Lakewood). 100 ml of the collagenase perfusion 
medium were kept and perfusion was continued with this remaining amount of 
medium. Collagenase treatment was performed for 15 to 20 min, depending on 
liver-section size. As soon as the tissue softened and liver cells appeared in the 
medium, the liver was cut into small peaces and the tissue was scratched off with 
a scalpel. If collagenase digestion was incomplete, the suspension was transferred 
to a sterile beaker and stirred for 10 min at 37°C. The cell suspension was filtrated 
through double-layered gaze and a 70 µm cell strainer. After centrifugation in       
50 ml Falcon tubes for 5 min at 50 x g at 10°C, the pellet was re-suspended in     
40 ml wash medium. The wash step was repeated three times. The cells were         
re-suspended in PHH medium and the cell number and viability was determined. 
The cells were seeded on collagenised cell culture dishes at a density of               
8 x 105 cells/ml of PHH medium supplemented with 10% FCS. After 3 h the 
medium was exchanged to remove non-adherent cells. One day post seeding, the 
cells were kept in medium containing 5% FCS. From day two post seeding the 
cells were cultivated in FCS-free medium and used for experiments. The obtained 
cell culture consisted of 85-95% PHHs and 5-15% non-parenchymal liver cells. 
The latter are not susceptible for adenovirus type 5 infections (Hegenbarth et al., 
2000; Schulze-Bergkamen et al., 2003)         
 
Peripheral blood mononuclear cells 
PBMCs were obtained from standard buffy coat preparations of healthy blood 
donors or fresh peripheral blood by Ficoll Paque (Pan Biotech, Aidenbach) density 
gradient centrifugation. The blood was diluted with PBS to a final volume of       
120 ml. 30 ml of the diluted buffy coat were carefully layered on top of 13 ml Ficoll 
solution (1.077 g/ml, Pan Biotech). Gradient centrifugation was performed for       
20 min at 320 x g without brake. Within the density gradient, the blood cells 
sediment in the Ficoll according to their density. Granulocytes and erythrocytes, 
which posses high densities, sediment at the bottom. PBMCs are located in the 
interface between Ficoll and the supernatant, which contains the plasma and 
thrombocytes. The interfaces were collected, combining interfaces of two tubes 
into one new tube. Tubes were filled up to 50 ml with PBS, centrifuged for 15 min 
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at 1500 rpm and the supernatant was completely removed. If the cell pellet 
contained many erythrocytes, an erythrocyte lysis was performed. Therefore, cells 
were incubated with 0.15 M NH4Cl at 37°C for 5 min. After another centrifugation 
step at 1000 rpm for 10 min, the cells were re-suspended in PBS, counted and the 
viability was checked with trypan blue. In case of a contamination with 
thrombocytes, cell were washed twice in 50 ml PBS and centrifuged at 1200 rpm 
for 10 min. PBMCs were seeded in RPMI medium containing 10% FCS at a 
density of 5 x 106 cells/ml.  
 
Monocytes  
Monocytes represent approx. 8% of PBMCs. Two methods were used to isolate 
monocytes from PBMCs. The plastic adherence method relies on the 
characteristic of CD14+ monocytes to adhere to plastic surfaces. Other cell types 
within the PBMCs culture do not posses this feature and can therefore be 
separated from the monocytes by washing steps. The PBMCs were seeded at a 
density of 5 x 106 cells/ml of RPMI 1640 medium supplemented with 10% FCS for 
2 h. Subsequently, non-adherent cells were removed by washing 4-fold with PBS. 
Plates were examined using a phase-contrast microscope, to determine the level 
of contamination with lymphocytes. These can be distinguished from monocytes 
by their very small size and round shape. If lymphocytes were present in the 
monocyte culture, additional washes were performed.  
Alternatively, monocytes were isolated by immuno-selection with                     
CD14 MicroBeads (Miltenyi Biotec, Bergisch Gladbach). This technique is referred 
to as magnetic cell sorting (MACS). The principle of this method is the labelling of 
cells with specific antibodies coupled to magnetic beads. All cells are incubated 
with the antibody-bead complexes and subsequently transferred to a column 
placed in a magnetic field in a MACS separator (Miltenyi Biotec, Bergisch 
Gladbach). Magnetically labelled cells are retained in the column, while unlabeled 
cells flow through. By removal of the magnetic field the labelled cells can be eluted 
from the column.  
The CD14 antigen is expressed on most monocytes and on macrophages. The 
method was performed according to the manufacturers’ instructions. The PBMCs 
were counted, washed in MACS buffer and centrifuged at 12000 rpm for 10 min at 
4°C. For more then 4 x 108 cells, the cells were split to perform two separate 
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stainings and separation in two columns. The cells were re-suspended in 400 µl 
MACS buffer per 1x 108 cells, and 50 µl CD14 MicroBeads were added per           
1 x 108 cells. After 15 min incubation at 4°C, 10 ml MACS buffer were added and 
cells were centrifuged at 1200 rpm for 10 min at 4°C. The pellet was re-suspended 
in 3 ml MACS buffer and applied to one or two equilibrated LS columns (Miltenyi 
Biotec, Bergisch Gladbach), located in the magnetic field of the MACS separator. 
The column was washed 3 times by adding 3 ml buffer. Then, the column was 
removed from the separator and the CD14+ cells were eluted in 5 ml MACS buffer. 
After a washing step in MACS buffer and centrifugation at 4°C and 1200 rpm, the 
cells were re-suspended in RPMI medium and cell number and viability were 
determined. The CD14+ cells were cultured in complete RPMI medium, with a 
density of 3 to 4 x 105 cells/ml.   
 
Monocyte-derived dendritic cells (moDC)  
Dendritic cells can directly be derived from CD14+ blood monocytes (Zhou and 
Tedder, 1996). Upon cultivation with cytokines, monocytes differentiate into a fairly 
homogenous cell population with dendritic cell morphology and functionality.  
Monocytes were prepared as described and cultured in complete RPMI medium 
supplemented with 10 ng/ml IL-4 and 10 ng/ml GM-CSF (R&D Systems, 
Wiesbaden) for three to five days to allow differentiation into immature DCs. For 
further maturation, immature moDCs were stimulated by addition of 1mg/ml LPS, 
50 ng/ml PGE2 (Sigma, Deisenhofen) and 50 ng/ml TNF-α (R&D Systems, 
Wiesbaden) for 24 to 48 h. Cell differentiation was monitored by light microscopy. 
After IL-4 and GM-CSF treatment, the monocytes built small semi-adherent 
clusters, and a small number of cells with dendrites could be seen. After cultivation 
with LPS, TNF-α and PGE2, the cells formed large clusters and exhibited    
dendritic-cell morphology.    
 
Plasmacytoid and myeloid dendritic cells 
Circulating pDCs and mDCs were gained from PBMCs of patients with chronic 
HBV infection and one healthy volunteer after informed consent.  
The isolation protocol is based on the MACS technique. In the first step, pDCs 
were separated by a positive selection using the BDCA-4 cell isolation kit (Miltenyi 
Biotec, Bergisch Gladbach) following the manufactures’ instructions. The BDCA-4 
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antigen is specifically expressed on pDCs, which make up approx. 0.5% of 
PBMCs.    
The PBMCs were obtained as outlined above and re-suspended in 300 µl MACS 
buffer per 1 x 108 cells. Cells were incubated with 100 µl blocking reagent and   
100 µl BDCA-4 MicroBeads per 1 x 108 cells for 15 min at 4°C. Cells were washed 
with 10 to 20 volumes of MACS buffer and centrifuged at 1200 rpm for 10 min at 
4°C. The supernatant was discarded and the cells were re-suspended in 500 µl 
buffer per 1x 108 cells. A MS column (Miltenyi Biotec, Bergisch Gladbach) was 
equilibrated with 0.5 ml buffer, before the cells were applied. The flow through 
containing the BDCA-4- cells was collected. Three washing steps with 0.5 ml 
buffer were performed and the flow through was combined with the BDCA-4- cells. 
pDCs were eluted from the column by addition of 1 ml buffer after removal of the 
magnetic field. To increase the purity of the pDC fractions, the separation 
procedure was repeated. Then the cells were counted and a small aliquot was 
subjected to FACS analysis (see below). The remaining cells were pelleted, frozen 
in liquid nitrogen and stored at -80°C. 
The flow through was used for the isolation of mDCs with the CD1c (BDCA-1) 
Dendritic Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach). The CD1c antigen 
is expressed on myeloid dendritic cells, but also on a subpopulation of CD19+        
B cells. Therefore, a two-step magnetic separation was necessary to obtain a pure 
population of mDCs.  
In the first step CD1c-expressing CD19+ B cells were depleted using anti CD19 
MicroBeads (Miltenyi Biotec, Bergisch Gladbach). This step is a so-called negative 
selection, with the target cell type, in this case mDCs, being in the flow through. In 
the second step, mDCs were separated in a positive selection step with anti CD1c 
MicroBeads.   
The pDC-depleted flow through was washed with MACS buffer and re-suspended 
in 200 µl buffer per 1 x 108 cells. Blocking reagent, CD19 MicroBeads and 
biotinylated CD1c MicroBeads, 100 µl each, were added to the cells. Incubation 
was performed at 4°C for 15 min, followed by a washing step with 10 to               
20 volumes of buffer. Cells were centrifuged and re-suspended in 500 µl buffer per    
1 x 108 cells. A LD column was equilibrated prior to the application of the cells. 
The flow through containing the CD19- cells was collected in the same tube as the 
flow through of the following two washing steps. The CD19+ cells were removed 
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from the column with 2 ml of buffer, counted and frozen as described above. A 
small aliquot was subjected to FACS analysis. 
The B-cell depleted flow through was centrifuged and re-suspended in 400 µl 
buffer per 1 x 108 cells. 100 µl of Anti-Biotin MicroBeads were added per                
1 x 108 cells. Following 15 min incubation at 4°C, the cells were pelleted and      
re-suspended in 500 µl buffer per 1 x 108 cells. The separation of the mDCs was 
performed with a MS column as previously described. The flow through was kept 
and subjected to further isolation steps (see Enriched lymphocyte fraction). After 
counting the cells, a small aliquot was kept for FACS analysis, and the remaining 
cells were frozen and stored at -80°C.    
 
Enriched lymphocytes fractions 
The flow through, which remained after the pDC and mDC isolation protocols, was 
used to obtain enriched lymphocyte fractions. The cells, which were already 
depleted for mDCs, B cells and pDCs, were further depleted for CD14+ 
monocytes. Isolation with the CD14 MicroBeads was performed as described, 
using a MS column for separation. The collected flow through, as well as the 
separated monocytes, were counted and frozen at -80°C. A small aliquot of both 
fractions was used for FACS analysis. 
 
 
 
4.2.1.5 Transfection of cells 
 
4.2.1.5.1 Calcium phosphate method 
Fifteen micrograms of plasmid DNA were re-suspended in 450 µl ddH2O and 50 µl 
of a 2.5 M calcium phosphate solution was carefully added. The mixture was 
dropped into a new tube containing 500 µl 2 x HBS while shaking on a vortexer. 
After 20 min of incubation, the DNA solution was added to the cells. The inoculum 
was removed on the next day. The cells were washed twice with PBS, and further 
cultivated in fresh medium.   
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4.2.1.5.2 FuGene6® 
HuH7 cell were transfected with indicated plasmids using FuGene6® (Roche 
Diagnostics, Mannheim) according to the manufacturers’ protocol: Cells were 
plated one day prior to transfection to obtain a 40 to 60% confluent monolayer at 
the following day. The medium was exchanged 1 to 3 h before transfection. For 
transfection, 1 µg plasmid per 1.2 x 106 cells was used. The DNA was mixed with 
serum free medium and 2 µl FuGene per µg DNA. After 20 min incubation the 
solution was added to the cells. Inoculums were left in the cell culture over night. 
Fresh medium was applied at the next day.      
 
 
4.2.1.6 Production of wild type HBV  
For the production of wtHBV, the HepG2.2.15 cell line was used. This         
HepG2-based cell line contains four dimeric HBV genomes stably integrated into 
the cellular genome (Sells et al., 1987). Therefore, this cell line permanently 
produces HBV, which can be purified from cell culture supernatants.  
For virus preparation, the cells were cultivated in complete DMEM medium until 
100% confluent. Then, the medium was exchanged to 50% PHH medium and 50% 
complete Williams E medium. Every three days, the virus-containing medium was 
collected. Cell debris was removed by centrifugation at 1000 rpm for 5 min. The 
supernatant was transferred to centrifugal filter devices (Centricon Plus-70, 
Biomax 100, Millipore Corp., Billerica) The first centrifugation was performed at 
3500 x g for 1 h at 4°C, to capture the virus particles in a filter. Due to the 
exclusion limit of 100 kDa, serum proteins flow through, while proteins larger than 
100 kDa remained in the filter. In a second, invert centrifugation step with the filter 
system turned upside down, performed at 2600 x g for 10 min, the virus was 
eluted. The virus concentrate was supplemented with 10% glycerol and stored at   
-80°C. The titer of the produced wtHBV was determined with Caesium chloride 
density-gradient, followed by dot blot analysis, as outlined below. 
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4.2.1.7 Production of recombinant HBV-based vectors 
HBV-based vectors (rHBV) were produced in HuH7 cells via transfection. The cells 
were seeded one day prior to transfection in 10 cm² cell culture dishes. At the next 
day, the cells were transfected with equal amounts of helper plasmid and transfer 
plamid using FuGene6® (Roche Diagnostics, Mannheim) as described.  
The transfer plasmid encodes the transgene, inserted in the HBV genome at the 
site of the S protein. All viral ORFs are knocked out. Therefore, only pregenomic 
RNA is transcribed from the transfer plasmid. The helper plasmid consists of an 
HBV genome with a deletion in the encapsidation signal. It provides all viral RNAs 
except the pregenomic RNA. This guarantees that only recombinant virions 
emerge, but no wtHBV.  
At the following day the HuH7 medium was exchanged with a 1:1 mixture of HuH7 
medium and PHH medium. At day two post transfection, PHH medium was 
applied. Another four days later, the medium was collected and the recombinant 
HBV particles were concentrated using centrifugal filter devices as described in 
4.2.1.6. Quantitative analysis of the produced rHBV stocks was performed with a 
caesium chloride density-gradient centrifugation and dot blot. 
 
 
4.2.1.8 Production of adenoviral vectors 
Adenoviruses (Ad) are known to infect a broad range of cells and are therefore 
widely used as vectors. The adenoviral vectors used in this study were based on 
Ad type 5 and produced as described in Sprinzl et al. (2001 and 2004). The 
plasmids were linearised with Pac1 before transfection of 293 cells using the 
calcium phosphate method. The 293 cells provide the adenoviral E1 genes in 
trans, which are necessary for virus production (Graham et al., 1977). After three 
days the cells died, due to the apoptosis induction of the Ad. At this time point, 
virions were present in the apoptotic cells and in the medium. The medium, 
containing dead cells and virions, was collected and subjected to three freeze and 
thaw cycles in liquid nitrogen and a 37°C water bath. This breaks the cells and 
sets free the intracellular virions. Following a centrifugation step for 5 min at     
2000 rpm to remove the cell debris, the virus containing supernatant was 
supplemented with 10% glycerol and stored at -80°C. To determine the titer of the 
produced Ad vectors, 293 cells were plated on a 12 well cell-culture dish. Serial 
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dilutions of the vector stock from 1:10 to 1:1000 were added to the confluent cells. 
The cytopathic effect as well as GFP fluorescence was monitored 48 h after 
transduction. Statistically, one GFP expressing or cytopathic cell has been 
transduced with three Ad particles. A moi of 1 was calculated for the dilution, 
which led to 80% GFP expressing cells or cytopathic cells.   
 
 
4.2.1.9 Caesium chloride (CsCl) density-gradient centrifugation 
During virus preparation, different types of viral particles are obtained: naked DNA, 
unenveloped DNA-containing capsids, and enveloped virions. Their different 
densities enable to separate them in a density gradient. DNA is centrifuged down 
to the bottom, due to the very small size. DNA-containing capsids sediment at a 
density of 1.3 g/l, while intact virions can be found in the 1.22 g/l fraction.      
The CsCl (Roth, Karlsruhe) density-gradient ultra centrifugation was performed 
with the SW-60 swing bucket rotor. In SW-60 polyallomer vials (Beranek 
Laborgeräte) 500 µl of CsCl solutions with the following densities were carefully 
layered one upon the other: 1.4 g/l, 1.3 g/l and 1.15 g/l. On top of the                
CsCl solutions, 500 µl of a 20% sucrose solution was layered, and the sample was 
applied. The vials were filled up with PBS and tared on micro scales.               
Ultra-centrifugation was performed at 55000 rpm at 20°C for 4 h to over night. The 
density fractions were collected with a Fraction recovery system (Beckman). Each 
fraction contained 6 drops, which approximates a volume of 175 µl. The fractions 
were subjected to quantitative dot blot analysis.       
 
 
4.2.1.10 Dot blot 
For quantitative and qualitative analysis of the produced wtHBV or rHBV, a       
DNA dot blot was performed. The DNA fractions, obtained by CsCl density 
centrifugation, were dotted to a nylon membrane (Roche Diagnostics, Mannheim) 
in a dot blot aperture (Schleicher & Schuell, Dassel). A HBV plasmid standard 
ranging from 8 pg to 1000 pg was added. The dotted samples and standards were 
washed with 200 µl PBS, before the membrane was transferred to a 3 mm 
Whatman paper soaked with denaturation solution. Subsequently the membrane 
was transferred to a 3 mm Whatman paper soaked with neutralisation solution. 
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Then the DNA was cross linked on the membrane in a UV oven. The membrane 
was hybridised with a 32P-labelled HBV DNA probe at 68°C over night. At the next 
day, the membrane was washed 3-fold 20 min each at 68°C with wash solution. 
After wrapping the radioactive membrane in seran wrap, the DNA was exposed to 
a phosphor-screen and quantified with a phosphoimager (BIO-RAD, Hercules). 
 
4.2.1.11 HBV infection of cells 
Infection of cells with HBV was performed in medium containing 5% PEG 8000 
(Gripon et al., 1993). The cells were incubated over night with HBV at a moi of  
100 vp/cell. If indicated, neutralising antibodies (1 IU/106 cells; Hepatect, Biotest 
Pharma, Dreieich) were added simultaneously (Schulze-Bergkamen et al., 2003). 
After over night inoculation, cells were washed 3-fold with PBS. Cells were further 
cultivated in fresh medium, and cell culture medium was collected at indicated time 
points. To monitor infection, HBsAg and HBeAg were determined using 
commercial immuno-assays (Axsym®, HBeAg 2.0, HBsAg V2, Abbott 
Laboratories, Wiesbaden) in the Institute of Virology at the University of Cologne.   
 
 
4.2.1.12 Transduction with HBV-based vectors 
The transduction of cells with HBV-based vectors was performed by the same 
protocol as HBV infection experiments (see 4.2.1.4).   
 
4.2.1.13 Transduction with adenoviral vectors 
Prior to transduction of cells with adenoviral vectors the medium was exchanged. 
The indicated moi of vector was added to the cells. After 3 h, the inoculum was 
removed and fresh medium was applied. 
 
4.2.1.14 Luciferase detection 
Renilla lucifase is an enzyme that converts its substrate coelenterazin to 
coelenteraid. The luciferase system is very sensitive. Detection is possible in a 
broad linear range, with the input not giving a background signal. Furthermore, 
background luminescence of cells is very weak and does not interfere with the 
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measurement (Matthews et al., 1977). In the enzyme reaction, light is emitted 
proportional to the enzyme concentration. To quantify the light emission the 
Renilla Luciferase Assay system (Promega, Mannheim) was used. 1 x 106 cells 
were lysed in 200 µl lysis buffer per well at day 4 post transduction. The samples 
were centrifuged for 1 min at      12000 rpm and 10 µl of the lysates were pipetted 
in a reaction vial. After mixing the samples with 100 µl substrate, the samples were 
transferred to a luminometer (Berthold Technologies, Bad Wildbad). After 2 sec, 
the light emission was measured for 3 sec. The relative light units (RLU) were 
normalised to the total protein content of the respective samples. Mock transduced 
cells served as negative controls. The RLU determined in these samples were 
defined as 1, the other values were adapted proportionally.    
   
4.2.2. DNA techniques 
 
4.2.2.1 Transformation 
Competent E.coli strains DH5α (Promega, Mannheim) and XL1blue (Stratagene, 
La Jolla) were produced as described by Inoue et al. (1990) and stored at -80°C.  
Bacteria aliquots of 25 µl per reaction were thawed on ice. 50 to 200 ng plasmid 
DNA were added to the bacteria and incubated for 30 min on ice to allow the 
attachment of the DNA to the bacteria. A 60 sec long heat shock at 42°C led to 
DNA uptake. The bacteria were directly incubated on ice for 5 min and                 
re-suspended in 500 µl LB medium without antibiotics. After 1h incubation at 37°C, 
the antibiotic resistance encoded on the transferred plasmid was established, and 
100 µl of the bacteria suspension were plated on LB agar plates containing the 
antibiotic corresponding to the resistance. Agar plates were incubated at 37°C 
over night.         
 
4.2.2.2 Plasmid preparation 
Plasmid preparation was either performed with the rapid boiling method for small 
DNA amounts or with the QiaQuick Maxiprep Kit (Qiagen, Hilden) for large 
amounts.  
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To obtain plasmid DNA with the rapid boiling method, 1.5 ml bacteria suspension 
were centrifuged for 5 min at 12000 rpm and the bacteria pellet was re-suspended 
in 300 µl STET buffer. Bacteria were lysed for 10 min and boiled for to 2 min at 
100°C. After centrifugation for 10 min at 12000 rpm, the pellet, consisting of 
protein and protein-associated genomic DNA, was removed. The plasmid DNA in 
the supernatant was precipitated with 500 µl of 75% isopropanol/ 2.5 M sodium 
acetate. After 20 min incubation and centrifugation for 10 min at 12000 rpm, the 
supernatant was discarded and the DNA pellet was washed with 80% ethanol. 
This step is necessary to remove salt and purify the DNA. Following an additional 
centrifugation step for 10 min at 12000 rpm, the pellet was dried and re-suspended 
in 30 µl ddH2O.  
The plasmid preparation using the QiaQuick Maxiprep Kit (Qiagen, Hilden) was 
performed according to the manufacturers’ instructions. The method is based on 
alkaline lysis of the bacteria. Proteins and protein-associated DNA are precipitated 
by neutralization. The following purification of plasmid DNA relies on anion 
exchange chromatography. After several washing steps the plasmid DNA was 
precipitated with 100% isopropanol and cleaned with 70% ethanol. The pellet was                  
re-suspended in 500 µl ddH2O.  
 
 
4.2.2.3 Calculation of DNA concentrations  
To calculate the concentration of a DNA preparation, the absorption at 260 nm and 
280 nm was determined with a photometer (Smart Spec 3000, BIO-RAD, 
Hercules). This technique relies on the characteristic of nucleic acids to absorb   
UV light with a wave length of 260 nm.  Absorption at 260 nm (OD260) of one 
equals a DNA concentration of 50 µg/ml. The ratio of the absorption at 260 nm and 
280 nm allows estimating the purity of the DNA and should range between 1.8 and 
2.0. The absorption was always normalised to ddH2O.   
 
 
4.2.2.4 Restriction  
Restriction endonucleases cut dsDNA at specific sequences. The ends generated 
in this process can either be blunt without ss overhangs, or sticky with small        
ss overhangs. Depending on the parental organism of the restriction 
  Material and Methods 
 126
endonucleases, they differ in the optimal temperature and chemical conditions. 
The enzyme activity is defined in units, with 1 unit enzyme cutting 1 mg DNA in      
1 h. Restrictions were always performed following the manufactures’ (Fermentas, 
St. Leon Roth) instructions.   
 
 
4.2.2.5 Ligation  
For a ligation reaction, 50 ng linearised vector DNA was mixed with 3 to 5-fold the 
amount of the insertion fragment in 1 x ligase buffer in a reaction volume of 20 µl. 
After addition of 1 unit T4 ligase (Roche Diagnostics, Mannheim) the DNA-enzyme 
mix was incubated for 1 to 2 h.   
 
 
4.2.2.6 Gel electrophoresis 
DNA molecules are negatively charged, with the charge being proportional to the 
molecular weight. Therefore, they can be separated according to their size in an 
electric field.  
 Electrophoresis was performed in 0.8 to 2% horizontal agarose gels. The agarose 
(Cambrex Bioscience, Rockland) was dissolved in 1 x TAE buffer, and ethidium 
bromide was added to a final concentration of 0.5 µg/ml after the agarose was 
cooled. Ethidium bromide intercalates into dsDNA. This results in a complex, 
which fluoresces when exposed to UV light (254 nm to 366 nm). Emission of      
590 nm light allows the visualisation of the DNA, with a detection limit of approx. 
20 ng dsDNA. The polymerised gel was covered with TAE buffer and 
electrophoresis was performed with a constant voltage of 50 to 120 V. The 
samples were mixed with 1x DNA sample buffer to firstly ballast the DNA with 
glycerol, and to secondly mark the separation front with bromphenol blue. In 
addition to the samples a DNA standard with defined DNA sizes was loaded on 
the gel.   
 
4.2.2.7 Gel elution 
To isolate a DNA fragment which was previously separated on a gel, the DNA 
band was excised as precisely as possible from the gel. The purification was 
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performed with the QiaQuick Gel Elution Kit (Qiagen, Hilden) according to the 
instructions. The DNA was eluted in 30 µl ddH2O.   
 
 
4.2.2.8 Cloning of RFP and GFP fusion proteins with HBV envelope proteins 
 
pCH S-GFP An-b-glob 
The plasmid pCH S-GFP An-b-glob encodes a fusion protein consisting of the 
HBV S protein and the C-terminally fused GFP. The protein is under CMV 
promoter control and contains the polyA chain from the β-globin gene. The GFP 
gene was obtained from the plasmid pCH GFP An-b-glob via PCR. The primer S-
GFP C-term fw contained a restriction site for AccI, the primer S-GFP C-term rev 
contained a restriction site for SpHI. The PCR product contained the GFP gene 
and the newly generated restrictions sites. Both the plasmid pCH SAg An-b-glob 
and the GFP PCR product were cleaved with AccI and SpHI. After ligation, the 
GFP gene was inserted in the plasmid at the C-terminus of the S gene.  
 
pCH GFP-S An-b-glob 
The plasmid pCH GFP-S An-b-glob encodes a fusion protein consisting of the 
HBV S protein and the N-terminally fused GFP. The protein is under CMV 
promoter control and contains the polyA chain from the β-globin gene. The GFP 
gene was obtained from the plasmid pCH GFP An-b-glob via PCR. The primer 
GFP-S N-term fw contained a restriction site for SalI, the primer GFP-S N-term rev 
contained a restriction site for KpnI. The PCR product contained the GFP gene 
and the newly generated restrictions sites. Both the plasmid pCH SAg An-b-glob 
and the GFP PCR product were cleaved with SalI and KpnI. After ligation the GFP 
gene was inserted in the plasmid at the N-terminus of the S gene.  
 
pCH GFP-sp-S An-b-glob 
This plasmid is based on pCH GFP-S An-b-glob. To introduce a spacer of 9 aa 
between the GFP gene and the S gene, a small spacer of 24 bp was generated 
(GFP-S N-term sp fw and GFP-S N-term sp rev). The spacer sequence contains a 
KpnI restriction site on both ends. The vector pCH GFP-S An-b-glob as well as the 
spacer sequence were cleaved with KpnI and ligated. The orientation of the insert 
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in the plasmid was controlled via restriction patterns after cleavage with different 
enzymes.      
 
pCH M-GFP An-b-glob 
To obtain a plasmid encoding the M gene with the GFP C-terminally fused to it, the 
plasmids 000HBV and pCH S-GFP An-b-glob were used. Via PCR using the 
primers M-GFP fw and M-GFP rev a sequence containing the preS1 region and 
the beginning of the S region, was amplified. In front of the sequence a KpnI 
restriction site was generated, at the 5`end of the minus strand a AvrII cleavage 
site was introduced. The ATG of the S region, which is the start codon of the S 
protein, was exchanged to ACG. The plasmid pCH S-GFP An-b-glob and the PCR 
product were cleaved with KpnI and AvrII and ligated.   
 
pCH L-GFP An-b-glob 
To obtain a plasmid encoding the L gene with the GFP C-terminally fused to it, the 
plasmids 000HBV and pCH S-GFP An-b-glob were used. Via PCR using the 
primers L-GFP fw and L-GFP rev a sequence containing the preS1 region and the 
beginning of the preS2 region was amplified. At the 5`end of the plus strand a KpnI 
restriction site was generated, at the 5`end of the minus strand a AvrII cleavage 
site was introduced. The ATG of the preS2 region, which is the start codon of the 
M protein, was exchanged to ACG. The plasmid pCH S-GFP An-b-glob and the 
PCR product were cleaved with KpnI and AvrII and ligated.  
   
pCH S-RFP An-b-glob 
The plasmid encodes the RFP gene C-terminally fused to the S gene. The mRFP 
gene was obtained from the mRFP1_pRSETB plasmid via PCR with the primers 
RFP fw and RFP rev. With the PCR restrictions sites for AccI and PeaI were 
generated at the 5`end of the plus strand and the 5`end of the minus strand, 
respectively. After restriction of the mRFP PCR fragment and the plasmid pCH S-
GFP An-b-glob with AccI and PaeI, the RFP was ligated into the plasmid pCH S-
GFP An-b-glob. The GFP was removed by the restriction. 
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pCH M-RFP An-b-glob 
The plasmid encodes the RFP gene C-terminally fused to the M gene. The mRFP 
gene was obtained from the mRFP1_pRSETB plasmid as described. After 
restriction of the mRFP PCR fragment and the plasmid pCH M-GFP An-b-glob 
with AccI and PaeI, the RFP was ligated into the plasmid pCH M-GFP An-b-glob. 
The GFP was removed by the restriction. 
 
pCH L-RFP An-b-glob 
The plasmid encodes the RFP gene C-terminally fused to the L gene. The mRFP 
gene was obtained from the mRFP1_pRSETB plasmid as described. After 
restriction of the mRFP PCR fragment and the plasmid pCH L-GFP An-b-glob with 
AccI and PaeI, the RFP was ligated into the plasmid pCH L-GFP An-b-glob. The 
GFP was removed by the restriction. 
 
 
4.2.2.9 Polymerase chain reaction  
PCR is a method to amplify specific DNA sequences located between two primers. 
These are complementary to the 5` and 3` ends of the sequence. The polymerase 
specifically amplifies the sequence in repeated amplification rounds.  
A master-mix was prepared with the following contends per reaction: 
 
Reagent        Concentration 
Polymerase buffer       4 µl 
Pfu polymerase        2 µl  
Primer fw         5 pmol 
Primer rev         5 pmol 
ddH2O         12 µl  
 
150 to 300 ng template DNA or ddH2O were added per reaction. The 
Thermocycler was programmed as follows: 
 
 
 
 
  Material and Methods 
 130
Step    Temperature  Time 
1. Initial denaturation  94°C   2 min      
2. Denaturation   94°C   30 sec 
3. Annealing   60°C   30 sec 
4. Elongation    72°C   90 sec 
5. Final elongation  72°C   5 min 
 
Steps two to four were repeated 30 times. The final elongation step is necessary 
to allow the complete amplification of the sequence fragments.    
 
 
4.2.2.10 Real-time quantitative polymerase chain reaction 
Real-time PCR detection techniques make a kinetic quantification possible. PCR 
amplification depends mostly on the template concentration. However, reaction 
efficiency is as well important: In high efficient reactions with low template 
concentrations the same plateau can be reached as in reactions with high 
template concentrations but low reaction efficiency. Therefore, end point 
quantification analyses are sometimes not accurate. The advantage of real time 
PCR is the measurement in the log-linear phase of constant amplification. This 
allows the precise quantification of the amount of starting material.  
The Light Cycler© instrument from Roche Diagnostics, Mannheim is a 
thermocycler, combined with a fluormeter. For fluorescence detection the       
SYBR Green I Dye was used. This fluorescent dye intercalates only in dsDNA. 
The fluorescence intensity of this DNA-SYBR green complex is much higher than 
the intensity of the dye alone. Therefore, during annealing and elongation phases 
the fluorescent signal increases. The signal intensity is directly proportional to the 
DNA amount, and the highest signal is obtained at the end of the elongation 
phase. Due to the glass capillary system, in which the PCR reaction takes place, a 
rapid thermal transfer is guaranteed. The glass capillaries are located in a 
continuously rotating carousel in a single thermal chamber. The fluorescence 
intensity is measured at the end of each elongation phase at a certain temperature 
in a single optical unit. The LightCycler PCR is very sensitive with a detection limit 
of one to ten copies for plasmid DNA per sample. For genomic DNA the detection 
of a single-copy gene in 3 pg DNA is estimated.    
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Different quantification methods are available with the LightCycler© System. 
Absolute quantification is performed with an external standard curve of known 
concentrations of the target DNA. The relative quantification expresses the target 
gene concentration in relation to a reference gene, usually a house keeping gene 
or mitochondrial DNA. Standard curves of both target and reference gene are 
used to obtain the concentrations. The template concentration is determined with 
so-called crossing points. These points are defined as the cycle numbers, in which 
all amplifications exhibit the same fluorescence intensity. The identification of 
specific DNA products is possible using melting curve profiles. The melting 
temperature of dsDNA depends on length, GC contend and sequence. Thus, 
every sequence has a specific melting curve profile. Within the PCR reaction, the 
melting curve is obtained by steadily increasing temperatures while the 
fluorescence is monitored.       
This sensitive PCR technique was used to detect low amounts of HBV rcDNA and 
cccDNA and to be able to clearly distinguish between the two DNA forms. 
Quantification was performed relative to an external plasmid HBV DNA standard 
on a Light Cycler© instrument with the LightCycler FastStart DNA Masterplus 
SYBR Green I (Roche Diagnostics, Mannheim). This reaction mix contains the 
Taq-DNA-polymerase, reaction buffer, magnesium chloride and dNTPs. The 
following master-mix was prepared per reaction:                 
 
Reagent        Vol. 
LightCycler FastStart DNA Masterplus SYBR Green I   4 µl 
Primer fw          1 µl 
Primer rev          1 µl 
ddH2O          12 µl  
 
2 µl template DNA or ddH2O were added to the mix. The light cycler instrument 
was programmed as shown: 
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Step    Temperature  Time 
1. Initial denaturation  95°C   5 min      
2. Denaturation   95°C   15 sec 
3. Annealing   60°C   4 sec 
4. Elongation    72°C   25 sec 
5. Detection   88°C   2 sec 
 
 
4.2.3. Protein analysis 
 
4.2.3.1 Protein precipitation 
 
4.2.3.1.1 Whole cell protein 
For whole cell proteins the cells were lysed in sample buffer.   
 
4.2.3.1.2 Sub-cellular fractionation   
To separate the membranous, cytosolic and nuclear fractions of cellular proteins, 
the cells were washed twice with PBS and scraped off the dishes. The cells were 
re-suspended in a minimal volume of pre-cooled NP40 buffer and incubated on ice 
for 20 min.. Afterwards, cells were aspirated with a syringe, and destroyed by 
passaging 10 times through a needle (24 gauge). Nuclei were pelleted at 800 x g 
for 5 min at 4°C. The supernatants were ultra-centrifuged at 100000 x g for 30 min 
at 4°C. The pelleted membrane proteins were re-suspended in 50 µl ddH20 or 
protein sample buffer. The cytosolic proteins in the supernatant were precipitated 
as follows: The supernatant was mixed with 4 vol. 100% aceton (pre-cooled at       
-20°C) and incubated for 2 to 3 h at -80°C. After centrifugation at 8000 x g for       
10 min, the protein pellet was air dried and re-suspended in 200 µl ddH20 or 
protein sample buffer.         
 
4.2.3.1.3 Immunoprecipitation  
To isolate proteins from supernatants of cells, 2 ml supernatant was mixed with  
50 µl sepharose, which has previously been washed once with PBS and 
centrifuged for 5 min. at 1000 x g. Hepatect (Biotest Pharma, Dreieich) was added 
in a concentration of 0.5 IE/ml. If rαHBvax (in-house production) was used, 2 µl/ml 
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were added. Supernatants slowly rotated o.n. at 4°C. After centrifugation at     
1000 x g for 5 min., the supernatant was discarded and the sepharose beads were 
washed twice with PBS. Protein sample buffer was added and the beads were 
incubated at 99°C for 10 min. After centrifugation the supernatant was transferred 
to SDS page and Western blot analysis.        
 
 
4.2.3.2 Calculation of protein concentrations 
To determine total protein concentrations, the BCATM Protein Assay Kit (Pierce, 
Rockford) was used. This assay is based on the reduction of Cu2+ to Cu+ by 
proteins in an alkaline medium, combined with the colorimetric detection of Cu+ 
with a reagent containing bicinchonic acid (BCA). The complex formed by the 
chelation of 2 BCA molecules with one Cu+ molecule exhibits a strong absorbance 
at 562 nm. The absorbance is linear with increasing protein concentrations over a 
working range of 20 to 2000 µg/ml. The reaction was performed according to the 
manufacturers’ introductions, and an albumin protein dilution series served as 
protein standard.  
 
 
4.2.3.3 SDS-page gel electrophoresis 
Protein samples were mixed with Laemmli buffer and boiled for 10 min at 99°C.   
10 to 30 µg of protein were transferred to a 12.5% SDS gel.  As a standard for 
protein size a pre-stained marker (Fermentas) was added. The proteins were 
electrophoresed in a blot chamber (MiniProtean®3 Cell, BIO-RAD, Hercules) with 
constant amperage (30 mA per gel).   
 
 
4.2.3.4 Western blot 
The proteins were transferred from the SDS gel onto a methanol-activated PVDF 
membrane (Amersham, Buckinghamshire) using a semi-dry transfer cell (BIORAD, 
Hercules). The amperage was calculated with the following formula:  
1.2 mA/cm² of the gel for 1 h transfer.  
After protein transfer the membrane was blocked in blocking solution for 1 h and 
probed for 1 h at RT or over night at 4°C with the indicated antibody. After three 
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washing steps 10 min each, the secondary antibody was added at in a 1: 2000 
dilution for 1 h. The detection was performed with the Enhanced 
Chemiluminescence detection kit (Amersham, Buckinghamshire).  
If re-probing of the membrane with another antibody was necessary, the 
membrane was previously stripped with 0.2 M NaOH for 10 min. PDVF 
membranes were re-activated in methanol, and blocking and antibody incubation 
were performed as described.  
 
 
4.2.3.5 ELISA 
The HBsAg ELISA (Murex, Abbott, Wiesbaden) detects different epitopes of the 
HBsAg. It was performed according to the manufacturers’ instructions. In short,   
75 µl of each sample was pipetted into the microtiter wells containing 25 µl sample 
dilution buffer. Additionally, a provided negative and positive control was applied. 
60 min incubation at 37°C allowed the binding reaction between the monoclonal 
anti HBsAg antibodies, which are immobilised on the well, and the antigen in the 
samples. 50 µl of conjugate were added to the samples. It consists of polyclonal 
antibodies against HBsAg, which are conjugated to HRP. If HBsAg was captured 
by the coated antibodies, a complex of antibody-antigen-antibody-HRP would 
form.  The plate was carefully moved to ensure mixing prior to 30 min incubation at 
37°C. Following several washes, 100 µl of the substrate for the HRP was added. 
After 30 min incubation at 37°C the colour reaction of HRP and substrate had 
preceded, and a stop solution, containing 0.5 m sulphuric acid, was added to stop 
the reaction. The readout was in dual frequencies at 450 nm and, as a reference 
wave length, 620 nm in a plate reader.  
The measurement of HBsAg and HBeAg in cell supernatants was performed in the 
diagnostic laboratory of the Institute for Virology, University of Cologne, with the 
commercial immuno-assays from Abbott, Wiesbaden (Axsym HBeAg 2.0 and 
HBsAg V2).             
 
 
4.2.3.6 Flow cytometry 
Flow cytometry is a technique used to separate cells by different parameters. A 
single cell suspension flows through multiple detectors, passing a laser light beam. 
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The suspended cells scatter the light beam in a specific way, depending on size 
and density. Fluorescently labelled cells emit light in specific wave lengths, which 
are picked up by the detectors. The data obtained by the flow cytometer are 
plotted 2-dimensional, and regions within the plot are subsequently separated by 
fluorescence intensity.   
This method was used to determine the purity of isolated cell populations. The 
cells were labelled with fluorescent antibodies specific for the targeted cell 
population. The maturation state of moDCs was examined by staining immature 
and mature moDCs with monoclonal antibodies against HLA-DR (BD Pharmingen, 
Dan Diego), CD80 (BD Pharmingen, Dan Diego), CD83 (Immunotech, Marseille) 
and CD86 (BD Pharmingen, Dan Diego) in the concentrations recommended by 
the manufacturers. To assay the purity of isolated mDCs, they were stained with 
monoclonal FITC-conjugated antibodies against the mDC markers BDCA-2 and 
CD123 (Miltenyi, Bergisch Gladbach). For pDCs, streptavidin-PE (BD Pharmingen, 
Dan Diego) was used to stain the biotinylated BDCA-1 antibody previously used 
for isolation. The cells were incubated in PBS with the indicated antibodies for     
30 min on ice, with occasional shaking. After two wash steps, the cells were re-
suspended in 400 µl PBS supplemented with propidium iodide, to stain for dead 
cells. The analysis was performed in a flow cytometer (FACSCantoTM, BD 
Biosciences, Heidelberg).        
 
 
4.2.3.7 Immuno-fluorescence staining 
HuH7 cells were plated on 8-well glass slides (Lab Tec, Nunc, Wiesbaden). At 
60% confluency, they were transfected with 0.1 µg of plasmid per well, using 
FuGene6®. 1 or 2 days post transfection, cells were washed 3-fold with PBS and 
fixed in 3.7% PFA for 10 min.. Immediately after fixation, the cells were incubated 
with 50 mM ammonium acetate to saturate the free PFA residues. Following three 
washes with PBS, the cells were permeabilised with 0.5% saponin/PBS for         
10 min.. Unspecific antibody binding sites were blocked with 10% serum in 0.1% 
saponin/PBS for 1 h. The primary antibody was added in a dilution of 1 : 500. 
Three washing steps with 0.1% saponin/PBS for 10 min each followed, before the 
cells were incubated for 1 h with the secondary antibody, diluted 1 : 2000 and 
supplemented with Dapi (0.5 µg/ml). The cells were washed 3-fold with           
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0.1% saponin/PBS. All incubation and washing steps were performed on a slowly 
rocking platform. After the staining procedure, the 8-well chambers were removed 
from the slide and the cells were mounted with Mowiol/Dabco. A cover slip was 
sealed on the slide with nail polish. The slides were stored at 4°C. 
Immunofluorescence analysis was performed on an Olympus IX81 microscope or 
on an Olympus FluoView1000 confocal microscope (Olympus, Hamburg).        
 
 
4.2.3.8 Co-localisation studies 
In the cell biological context, co-localisation is defined as the presence of two 
molecules in the same physiological location within a specimen, for example in the 
same organelle or cellular compartment or bound to the same receptor. Regarding 
digital imaging, co-localisation means that the same pixel of an image is shared by 
different colours, which are emitted by fluorophores.  
To be able to obtain trustable and reproducible results from co-localisation studies, 
a few points have to be considered. First of all, the sample preparation and 
staining should be optimised in a way, that unspecific labelling and                   
auto-fluorescence are reduced to a minimum. Furthermore, selected fluorophore 
combinations should have widely separated emission spectra to avoid            
bleed-through artefacts. Another important consideration for choice of fluorophores 
is the matching to the power spectrum of the laser lines.  
Each antibody and fluorophore needs to be controlled in separate labelling 
experiments to determine the bleed-through under the actual experimental 
conditions. Auto-fluorescence of the specimen can be monitored in an unlabeled 
control. On the basis of these data, parameters such as photomultiplier voltage, 
offset and gain can be adjusted separately for each channel. It is important to find 
the conditions in which all fluorophores are displayed in the full 8-bit range. 
Differences in the intensities of the different fluorophores that are to be analysed 
for co-localisation can lead to false negative or positive results.         
The co-localisation studies were performed using the Olympus FluoView1000 
confocal microscope (Olympus, Hamburg). Single-labelled samples and negative 
controls were examined in both wavelengths to determine the experimental 
settings and to exclude bleed-through. Images were obtained using sequential 
excitation in the confocal microscope scanning configuration. At least 6 images 
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were examined in each experiment and analysed using the co-localisation tool of 
the FV10-ASW software (Version 1.6a, AnalySIS, Soft Imaging System GmbH, 
Münster).  
 
 
4.2.3.9 Electron microscopy 
The cells were pelleted in a 1.5 ml microfuge tube at 1000 x g. The supernatant 
was removed, and the cell pellet was fixed in 2.5% glutaraldehyde for 12 h at 4°C. 
After 3-fold washing in PBS, the cells were incubated in 2% OsO4 and                 
1% K3Fe(CN)6 for 1 h. After three further washes, the pellets were dehydrated and 
infiltrated in a 1:1 mixture of propylene oxide (Polybed 812 and epoxy resin; 
Polysciences) and embedded in resin. Ultra thin (50-nm) sections were collected 
on 200-mesh copper grids and stained with 6% uranyl acetate in ddH2O for 10 min 
followed by 1% lead citrate for 15 min. Sections were viewed using a Zeiss 902 
transmission electron microscope at 50 kV (Carl Zeiss AG, Jena). 
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6. Abbreviations 
 
aa      Amino acid 
Amp     Ampicillin 
Approx.    Approximately 
APS     Ammonium persulphate 
α     Anti  
BDCA    Blood dendritic cell antigen    
bp      Base pairs 
cccDNA     Covalently closed circular DNA 
CD     Cluster of differntiation 
CMV    Cytomegalovirus  
CMV-promoter    CMV-IE-Promoter 
CsCl    Cesium chloride    
C-terminal    Carboxy-terminal 
DABCO   1,4- Diazabicyclo[2,2,2]octane 98%)   
DAPI    4',6-Diamidino-2-phenylindol 
DC     Dendritic cell  
ddH2O     Double distilled water 
DMSO    Dimethylsulfoxid 
DNA     Desoxyribonucleic acid 
Ds     Double-stranded 
EDTA    Ethylenedinitrilotetraacedic acid 
EEA1    Early endosomal antigen 1 
e.g.    exempli gratia 
EGTA    Ethylene glycol bis2-aminoethyl)-tetraacetic acid  
EtBr     Ethidiumbromide 
ELISA     Enzyme linked immunosorbent assay 
Enh     Enhancer 
FCS    Fetal Calf serum 
GFP   Green fluorescent protein 
GM130  Golgi matrix protein 130 
GMCSF Granulocyte-makrophage colony stimulating      
   factor 
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h  Hour 
HBsAg  S antigen of HBV 
HBV  Hepatitis B Virus 
HCC  Hepatocellular carcinoma 
HCV  Hepatitis C Virus 
HNF Hepatic nuclear factor 
HRP  Horse radish peroxidase 
HSP90  Heatshock protein 90 
l  Liter 
lamp1 Lysosome associated membrane protein 1 
Ig  Immunglobulin 
IL-4    Interleucin-4 
kb      Kilo base 
kDa     Kilo dalton 
LPS    Lipopolysaccharid 
mA     Milli-Ampere 
mDC    Myeloid dendritic cell 
µg      Microgram 
µl      Microliter 
µM     Micromolar 
mg     Milligram 
MHC    Major histocompatibility complex 
Min     Minute 
ml     Milliliter 
mM     Millimolar 
moDC    Monocyte derived dendritic cell 
MOI     Multiplicity of infection 
mRNA    Messenger RNA 
MRP2    Multidrug resistant protein 2 
NEAA    Non-essential amino acids 
nM      Nanomolar 
N-terminal    Amino-terminal 
nt      Nucleotide 
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OD     Optical density 
ori      Origin of replication 
ORF     Open reading frame 
PAA     Polyacrylamid 
PAGE     Polyacrylamid gel electrophorese 
PBMC    Peripheral blood mononuclear cells 
PBS     Phosphate buffered saline 
PCR     Polymerase chain reaction 
pDC    Plasmacytoid dendritic cell 
Pg     Pregenomic 
PGE2    Prostaglandin E2 
PHH    Primary human hepatocytes 
P/S     Penicillin/Streptomycin 
Rab6    Ras-like GTPase 6 
Rc     Relaxed circular 
RFP    Red fluorescent protein 
RLU    Relative light units  
Sec    Second  
Ss     Single-stranded 
SVP    Subviral particle 
TAE     Tris-Acetat-EDTA buffer 
TEMED    N,N,N’,N’-Tetramethylethylendiamin 
TGN    trans-Golgi network 
TNFα    Tumor necrosis factor α 
Tween 20    Polyoxyethylensorbitanmonolaurat 
V     Volt 
VP     Virus particle 
w/v     Weight per volume 
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7. Sequences 
 
pCH -9/3091 
(HBV sequence underlined) 
 
ATGGACATCGACCCTTATAAAGAATTTGGAGCTACTGTGGAGTTACTCTCGTTTTTGCCTTCTG
ACTTCTTTCCTTCAGTACGAGATCTTCTAGATACCGCCTCAGCTCTGTATCGGGAAGCCTTAGA
GTCTCCTGAGCATTGTTCACCTCACCATACTGCACTCAGGCAAGCAATTCTTTGCTGGGGGGAA
CTAATGACTCTAGCTACCTGGGTGGGTGTTAATTTGGAAGATCCAGCGTCTAGAGACCTAGTAG
TCAGTTATGTCAACACTAATATGGGCCTAAAGTTCAGGCAACTCTTGTGGTTTCACATTTCTTG
TCTCACTTTTGGAAGAGAAACAGTTATAGAGTATTTGGTGTCTTTCGGAGTGTGGATTCGCACT
CCTCCAGCTTATAGACCACCAAATGCCCCTATCCTATCAACACTTCCGGAGACTACTGTTGTTA
GACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAGACGAAGGTCTCAATCGCC
GCGTCGCAGAAGATCTCAATCTCGGGAATCTCAATGTTAGTATTCCTTGGACTCATAAGGTGGG
GAACTTTACTGGGCTTTATTCTTCTACTGTACCTGTCTTTAATCCTCATTGGAAAACACCATCT
TTTCCTAATATACATTTACACCAAGACATTATCAAAAAATGTGAACAGTTTGTAGGCCCACTCA
CAGTTAATGAGAAAAGAAGATTGCAATTGATTATGCCTGCCAGGTTTTATCCAAAGGTTACCAA
ATATTTACCATTGGATAAGGGTATTAAACCTTATTATCCAGAACATCTAGTTAATCATTACTTC
CAAACTAGACACTATTTACACACTCTATGGAAGGCGGGTATATTATATAAGAGAGAAACAACAC
ATAGCGCCTCATTTTGTGGGTCACCATATTCTTGGGAACAAGATCTACAGCATGGGGCAGAATC
TTTCCACCAGCAATCCTCTGGGATTCTTTCCCGACCACCAGTTGGATCCAGCCTTCAGAGCAAA
CACCGCAAATCCAGATTGGGACTTCAATCCCAACAAGGACACCTGGCCAGACGCCAACAAGGTA
GGAGCTGGAGCATTCGGGCTGGGTTTCACCCCACCGCACGGAGGCCTTTTGGGGTGGAGCCCTC
AGGCTCAGGGCATACTACAAACTTTGCCAGCAAATCCGCCTCCTGCCTCCACCAATCGCCAGTC
AGGAAGGCAGCCTACCCCGCTGTCTCCACCTTTGAGAAACACTCATCCTCAGGCCATGCAGTGG
AATTCCACAACCTTCCACCAAACTCTGCAAGATCCCAGAGTGAGAGGCCTGTATTTCCCTGCTG
GTGGCTCCAGTTCAGGAACAGTAAACCCTGTTCTGACTACTGCCTCTCCCTTATCGTCAATCTT
CTCGAGGATTGGGGACCCTGCGCTGAACATGGAGAACATCACATCAGGATTCCTAGGACCCCTT
CTCGTGTTACAGGCGGGGTTTTTCTTGTTGACAAGAATCCTCACAATACCGCAGAGTCTAGACT
CGTGGTGGACTTCTCTCAATTTTCTAGGGGGAACTACCGTGTGTCTTGGCCAAAATTCGCAGTC
CCCAACCTCCAATCACTCACCAACCTCTTGTCCTCCAACTTGTCCTGGTTATCGCTGGATGTGT
CTGCGGCGTTTTATCATCTTCCTCTTCATCCTGCTGCTATGCCTCATCTTCTTGTTGGTTCTTC
TGGACTATCAAGGTATGTTGCCCGTTTGTCCTCTAATTCCAGGATCCTCAACAACCAGCACGGG
ACCATGCCGGACCTGCATGACTACTGCTCAAGGAACCTCTATGTATCCCTCCTGTTGCTGTACC
AAACCTTCGGACGGAAATTGCACCTGTATTCCCATCCCATCATCCTGGGCTTTCGGAAAATTCC
TATGGGAGTGGGCCTCAGCCCGTTTCTCCTGGCTCAGTTTACTAGTGCCATTTGTTCAGTGGTT
CGTAGGGCTTTCCCCCACTGTTTGGCTTTCAGTTATATGGATGATGTGGTATTGGGGGCCAAGT
CTGTACAGCATCTTGAGTCCCTTTTTACCGCTGTTACCAATTTTCTTTTGTCTTTGGGTATACA
TTTAAACCCTAACAAAACAAAGAGATGGGGTTACTCTCTAAATTTTATGGGTTATGTCATTGGA
TGTTATGGGTCCTTGCCACAAGAACACATCATACAAAAAATCAAAGAATGTTTTAGAAAACTTC
CTATTAACAGGCCTATTGATTGGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGTTTTGCTGC
CCCTTTTACACAATGTGGTTATCCTGCGTTGATGCCTTTGTATGCATGTATTCAATCTAAGCAG
GCTTTCACTTTCTCGCCAACTTACAAGGCCTTTCTGTGTAAACAATACCTGAACCTTTACCCCG
TTGCCCGGCAACGGCCAGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGCTGGGGCTT
GGTCATGGGCCATCAGCGCATGCGTGGAACCTTTTCGGCTCCTCTGCCGATCCATACTGCGGAA
CTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGAGCAAACATTATCGGGACTGATAACTCTG
TTGTCCTATCCCGCAAATATACATCGTTTCCATGGCTGCTAGGCTGTGCTGCCAACTGGATCCT
GCGCGGGACGTCCTTTGTTTACGTCCCGTCGGCGCTGAATCCTGCGGACGACCCTTCTCGGGGT
CGCTTGGGACTCTCTCGTCCCCTTCTCCGTCTGCCGTTCCGACCGACCACGGGGCGCACCTCTC
TTTACGCGGACTCCCCGTCTGTGCCTTCTCATCTGCCGGACCGTGTGCACTTCGCTTCACCTCT
GCACGTCGCATGGAGACCACCGTGAACGCCCACCAAATATTGCCCAAGGTCTTACATAAGAGGA
CTCTTGGACTCTCAGCAATGTCAACGACCGACCTTGAGGCATACTTCAAAGACTGTTTGTTTAA
AGACTGGGAGGAGTTGGGGGAGGAGATTAGGTTAAAGGTCTTTGTACTAGGAGGCTGTAGGCAT
AAATTGGTCTGCGCACCAGCACCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTTCATG
TCCTACTGTTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGGGCATGGACATCGACCCTTAT
AAAGAATTTGGAGCTACTGTGGAGTTACTCTCGTTTTTGCCTTCTGACTTCTTTCCTTCAGTAC
GAGATCCCCGGGCGAGCTCGCTAGCCCTATAGTGAGTCGTATTAATAGCTCGAATTGATCTGAT
CAAATTCCGTGTATTCTATAGTGTCACCTAAATCGTATGTGTATGATACATAAGGTTATGTATT
AATTGTAGCCGCGTTCTAACGACAATATGTGGCCTCGTGATACGCCTATTTTTATAGGTTAATG
TCATGATAATAATGGTTTCTTAGCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATT
TGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGC
TTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTT
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TTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCT
GAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTG
AGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGC
GGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAAT
GACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAAT
TATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGG
AGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGT
TGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAA
TGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATT
AATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGC
TGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGG
GGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGA
TGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGAC
CAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGG
TGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGC
GTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGC
TGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAA
CTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTA
GCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATC
CTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGAT
AGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGA
GCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCC
GAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGG
AGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGA
GCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCC
TTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTG
ATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGAC
CGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCC
GCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTG
AGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCT
TCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGAC
CATGATTACGCCAAGCTGCTTGGGctgcaGATTATTGACTAGTTATTAATAGTAATCAATTACG
GGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGC
CTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAAC
GCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCA
GTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCG
CCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATT
AGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTT
GACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGTACCAAA
ATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCG
TGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTCGACGCACCATGCAACTTTTTCACCTCTGC
CTAATCATCTCTTGTTCATGTCCTACTGTTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGG
GC 
 
 
pCH GFP An-b-glob 
(GFP sequence underlined) 
 
ATGAGCAAGGGCGAGGAACTGTTCACTGGCGTGGTCCCAATTCTCGTGGAACTGGATGGCGATG
TGAATGGGCACAAATTTTCTGTCAGCGGAGAGGGTGAAGGTGATGCCACATACGGAAAGCTCAC
CCTGAAATTCATCTGCACCACTGGAAAGCTCCCTGTGCCATGGCCAACACTGGTCACTACCTTC
ACCTATGGCGTGCAGTGCTTTTCCAGATACCCAGACCATATGAAGCAGCATGACTTTTTCAAGA
GCGCCATGCCCGAGGGCTATGTGCAGGAGAGAACCATCTTTTTCAAAGATGACGGGAACTACAA
GACCCGCGCTGAAGTCAAGTTCGAAGGTGACACCCTGGTGAATAGAATCGAGCTGAAGGGCATT
GACTTTAAGGAGGATGGAAACATTCTCGGCCACAAGCTGGAATACAACTATAACTCCCACAATG
TGTACATCATGGCCGACAAGCAAAAGAATGGCATCAAGGTCAACTTCAAGATCAGACACAACAT
TGAGGATGGATCCGTGCAGCTGGCCGACCATTATCAACAGAACACTCCAATCGGCGACGGCCCT
GTGCTCCTCCCAGACAACCATTACCTGTCCACCCAGTCTGCCCTGTCTAAAGATCCCAACGAAA
AGAGAGACCACATGGTCCTGCTGGAGTTTGTGACCGCTGCTGGGATCACACATGGCATGGACGA
GCTGTACAAGTGAGATCGATTCGAAGCTTGCATGCGCGGCCGCTTCAGGGTGAGTTTGGGGACC
CTTGATTGTTCTTTCTTTTTCGCTATTGTAAAATTCATGTTATATGGAGGGGGCAAAGTTTTCA
GGGTGTTGTTTAGAATGGGAAGATGTCCCTTGTATCACCATGGACCCTCATGATAATTTTGTTT
CTTTCACTTTCTACTCTGTTGACAACCATTGTCTCCTCTTATTTTCTTTTCATTTTCTGTAACT
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TTTTCGTTAAACTTTAGCTTGCATTTGTAACGAATTTTTAAATTCACTTTTGTTTATTTGTCAG
ATTGTAAGTACTTTCTCTAATCATTTTTTTTTCAAGGCAATCAGGGTATATTATATTGTACTTC
AGCACAGTTTTAGAGAACAATTGTTATAATTAAATGATAAGGTAGAATATTTCTGCATATAAAT
TCTGGCTGGCGTGGAAATATTCTTATTGGTAGAAACAACTACACCCTGGTCATCATCCTGCCTT
TCTCTTTATGGTTACAATGATATACACTGTTTGAGATGAGGATAAAATACTCTGAGTCCAAACC
GGGCCCCTCTGCTAACCATGTTCATGCCTTCTTCTCTTTCCTACAGCTCCTGGGCAACGTGCTG
GTTGTTGTGCTGTCTCATCATTTTGGCAAAGAATTCACTCCTCAGGTGCAGGCTGCCTATCAGA
AGGTGGTGGCTGGTGTGGCCAATGCCCTGGCTCACAAATACCACTGAGATCTTTTTCCCTCTGC
CAAAAATTATGGGGACATCATGAAGCCCCTTGAGCATCTGACTTCTGGCTAATAAAGGAAATTT
ATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGG
CAAATCATTTAAAACATCAGAATGAGTATTTGGTTTAGAGTTTGGCTAGCCCTATAGTGAGTCG
TATTAATAGCTCGAATTGATCTGATCAAATTCCGTGTATTCTATAGTGTCACCTAAATCGTATG
TGTATGATACATAAGGTTATGTATTAATTGTAGCCGCGTTCTAACGACAATATGTGGCCTCGTG
ATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGCAGGTGGCACTTTTCG
GGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTC
ATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAAC
ATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGA
AACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTG
GATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCA
CTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGG
TCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTT
ACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGG
CCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGG
GGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAG
CGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTAC
TTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACT
TCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGG
TCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACA
CGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACT
GATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTT
CATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTT
AACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGA
TCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTT
TGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGA
TACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACC
GCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGT
CTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGG
GTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGA
GCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGG
GTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTG
TCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCT
ATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCAC
ATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTG
ATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCG
CCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGG
TTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGG
CACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACA
ATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTGCTTGGGCTGCAGATTATTGAC
TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTT
ACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAA
TAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTA
TTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATT
GACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTC
CTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGcatgGTGATGCGGTTTTGGC
AGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGA
CGTCAATGGGAGTTTGTTTTgcAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCC
CATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGGTCGAGGATT
GGGGACCCTGCGCTGAACATGGAGAACGGTACC 
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mRFP1_pRSETB 
(RFP sequence underlined) 
 
ATGGCCTCCTCCGAGGACGTCATCAAGGAGTTCATGCGCTTCAAGGTGCGCATGGAGGGCTCCG
TGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGAC
CGCCAAGCTGAAGGTGACCAAGGGCGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCTCAG
TTCCAGTACGGCTCCAAGGCCTACGTGAAGCACCCCGCCGACATTCCCCGACTACTTGAAGCTG
TCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCGTGGTGACCG
TGACCCAGGACTCCTCCCTGCAGGACGGCGAGTTCATCTACAAGGTGAAGCTGCGCGGCACCAA
CTTCCCCTCCGACGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCCTCCACCGAGCGG
ATGTACCCCGAGGACGGCGCCCTGAAGGGCGAGATCAAGATGAGGCTGAAGCTGAAGGACGGCG
GCCACTACGACGCCGAGGTCAAGACCACCTACATGGCCAAGAAGCCCGTGCAGCTGCCCGGCGC
CTACAAGACCGACATCAAGCTGGACATCACCTCCCACAACGAGGACTACACCATCGTGGAACAG
TACGAGCGCGCCGAGGGCCGCCACTCCACCGGCGCCTAAGAATTCGAAGCTTGATCCGGCTGCT
AACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCC
TTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATCTGG
CGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAAT
GGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGC
TACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTC
GCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTAC
GGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATA
GACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACT
GGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGG
CCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAAC
GCTTACAATTTAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCT
AAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTG
AAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTT
TGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGG
GTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCC
CGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGT
ATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGT
ACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGC
CATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAG
CTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGC
TGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTT
GCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATG
GAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTG
ATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAA
GCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGA
CAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCAT
ATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTT
TGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTA
GAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAA
AAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAA
GGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGC
CACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGG
CTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAA
GGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTAC
ACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGG
CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGG
AAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTG
TGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCC
TGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAA
CCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAG
TCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGA
TTCATTAATGCAGGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAACGG
TTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGCGGGGTTCTCATC
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ATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGGGATCTGTACGA
CGATGACGATAAGGATCCG 
 
 
pCH mRFP An-b-glob 
(RFP sequence underlined) 
 
ATGGCCTCCTCCGAGGACGTCATCAAGGAGTTCATGCGCTTCAAGGTGCGCATGGAGGGCTCCG
TGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGAC
CGCCAAGCTGAAGGTGACCAAGGGCGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCTCAG
TTCCAGTACGGCTCCAAGGCCTACGTGAAGCACCCCGCCGACATTCCCCGACTACTTGAAGCTG
TCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCGTGGTGACCG
TGACCCAGGACTCCTCCCTGCAGGACGGCGAGTTCATCTACAAGGTGAAGCTGCGCGGCACCAA
CTTCCCCTCCGACGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCCTCCACCGAGCGG
ATGTACCCCGAGGACGGCGCCCTGAAGGGCGAGATCAAGATGAGGCTGAAGCTGAAGGACGGCG
GCCACTACGACGCCGAGGTCAAGACCACCTACATGGCCAAGAAGCCCGTGCAGCTGCCCGGCGC
CTACAAGACCGACATCAAGCTGGACATCACCTCCCACAACGAGGACTACACCATCGTGGAACAG
TACGAGCGCGCCGAGGGCCGCCACTCCACCGGCGCCTAAGAATTGATCGATTCGAAGCTTGCAT
GCGCGGCCGCTTCAGGGTGAGTTTGGGGACCCTTGATTGTTCTTTCTTTTTCGCTATTGTAAAA
TTCATGTTATATGGAGGGGGCAAAGTTTTCAGGGTGTTGTTTAGAATGGGAAGATGTCCCTTGT
ATCACCATGGACCCTCATGATAATTTTGTTTCTTTCACTTTCTACTCTGTTGACAACCATTGTC
TCCTCTTATTTTCTTTTCATTTTCTGTAACTTTTTCGTTAAACTTTAGCTTGCATTTGTAACGA
ATTTTTAAATTCACTTTTGTTTATTTGTCAGATTGTAAGTACTTTCTCTAATCATTTTTTTTTC
AAGGCAATCAGGGTATATTATATTGTACTTCAGCACAGTTTTAGAGAACAATTGTTATAATTAA
ATGATAAGGTAGAATATTTCTGCATATAAATTCTGGCTGGCGTGGAAATATTCTTATTGGTAGA
AACAACTACACCCTGGTCATCATCCTGCCTTTCTCTTTATGGTTACAATGATATACACTGTTTG
AGATGAGGATAAAATACTCTGAGTCCAAACCGGGCCCCTCTGCTAACCATGTTCATGCCTTCTT
CTCTTTCCTACAGCTCCTGGGCAACGTGCTGGTTGTTGTGCTGTCTCATCATTTTGGCAAAGAA
TTCACTCCTCAGGTGCAGGCTGCCTATCAGAAGGTGGTGGCTGGTGTGGCCAATGCCCTGGCTC
ACAAATACCACTGAGATCTTTTTCCCTCTGCCAAAAATTATGGGGACATCATGAAGCCCCTTGA
GCATCTGACTTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTG
TGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCATTTAAAACATCAGAATGAGTATTTGG
TTTAGAGTTTGGCTAGCCCTATAGTGAGTCGTATTAATAGCTCGAATTGATCTGATCAAATTCC
GTGTATTCTATAGTGTCACCTAAATCGTATGTGTATGATACATAAGGTTATGTATTAATTGTAG
CCGCGTTCTAACGACAATATGTGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATA
ATAATGGTTTCTTAGCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATT
TTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAA
TATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGG
CATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCA
GTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTT
CGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTAT
CCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGT
TGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGT
GCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGA
AGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACC
GGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACA
ACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACT
GGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTAT
TGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGAT
GGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAA
ATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTA
CTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATC
CTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACC
CCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCA
AACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTT
CCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGT
TAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACC
AGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCG
GATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGA
CCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAG
AAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCA
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GGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGAT
TTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACG
GTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTG
GATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCA
GCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTG
GCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAAC
GCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTC
GTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTA
CGCCAAGCTGCTTGGGCTGCAGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATT
AGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGA
CCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAG
GGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCA
AGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCAT
TATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCG
CTATTACCATGcatgGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACT
CACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTgcAAAATCAACGG
GACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGT
GGGAGGTCTATATAAGCAGAGGTCGAGGATTGGGGACCCTGCGCTGAACATGGAGAACGGTACC 
 
 
pCH S-Ag An-b-glob 
(S sequence underlined) 
 
ATGGAGAACATCACATCAGGATTCCTAGGACCCCTTCTCGTGTTACAGGCGGGGTTTTTCTTGT
TGACAAGAATCCTCACAATACCGCAGAGTCTAGACTCGTGGTGGACTTCTCTCAATTTTCTAGG
GGGAACTACCGTGTGTCTTGGCCAAAATTCGCAGTCCCCAACCTCCAATCACTCACCAACCTCT
TGTCCTCCAACTTGTCCTGGTTATCGCTGGATGTGTCTGCGGCGTTTTATCATCTTCCTCTTCA
TCCTGCTGCTATGCCTCATCTTCTTGTTGGTTCTTCTGGACTATCAAGGTATGTTGCCCGTTTG
TCCTCTAATTCCAGGATCCTCAACAACCAGCACGGGACCATGCCGGACCTGCATGACTACTGCT
CAAGGAACCTCTATGTATCCCTCCTGTTGCTGTACCAAACCTTCGGACGGAAATTGCACCTGTA
TTCCCATCCCATCATCCTGGGCTTTCGGAAAATTCCTATGGGAGTGGGCCTCAGCCCGTTTCTC
CTGGCTCAGTTTACTAGTGCCATTTGTTCAGTGGTTCGTAGGGCTTTCCCCCACTGTTTGGCTT
TCAGTTATATGGATGATGTGGTATTGGGGGCCAAGTCTGTACAGCATCTTGAGTCCCTTTTTAC
CGCTGTTACCAATTTTCTTTTGTCTTTGGGTATACATTTAACAAGCTTGCATGCGCGGCCGCTT
CAGGGTGAGTTTGGGGACCCTTGATTGTTCTTTCTTTTTCGCTATTGTAAAATTCATGTTATAT
GGAGGGGGCAAAGTTTTCAGGGTGTTGTTTAGAATGGGAAGATGTCCCTTGTATCACCATGGAC
CCTCATGATAATTTTGTTTCTTTCACTTTCTACTCTGTTGACAACCATTGTCTCCTCTTATTTT
CTTTTCATTTTCTGTAACTTTTTCGTTAAACTTTAGCTTGCATTTGTAACGAATTTTTAAATTC
ACTTTTGTTTATTTGTCAGATTGTAAGTACTTTCTCTAATCATTTTTTTTTCAAGGCAATCAGG
GTATATTATATTGTACTTCAGCACAGTTTTAGAGAACAATTGTTATAATTAAATGATAAGGTAG
AATATTTCTGCATATAAATTCTGGCTGGCGTGGAAATATTCTTATTGGTAGAAACAACTACACC
CTGGTCATCATCCTGCCTTTCTCTTTATGGTTACAATGATATACACTGTTTGAGATGAGGATAA
AATACTCTGAGTCCAAACCGGGCCCCTCTGCTAACCATGTTCATGCCTTCTTCTCTTTCCTACA
GCTCCTGGGCAACGTGCTGGTTGTTGTGCTGTCTCATCATTTTGGCAAAGAATTCACTCCTCAG
GTGCAGGCTGCCTATCAGAAGGTGGTGGCTGGTGTGGCCAATGCCCTGGCTCACAAATACCACT
GAGATCTTTTTCCCTCTGCCAAAAATTATGGGGACATCATGAAGCCCCTTGAGCATCTGACTTC
TGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCACTC
GGAAGGACATATGGGAGGGCAAATCATTTAAAACATCAGAATGAGTATTTGGTTTAGAGTTTGG
CTAGCCCTATAGTGAGTCGTATTAATAGCTCGAATTGATCTGATCAAATTCCGTGTATTCTATA
GTGTCACCTAAATCGTATGTGTATGATACATAAGGTTATGTATTAATTGTAGCCGCGTTCTAAC
GACAATATGTGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCT
TAGCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACA
TTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGG
AAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTC
CTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACG
AGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAA
CGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACG
CCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACC
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AGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACC
ATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCG
CTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGA
AGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAA
CTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGG
ATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATC
TGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCC
CGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCG
CTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACT
TTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAAT
CTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGA
TCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACC
ACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACT
GGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACT
TCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGC
CAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAG
CGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAAC
TGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAG
GTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCC
TGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCT
CGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTT
TTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATT
ACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGA
GCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTA
ATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTG
AGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTG
GAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACgccAagctGCT
TGGGctgcagATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCC
ATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGAC
CCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATT
GACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATAT
GCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTAC
ATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGc
atgGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTC
CAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGCAAAATCAACGGGACTTTCCAAAA
TGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATA
TAAGCAGAGGTCGAGGATTGGGGACCCTGCGCTGAACATGGAGAACGGTACC 
 
 
pCH GFP-S An-b-glob 
(GFP-S sequence underlined) 
 
ATGAGCAAGGGCGAGGAACTGTTCACTGGCGTGGTCCCAATTCTCGTGGAACTGGATGGCGATG
TGAATGGGCACAAATTTTCTGTCAGCGGAGAGGGTGAAGGTGATGCCACATACGGAAAGCTCAC
CCTGAAATTCATCTGCACCACTGGAAAGCTCCCTGTGCCATGGCCAACACTGGTCACTACCTTC
ACCTATGGCGTGCAGTGCTTTTCCAGATACCCAGACCATATGAAGCAGCATGACTTTTTCAAGA
GCGCCATGCCCGAGGGCTATGTGCAGGAGAGAACCATCTTTTTCAAAGATGACGGGAACTACAA
GACCCGCGCTGAAGTCAAGTTCGAAGGTGACACCCTGGTGAATAGAATCGAGCTGAAGGGCATT
GACTTTAAGGAGGATGGAAACATTCTCGGCCACAAGCTGGAATACAACTATAACTCCCACAATG
TGTACATCATGGCCGACAAGCAAAAGAATGGCATCAAGGTCAACTTCAAGATCAGACACAACAT
TGAGGATGGATCCGTGCAGCTGGCCGACCATTATCAACAGAACACTCCAATCGGCGACGGCCCT
GTGCTCCTCCCAGACAACCATTACCTGTCCACCCAGTCTGCCCTGTCTAAAGATCCCAACGAAA
AGAGAGACCACATGGTCCTGCTGGAGTTTGTGACCGCTGCTGGGATCACACATGGCATGGACGA
GCTGTACAAGggtaccATGGAGAACATCACATCAGGATTCCTAGGACCCCTTCTCGTGTTACAG
GCGGGGTTTTTCTTGTTGACAAGAATCCTCACAATACCGCAGAGTCTAGACTCGTGGTGGACTT
CTCTCAATTTTCTAGGGGGAACTACCGTGTGTCTTGGCCAAAATTCGCAGTCCCCAACCTCCAA
TCACTCACCAACCTCTTGTCCTCCAACTTGTCCTGGTTATCGCTGGATGTGTCTGCGGCGTTTT
ATCATCTTCCTCTTCATCCTGCTGCTATGCCTCATCTTCTTGTTGGTTCTTCTGGACTATCAAG
GTATGTTGCCCGTTTGTCCTCTAATTCCAGGATCCTCAACAACCAGCACGGGACCATGCCGGAC
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CTGCATGACTACTGCTCAAGGAACCTCTATGTATCCCTCCTGTTGCTGTACCAAACCTTCGGAC
GGAAATTGCACCTGTATTCCCATCCCATCATCCTGGGCTTTCGGAAAATTCCTATGGGAGTGGG
CCTCAGCCCGTTTCTCCTGGCTCAGTTTACTAGTGCCATTTGTTCAGTGGTTCGTAGGGCTTTC
CCCCACTGTTTGGCTTTCAGTTATATGGATGATGTGGTATTGGGGGCCAAGTCTGTACAGCATC
TTGAGTCCCTTTTTACCGCTGTTACCAATTTTCTTTTGTCTTTGGGTATACATTTAACAAGCTT
GCATGCGCGGCCGCTTCAGGGTGAGTTTGGGGACCCTTGATTGTTCTTTCTTTTTCGCTATTGT
AAAATTCATGTTATATGGAGGGGGCAAAGTTTTCAGGGTGTTGTTTAGAATGGGAAGATGTCCC
TTGTATCACCATGGACCCTCATGATAATTTTGTTTCTTTCACTTTCTACTCTGTTGACAACCAT
TGTCTCCTCTTATTTTCTTTTCATTTTCTGTAACTTTTTCGTTAAACTTTAGCTTGCATTTGTA
ACGAATTTTTAAATTCACTTTTGTTTATTTGTCAGATTGTAAGTACTTTCTCTAATCATTTTTT
TTTCAAGGCAATCAGGGTATATTATATTGTACTTCAGCACAGTTTTAGAGAACAATTGTTATAA
TTAAATGATAAGGTAGAATATTTCTGCATATAAATTCTGGCTGGCGTGGAAATATTCTTATTGG
TAGAAACAACTACACCCTGGTCATCATCCTGCCTTTCTCTTTATGGTTACAATGATATACACTG
TTTGAGATGAGGATAAAATACTCTGAGTCCAAACCGGGCCCCTCTGCTAACCATGTTCATGCCT
TCTTCTCTTTCCTACAGCTCCTGGGCAACGTGCTGGTTGTTGTGCTGTCTCATCATTTTGGCAA
AGAATTCACTCCTCAGGTGCAGGCTGCCTATCAGAAGGTGGTGGCTGGTGTGGCCAATGCCCTG
GCTCACAAATACCACTGAGATCTTTTTCCCTCTGCCAAAAATTATGGGGACATCATGAAGCCCC
TTGAGCATCTGACTTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTT
TTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCATTTAAAACATCAGAATGAGTAT
TTGGTTTAGAGTTTGGCTAGCCCTATAGTGAGTCGTATTAATAGCTCGAATTGATCTGATCAAA
TTCCGTGTATTCTATAGTGTCACCTAAATCGTATGTGTATGATACATAAGGTTATGTATTAATT
GTAGCCGCGTTCTAACGACAATATGTGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCAT
GATAATAATGGTTTCTTAGCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTT
TATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCA
ATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTT
GCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAG
ATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAG
TTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTA
TTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACT
TGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATG
CAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGA
CCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGG
AACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGC
AACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATA
GACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGT
TTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCC
AGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAA
CGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAG
TTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAA
GATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCA
GACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCT
TGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCT
TTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCG
TAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGT
TACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTT
ACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGA
ACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAG
GGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCT
TCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGT
CGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTT
TACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTC
TGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAG
CGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGC
GTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCG
CAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCG
GCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATG
ATTACgccAagctGCTTGGGctgcagATTATTGACTAGTTATTAATAGTAATCAATTACGGGGT
CATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGG
CTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCA
ATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTAC
ATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTG
GCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTC
ATCGCTATTACCATGcatgGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTT
GACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTgcAAAATCA
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ACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTA
CGGTGGGAGGTCTATATAAGCAGAGGTCGAC 
 
 
pCH GFP-sp-S An-b-glob 
(GFP-sp-S sequence underlined, spacer in small letters) 
 
ATGAGCAAGGGCGAGGAACTGTTCACTGGCGTGGTCCCAATTCTCGTGGAACTGGATGGCGATG
TGAATGGGCACAAATTTTCTGTCAGCGGAGAGGGTGAAGGTGATGCCACATACGGAAAGCTCAC
CCTGAAATTCATCTGCACCACTGGAAAGCTCCCTGTGCCATGGCCAACACTGGTCACTACCTTC
ACCTATGGCGTGCAGTGCTTTTCCAGATACCCAGACCATATGAAGCAGCATGACTTTTTCAAGA
GCGCCATGCCCGAGGGCTATGTGCAGGAGAGAACCATCTTTTTCAAAGATGACGGGAACTACAA
GACCCGCGCTGAAGTCAAGTTCGAAGGTGACACCCTGGTGAATAGAATCGAGCTGAAGGGCATT
GACTTTAAGGAGGATGGAAACATTCTCGGCCACAAGCTGGAATACAACTATAACTCCCACAATG
TGTACATCATGGCCGACAAGCAAAAGAATGGCATCAAGGTCAACTTCAAGATCAGACACAACAT
TGAGGATGGATCCGTGCAGCTGGCCGACCATTATCAACAGAACACTCCAATCGGCGACGGCCCT
GTGCTCCTCCCAGACAACCATTACCTGTCCACCCAGTCTGCCCTGTCTAAAGATCCCAACGAAA
AGAGAGACCACATGGTCCTGCTGGAGTTTGTGACCGCTGCTGGGATCACACATGGCATGGACGA
GCTGTACAAGggtACTTCTggaggcggagggtccggtACCATGGAGAACATCACATCAGGATTC
CTAGGACCCCTTCTCGTGTTACAGGCGGGGTTTTTCTTGTTGACAAGAATCCTCACAATACCGC
AGAGTCTAGACTCGTGGTGGACTTCTCTCAATTTTCTAGGGGGAACTACCGTGTGTCTTGGCCA
AAATTCGCAGTCCCCAACCTCCAATCACTCACCAACCTCTTGTCCTCCAACTTGTCCTGGTTAT
CGCTGGATGTGTCTGCGGCGTTTTATCATCTTCCTCTTCATCCTGCTGCTATGCCTCATCTTCT
TGTTGGTTCTTCTGGACTATCAAGGTATGTTGCCCGTTTGTCCTCTAATTCCAGGATCCTCAAC
AACCAGCACGGGACCATGCCGGACCTGCATGACTACTGCTCAAGGAACCTCTATGTATCCCTCC
TGTTGCTGTACCAAACCTTCGGACGGAAATTGCACCTGTATTCCCATCCCATCATCCTGGGCTT
TCGGAAAATTCCTATGGGAGTGGGCCTCAGCCCGTTTCTCCTGGCTCAGTTTACTAGTGCCATT
TGTTCAGTGGTTCGTAGGGCTTTCCCCCACTGTTTGGCTTTCAGTTATATGGATGATGTGGTAT
TGGGGGCCAAGTCTGTACAGCATCTTGAGTCCCTTTTTACCGCTGTTACCAATTTTCTTTTGTC
TTTGGGTATACATTTAACAAGCTTGCATGCGCGGCCGCTTCAGGGTGAGTTTGGGGACCCTTGA
TTGTTCTTTCTTTTTCGCTATTGTAAAATTCATGTTATATGGAGGGGGCAAAGTTTTCAGGGTG
TTGTTTAGAATGGGAAGATGTCCCTTGTATCACCATGGACCCTCATGATAATTTTGTTTCTTTC
ACTTTCTACTCTGTTGACAACCATTGTCTCCTCTTATTTTCTTTTCATTTTCTGTAACTTTTTC
GTTAAACTTTAGCTTGCATTTGTAACGAATTTTTAAATTCACTTTTGTTTATTTGTCAGATTGT
AAGTACTTTCTCTAATCATTTTTTTTTCAAGGCAATCAGGGTATATTATATTGTACTTCAGCAC
AGTTTTAGAGAACAATTGTTATAATTAAATGATAAGGTAGAATATTTCTGCATATAAATTCTGG
CTGGCGTGGAAATATTCTTATTGGTAGAAACAACTACACCCTGGTCATCATCCTGCCTTTCTCT
TTATGGTTACAATGATATACACTGTTTGAGATGAGGATAAAATACTCTGAGTCCAAACCGGGCC
CCTCTGCTAACCATGTTCATGCCTTCTTCTCTTTCCTACAGCTCCTGGGCAACGTGCTGGTTGT
TGTGCTGTCTCATCATTTTGGCAAAGAATTCACTCCTCAGGTGCAGGCTGCCTATCAGAAGGTG
GTGGCTGGTGTGGCCAATGCCCTGGCTCACAAATACCACTGAGATCTTTTTCCCTCTGCCAAAA
ATTATGGGGACATCATGAAGCCCCTTGAGCATCTGACTTCTGGCTAATAAAGGAAATTTATTTT
CATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAAT
CATTTAAAACATCAGAATGAGTATTTGGTTTAGAGTTTGGCTAGCCCTATAGTGAGTCGTATTA
ATAGCTCGAATTGATCTGATCAAATTCCGTGTATTCTATAGTGTCACCTAAATCGTATGTGTAT
GATACATAAGGTTATGTATTAATTGTAGCCGCGTTCTAACGACAATATGTGGCCTCGTGATACG
CCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGCAGGTGGCACTTTTCGGGGAA
ATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAG
ACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTC
CGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGC
TGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCT
CAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTT
AAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCC
GCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGA
TGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAAC
TTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATC
ATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGA
CACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACT
CTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGC
GCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCG
CGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACG
GGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTA
AGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTT
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TTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGT
GAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTT
TTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTT
GCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCA
AATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTA
CATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTAC
CGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCG
TGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTAT
GAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGG
AACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGG
TTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGA
AAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTT
CTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACC
GCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAA
TACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCC
CGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCC
CAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTC
ACACAGGAAACAGCTATGACCATGATTACGCCAAGCTGCTTGGGctgcagATTATTGACTAGTT
ATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATA
ACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATG
ACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTAC
GGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGT
CAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACT
TGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGcatgGTGATGCGGTTTTGGCAGTAC
ATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCA
ATGGGAGTTTGTTTTgcAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTG
ACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGGTCGAC 
 
 
pCH S-GFP An-b-glob 
(S-GFP sequence underlined) 
 
ATGGAGAACATCACATCAGGATTCCTAGGACCCCTTCTCGTGTTACAGGCGGGGTTTTTCTTGT
TGACAAGAATCCTCACAATACCGCAGAGTCTAGACTCGTGGTGGACTTCTCTCAATTTTCTAGG
GGGAACTACCGTGTGTCTTGGCCAAAATTCGCAGTCCCCAACCTCCAATCACTCACCAACCTCT
TGTCCTCCAACTTGTCCTGGTTATCGCTGGATGTGTCTGCGGCGTTTTATCATCTTCCTCTTCA
TCCTGCTGCTATGCCTCATCTTCTTGTTGGTTCTTCTGGACTATCAAGGTATGTTGCCCGTTTG
TCCTCTAATTCCAGGATCCTCAACAACCAGCACGGGACCATGCCGGACCTGCATGACTACTGCT
CAAGGAACCTCTATGTATCCCTCCTGTTGCTGTACCAAACCTTCGGACGGAAATTGCACCTGTA
TTCCCATCCCATCATCCTGGGCTTTCGGAAAATTCCTATGGGAGTGGGCCTCAGCCCGTTTCTC
CTGGCTCAGTTTACTAGTGCCATTTGTTCAGTGGTTCGTAGGGCTTTCCCCCACTGTTTGGCTT
TCAGTTATATGGATGATGTGGTATTGGGGGCCAAGTCTGTACAGCATCTTGAGTCCCTTTTTAC
CGCTGTTACCAATTTTCTTTTGTCTTTGGGTATACATTATGAGCAAGGGCGAGGAACTGTTCAC
TGGCGTGGTCCCAATTCTCGTGGAACTGGATGGCGATGTGAATGGGCACAAATTTTCTGTCAGC
GGAGAGGGTGAAGGTGATGCCACATACGGAAAGCTCACCCTGAAATTCATCTGCACCACTGGAA
AGCTCCCTGTGCCATGGCCAACACTGGTCACTACCTTCACCTATGGCGTGCAGTGCTTTTCCAG
ATACCCAGACCATATGAAGCAGCATGACTTTTTCAAGAGCGCCATGCCCGAGGGCTATGTGCAG
GAGAGAACCATCTTTTTCAAAGATGACGGGAACTACAAGACCCGCGCTGAAGTCAAGTTCGAAG
GTGACACCCTGGTGAATAGAATCGAGCTGAAGGGCATTGACTTTAAGGAGGATGGAAACATTCT
CGGCCACAAGCTGGAATACAACTATAACTCCCACAATGTGTACATCATGGCCGACAAGCAAAAG
AATGGCATCAAGGTCAACTTCAAGATCAGACACAACATTGAGGATGGATCCGTGCAGCTGGCCG
ACCATTATCAACAGAACACTCCAATCGGCGACGGCCCTGTGCTCCTCCCAGACAACCATTACCT
GTCCACCCAGTCTGCCCTGTCTAAAGATCCCAACGAAAAGAGAGACCACATGGTCCTGCTGGAG
TTTGTGACCGCTGCTGGGATCACACATGGCATGGACGAGCTGTACAAGTGAGCATGCGCGGCCG
CTTCAGGGTGAGTTTGGGGACCCTTGATTGTTCTTTCTTTTTCGCTATTGTAAAATTCATGTTA
TATGGAGGGGGCAAAGTTTTCAGGGTGTTGTTTAGAATGGGAAGATGTCCCTTGTATCACCATG
GACCCTCATGATAATTTTGTTTCTTTCACTTTCTACTCTGTTGACAACCATTGTCTCCTCTTAT
TTTCTTTTCATTTTCTGTAACTTTTTCGTTAAACTTTAGCTTGCATTTGTAACGAATTTTTAAA
TTCACTTTTGTTTATTTGTCAGATTGTAAGTACTTTCTCTAATCATTTTTTTTTCAAGGCAATC
AGGGTATATTATATTGTACTTCAGCACAGTTTTAGAGAACAATTGTTATAATTAAATGATAAGG
TAGAATATTTCTGCATATAAATTCTGGCTGGCGTGGAAATATTCTTATTGGTAGAAACAACTAC
ACCCTGGTCATCATCCTGCCTTTCTCTTTATGGTTACAATGATATACACTGTTTGAGATGAGGA
TAAAATACTCTGAGTCCAAACCGGGCCCCTCTGCTAACCATGTTCATGCCTTCTTCTCTTTCCT
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ACAGCTCCTGGGCAACGTGCTGGTTGTTGTGCTGTCTCATCATTTTGGCAAAGAATTCACTCCT
CAGGTGCAGGCTGCCTATCAGAAGGTGGTGGCTGGTGTGGCCAATGCCCTGGCTCACAAATACC
ACTGAGATCTTTTTCCCTCTGCCAAAAATTATGGGGACATCATGAAGCCCCTTGAGCATCTGAC
TTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCA
CTCGGAAGGACATATGGGAGGGCAAATCATTTAAAACATCAGAATGAGTATTTGGTTTAGAGTT
TGGCTAGCCCTATAGTGAGTCGTATTAATAGCTCGAATTGATCTGATCAAATTCCGTGTATTCT
ATAGTGTCACCTAAATCGTATGTGTATGATACATAAGGTTATGTATTAATTGTAGCCGCGTTCT
AACGACAATATGTGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTT
TCTTAGCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAAT
ACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAA
AGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCC
TTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGC
ACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAA
GAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTG
ACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTC
ACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATA
ACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAA
CCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAA
TGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGC
AAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGG
CGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAA
ATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCC
TCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGA
TCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATAT
ACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGAT
AATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAA
AGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAA
ACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTA
ACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACC
ACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGC
TGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCG
CAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCG
AACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGA
CAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAAC
GCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGAT
GCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGC
CTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGT
ATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAG
TGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCA
TTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAAT
GTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGT
GTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCT
GCTTGGGctgcagATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAG
CCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAAC
GACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCC
ATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCA
TATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAG
TACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCA
TGcatgGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGAT
TTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTgcAAAATCAACGGGACTTTCCA
AAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCT
ATATAAGCAGAGGTCGAGGATTGGGGACCCTGCGCTGAACATGGAGAACGGTAC 
 
 
pCH M-GFP An-b-glob 
(M-GFP sequence underlined) 
 
ATGCAGTGGAATTCCACAACCTTCCACCAAACTCTGCAAGATCCCAGAGTGAGAGGCCTGTATT
TCCCTGCTGGTGGCTCCAGTTCAGGAACAGTAAACCCTGTTCTGACTACTGCCTCTCCCTTATC
GTCAATCTTCTCGAGGATTGGGGACCCTGCGCTGAACAAcGGAGAACATCACATCAGGATTCCT
AGGACCCCTTCTCGTGTTACAGGCGGGGTTTTTCTTGTTGACAAGAATCCTCACAATACCGCAG
AGTCTAGACTCGTGGTGGACTTCTCTCAATTTTCTAGGGGGAACTACCGTGTGTCTTGGCCAAA
ATTCGCAGTCCCCAACCTCCAATCACTCACCAACCTCTTGTCCTCCAACTTGTCCTGGTTATCG
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CTGGATGTGTCTGCGGCGTTTTATCATCTTCCTCTTCATCCTGCTGCTATGCCTCATCTTCTTG
TTGGTTCTTCTGGACTATCAAGGTATGTTGCCCGTTTGTCCTCTAATTCCAGGATCCTCAACAA
CCAGCACGGGACCATGCCGGACCTGCATGACTACTGCTCAAGGAACCTCTATGTATCCCTCCTG
TTGCTGTACCAAACCTTCGGACGGAAATTGCACCTGTATTCCCATCCCATCATCCTGGGCTTTC
GGAAAATTCCTATGGGAGTGGGCCTCAGCCCGTTTCTCCTGGCTCAGTTTACTAGTGCCATTTG
TTCAGTGGTTCGTAGGGCTTTCCCCCACTGTTTGGCTTTCAGTTATATGGATGATGTGGTATTG
GGGGCCAAGTCTGTACAGCATCTTGAGTCCCTTTTTACCGCTGTTACCAATTTTCTTTTGTCTT
TGGGTatacattATGAGCAAGGGCGAGGAACTGTTCACTGGCGTGGTCCCAATTCTCGTGGAAC
TGGATGGCGATGTGAATGGGCACAAATTTTCTGTCAGCGGAGAGGGTGAAGGTGATGCCACATA
CGGAAAGCTCACCCTGAAATTCATCTGCACCACTGGAAAGCTCCCTGTGCCATGGCCAACACTG
GTCACTACCTTCACCTATGGCGTGCAGTGCTTTTCCAGATACCCAGACCATATGAAGCAGCATG
ACTTTTTCAAGAGCGCCATGCCCGAGGGCTATGTGCAGGAGAGAACCATCTTTTTCAAAGATGA
CGGGAACTACAAGACCCGCGCTGAAGTCAAGTTCGAAGGTGACACCCTGGTGAATAGAATCGAG
CTGAAGGGCATTGACTTTAAGGAGGATGGAAACATTCTCGGCCACAAGCTGGAATACAACTATA
ACTCCCACAATGTGTACATCATGGCCGACAAGCAAAAGAATGGCATCAAGGTCAACTTCAAGAT
CAGACACAACATTGAGGATGGATCCGTGCAGCTGGCCGACCATTATCAACAGAACACTCCAATC
GGCGACGGCCCTGTGCTCCTCCCAGACAACCATTACCTGTCCACCCAGTCTGCCCTGTCTAAAG
ATCCCAACGAAAAGAGAGACCACATGGTCCTGCTGGAGTTTGTGACCGCTGCTGGGATCACACA
TGGCATGGACGAGCTGTACAAGTGAGCATGCGCGGCCGCTTCAGGGTGAGTTTGGGGACCCTTG
ATTGTTCTTTCTTTTTCGCTATTGTAAAATTCATGTTATATGGAGGGGGCAAAGTTTTCAGGGT
GTTGTTTAGAATGGGAAGATGTCCCTTGTATCACCATGGACCCTCATGATAATTTTGTTTCTTT
CACTTTCTACTCTGTTGACAACCATTGTCTCCTCTTATTTTCTTTTCATTTTCTGTAACTTTTT
CGTTAAACTTTAGCTTGCATTTGTAACGAATTTTTAAATTCACTTTTGTTTATTTGTCAGATTG
TAAGTACTTTCTCTAATCATTTTTTTTTCAAGGCAATCAGGGTATATTATATTGTACTTCAGCA
CAGTTTTAGAGAACAATTGTTATAATTAAATGATAAGGTAGAATATTTCTGCATATAAATTCTG
GCTGGCGTGGAAATATTCTTATTGGTAGAAACAACTACACCCTGGTCATCATCCTGCCTTTCTC
TTTATGGTTACAATGATATACACTGTTTGAGATGAGGATAAAATACTCTGAGTCCAAACCGGGC
CCCTCTGCTAACCATGTTCATGCCTTCTTCTCTTTCCTACAGCTCCTGGGCAACGTGCTGGTTG
TTGTGCTGTCTCATCATTTTGGCAAAGAATTCACTCCTCAGGTGCAGGCTGCCTATCAGAAGGT
GGTGGCTGGTGTGGCCAATGCCCTGGCTCACAAATACCACTGAGATCTTTTTCCCTCTGCCAAA
AATTATGGGGACATCATGAAGCCCCTTGAGCATCTGACTTCTGGCTAATAAAGGAAATTTATTT
TCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAA
TCATTTAAAACATCAGAATGAGTATTTGGTTTAGAGTTTGGCTAGCCCTATAGTGAGTCGTATT
AATAGCTCGAATTGATCTGATCAAATTCCGTGTATTCTATAGTGTCACCTAAATCGTATGTGTA
TGATACATAAGGTTATGTATTAATTGTAGCCGCGTTCTAACGACAATATGTGGCCTCGTGATAC
GCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGCAGGTGGCACTTTTCGGGGA
AATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGA
GACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTT
CCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACG
CTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATC
TCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTT
TAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGC
CGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGG
ATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAA
CTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGAT
CATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTG
ACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTAC
TCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTG
CGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTC
GCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGAC
GGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATT
AAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATT
TTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACG
TGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCT
TTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTT
TGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACC
AAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCT
ACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTA
CCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTC
GTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTA
TGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCG
GAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGG
GTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGG
AAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGT
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TCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATAC
CGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCA
ATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTC
CCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACC
CCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTT
CACACAGGAAACAGCTATGACCATGATTACgccAagctGCTTGGGctgcagATTATTGACTAGT
TATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACAT
AACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAAT
GACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTA
CGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACG
TCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTAC
TTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGcatgGTGATGCGGTTTTGGCAGTA
CATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTC
AATGGGAGTTTGTTTTgcAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATT
GACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGGTCGAGGATTGGGG
ACCCTGCGCTGAACATGGAGAACGGTACC 
 
 
pCH L-GFP An-b-glob 
(L-GFP sequence underlined) 
 
ATGGGGCAGAATCTTTCCACCAGCAATCCTCTGGGATTCTTTCCCGACCACCAGTTGGATCCAG
CCTTCAGAGCAAACACCGCAAATCCAGATTGGGACTTCAATCCCAACAAGGACACCTGGCCAGA
CGCCAACAAGGTAGGAGCTGGAGCATTCGGGCTGGGTTTCACCCCACCGCACGGAGGCCTTTTG
GGGTGGAGCCCTCAGGCTCAGGGCATACTACAAACTTTGCCAGCAAATCCGCCTCCTGCCTCCA
CCAATCGCCAGTCAGGAAGGCAGCCTACCCCGCTGTCTCCACCTTTGAGAAACACTCATCCTCA
GGCCAcGCAGTGGAATTCCACAACCTTCCACCAAACTCTGCAAGATCCCAGAGTGAGAGGCCTG
TATTTCCCTGCTGGTGGCTCCAGTTCAGGAACAGTAAACCCTGTTCTGACTACTGCCTCTCCCT
TATCGTCAATCTTCTCGAGGATTGGGGACCCTGCGCTGAACAAcGGAGAACATCACATCAGGAT
TCCTAGGACCCCTTCTCGTGTTACAGGCGGGGTTTTTCTTGTTGACAAGAATCCTCACAATACC
GCAGAGTCTAGACTCGTGGTGGACTTCTCTCAATTTTCTAGGGGGAACTACCGTGTGTCTTGGC
CAAAATTCGCAGTCCCCAACCTCCAATCACTCACCAACCTCTTGTCCTCCAACTTGTCCTGGTT
ATCGCTGGATGTGTCTGCGGCGTTTTATCATCTTCCTCTTCATCCTGCTGCTATGCCTCATCTT
CTTGTTGGTTCTTCTGGACTATCAAGGTATGTTGCCCGTTTGTCCTCTAATTCCAGGATCCTCA
ACAACCAGCACGGGACCATGCCGGACCTGCATGACTACTGCTCAAGGAACCTCTATGTATCCCT
CCTGTTGCTGTACCAAACCTTCGGACGGAAATTGCACCTGTATTCCCATCCCATCATCCTGGGC
TTTCGGAAAATTCCTATGGGAGTGGGCCTCAGCCCGTTTCTCCTGGCTCAGTTTACTAGTGCCA
TTTGTTCAGTGGTTCGTAGGGCTTTCCCCCACTGTTTGGCTTTCAGTTATATGGATGATGTGGT
ATTGGGGGCCAAGTCTGTACAGCATCTTGAGTCCCTTTTTACCGCTGTTACCAATTTTCTTTTG
TCTTTGGGTATACATTATGAGCAAGGGCGAGGAACTGTTCACTGGCGTGGTCCCAATTCTCGTG
GAACTGGATGGCGATGTGAATGGGCACAAATTTTCTGTCAGCGGAGAGGGTGAAGGTGATGCCA
CATACGGAAAGCTCACCCTGAAATTCATCTGCACCACTGGAAAGCTCCCTGTGCCATGGCCAAC
ACTGGTCACTACCTTCACCTATGGCGTGCAGTGCTTTTCCAGATACCCAGACCATATGAAGCAG
CATGACTTTTTCAAGAGCGCCATGCCCGAGGGCTATGTGCAGGAGAGAACCATCTTTTTCAAAG
ATGACGGGAACTACAAGACCCGCGCTGAAGTCAAGTTCGAAGGTGACACCCTGGTGAATAGAAT
CGAGCTGAAGGGCATTGACTTTAAGGAGGATGGAAACATTCTCGGCCACAAGCTGGAATACAAC
TATAACTCCCACAATGTGTACATCATGGCCGACAAGCAAAAGAATGGCATCAAGGTCAACTTCA
AGATCAGACACAACATTGAGGATGGATCCGTGCAGCTGGCCGACCATTATCAACAGAACACTCC
AATCGGCGACGGCCCTGTGCTCCTCCCAGACAACCATTACCTGTCCACCCAGTCTGCCCTGTCT
AAAGATCCCAACGAAAAGAGAGACCACATGGTCCTGCTGGAGTTTGTGACCGCTGCTGGGATCA
CACATGGCATGGACGAGCTGTACAAGTGAGCATGCGCGGCCGCTTCAGGGTGAGTTTGGGGACC
CTTGATTGTTCTTTCTTTTTCGCTATTGTAAAATTCATGTTATATGGAGGGGGCAAAGTTTTCA
GGGTGTTGTTTAGAATGGGAAGATGTCCCTTGTATCACCATGGACCCTCATGATAATTTTGTTT
CTTTCACTTTCTACTCTGTTGACAACCATTGTCTCCTCTTATTTTCTTTTCATTTTCTGTAACT
TTTTCGTTAAACTTTAGCTTGCATTTGTAACGAATTTTTAAATTCACTTTTGTTTATTTGTCAG
ATTGTAAGTACTTTCTCTAATCATTTTTTTTTCAAGGCAATCAGGGTATATTATATTGTACTTC
AGCACAGTTTTAGAGAACAATTGTTATAATTAAATGATAAGGTAGAATATTTCTGCATATAAAT
TCTGGCTGGCGTGGAAATATTCTTATTGGTAGAAACAACTACACCCTGGTCATCATCCTGCCTT
TCTCTTTATGGTTACAATGATATACACTGTTTGAGATGAGGATAAAATACTCTGAGTCCAAACC
GGGCCCCTCTGCTAACCATGTTCATGCCTTCTTCTCTTTCCTACAGCTCCTGGGCAACGTGCTG
GTTGTTGTGCTGTCTCATCATTTTGGCAAAGAATTCACTCCTCAGGTGCAGGCTGCCTATCAGA
AGGTGGTGGCTGGTGTGGCCAATGCCCTGGCTCACAAATACCACTGAGATCTTTTTCCCTCTGC
CAAAAATTATGGGGACATCATGAAGCCCCTTGAGCATCTGACTTCTGGCTAATAAAGGAAATTT
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ATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGG
CAAATCATTTAAAACATCAGAATGAGTATTTGGTTTAGAGTTTGGCTAGCCCTATAGTGAGTCG
TATTAATAGCTCGAATTGATCTGATCAAATTCCGTGTATTCTATAGTGTCACCTAAATCGTATG
TGTATGATACATAAGGTTATGTATTAATTGTAGCCGCGTTCTAACGACAATATGTGGCCTCGTG
ATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGCAGGTGGCACTTTTCG
GGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTC
ATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAAC
ATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGA
AACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTG
GATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCA
CTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGG
TCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTT
ACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGG
CCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGG
GGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAG
CGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTAC
TTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACT
TCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGG
TCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACA
CGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACT
GATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTT
CATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTT
AACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGA
TCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTT
TGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGA
TACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACC
GCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGT
CTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGG
GTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGA
GCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGG
GTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTG
TCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCT
ATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCAC
ATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTG
ATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCG
CCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGG
TTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGG
CACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACA
ATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTGCTTGGGCTGCAGATTATTGAC
TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTT
ACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAA
TAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTA
TTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATT
GACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTC
CTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGCATGGTGATGCGGTTTTGGC
AGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGA
CGTCAATGGGAGTTTGTTTTGCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCC
CATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGGTCGAGGATT
GGGGACCCTGCGCTGAACATGGAGAACGGTACC 
 
 
pCH S-RFP An-b-glob 
(S-RFP sequence underlined) 
 
ATGGAGAACATCACATCAGGATTCCTAGGACCCCTTCTCGTGTTACAGGCGGGGTTTTTCTTGT
TGACAAGAATCCTCACAATACCGCAGAGTCTAGACTCGTGGTGGACTTCTCTCAATTTTCTAGG
GGGAACTACCGTGTGTCTTGGCCAAAATTCGCAGTCCCCAACCTCCAATCACTCACCAACCTCT
TGTCCTCCAACTTGTCCTGGTTATCGCTGGATGTGTCTGCGGCGTTTTATCATCTTCCTCTTCA
TCCTGCTGCTATGCCTCATCTTCTTGTTGGTTCTTCTGGACTATCAAGGTATGTTGCCCGTTTG
TCCTCTAATTCCAGGATCCTCAACAACCAGCACGGGACCATGCCGGACCTGCATGACTACTGCT
CAAGGAACCTCTATGTATCCCTCCTGTTGCTGTACCAAACCTTCGGACGGAAATTGCACCTGTA
TTCCCATCCCATCATCCTGGGCTTTCGGAAAATTCCTATGGGAGTGGGCCTCAGCCCGTTTCTC
CTGGCTCAGTTTACTAGTGCCATTTGTTCAGTGGTTCGTAGGGCTTTCCCCCACTGTTTGGCTT
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TCAGTTATATGGATGATGTGGTATTGGGGGCCAAGTCTGTACAGCATCTTGAGTCCCTTTTTAC
CGCTGTTACCAATTTTCTTTTGTCTTTGGGTATACATTATGGCCTCCTCCGAGGACGTCATCAA
GGAGTTCATGCGCTTCAAGGTGCGCATGGAGGGCTCCGTGAACGGCCACGAGTTCGAGATCGAG
GGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGGGCG
GCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCTCAGTTCCAGTACGGCTCCAAGGCCTACGT
GAAGCACCCCGCCGACATTCCCCGACTACTTGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGA
GCGCGTGATGAACTTCGAGGACGGCGGCGTGGTGACCGTGACCCAGGACTCCTCCCTGCAGGAC
GGCGAGTTCATCTACAAGGTGAAGCTGCGCGGCACCAACTTCCCCTCCGACGGCCCCGTAATGC
AGAAGAAGACCATGGGCTGGGAGGCCTCCACCGAGCGGATGTACCCCGAGGACGGCGCCCTGAA
GGGCGAGATCAAGATGAGGCTGAAGCTGAAGGACGGCGGCCACTACGACGCCGAGGTCAAGACC
ACCTACATGGCCAAGAAGCCCGTGCAGCTGCCCGGCGCCTACAAGACCGACATCAAGCTGGACA
TCACCTCCCACAACGAGGACTACACCATCGTGGAACAGTACGAGCGCGCCGAGGGCCGCCACTC
CACCGGCGCCTAAGCATGCGCGGCCGCTTCAGGGTGAGTTTGGGGACCCTTGATTGTTCTTTCT
TTTTCGCTATTGTAAAATTCATGTTATATGGAGGGGGCAAAGTTTTCAGGGTGTTGTTTAGAAT
GGGAAGATGTCCCTTGTATCACCATGGACCCTCATGATAATTTTGTTTCTTTCACTTTCTACTC
TGTTGACAACCATTGTCTCCTCTTATTTTCTTTTCATTTTCTGTAACTTTTTCGTTAAACTTTA
GCTTGCATTTGTAACGAATTTTTAAATTCACTTTTGTTTATTTGTCAGATTGTAAGTACTTTCT
CTAATCATTTTTTTTTCAAGGCAATCAGGGTATATTATATTGTACTTCAGCACAGTTTTAGAGA
ACAATTGTTATAATTAAATGATAAGGTAGAATATTTCTGCATATAAATTCTGGCTGGCGTGGAA
ATATTCTTATTGGTAGAAACAACTACACCCTGGTCATCATCCTGCCTTTCTCTTTATGGTTACA
ATGATATACACTGTTTGAGATGAGGATAAAATACTCTGAGTCCAAACCGGGCCCCTCTGCTAAC
CATGTTCATGCCTTCTTCTCTTTCCTACAGCTCCTGGGCAACGTGCTGGTTGTTGTGCTGTCTC
ATCATTTTGGCAAAGAATTCACTCCTCAGGTGCAGGCTGCCTATCAGAAGGTGGTGGCTGGTGT
GGCCAATGCCCTGGCTCACAAATACCACTGAGATCTTTTTCCCTCTGCCAAAAATTATGGGGAC
ATCATGAAGCCCCTTGAGCATCTGACTTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAG
TGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCATTTAAAACA
TCAGAATGAGTATTTGGTTTAGAGTTTGGCTAGCCCTATAGTGAGTCGTATTAATAGCTCGAAT
TGATCTGATCAAATTCCGTGTATTCTATAGTGTCACCTAAATCGTATGTGTATGATACATAAGG
TTATGTATTAATTGTAGCCGCGTTCTAACGACAATATGTGGCCTCGTGATACGCCTATTTTTAT
AGGTTAATGTCATGATAATAATGGTTTCTTAGCAGGTGGCACTTTTCGGGGAAATGTGCGCGGA
ACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCT
GATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCT
TATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTA
AAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTA
AGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCT
ATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTAT
TCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAG
TAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGAC
AACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGC
CTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGC
CTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCG
GCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTT
CCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTG
CAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGC
AACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA
CTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAA
GGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTT
CCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGC
GTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAG
AGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCT
TCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCT
CTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACT
CAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCC
CAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCC
ACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGC
GCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCT
CTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGC
AACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGT
TATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAG
CCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCG
CCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAG
CGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACA
CTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAAC
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AGCTATGACCATGATTACGCCAAGCTGCTTGGGCTGCAGATTATTGACTAGTTATTAATAGTAA
TCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAA
ATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCC
CATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCC
CACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTA
AATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACAT
CTACGTATTAGTCATCGCTATTACCATGCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCG
TGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTG
TTTTGCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGG
CGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGGTCTATATAAGCAGAGGTCGAGGATT
GGGGACCCTGCGCTGAACATGGAGAACGGTACC 
 
 
pCH M-RFP An-b-glob 
(M-RFP sequence underlined) 
 
ATGCAGTGGAATTCCACAACCTTCCACCAAACTCTGCAAGATCCCAGAGTGAGAGGCCTGTATT
TCCCTGCTGGTGGCTCCAGTTCAGGAACAGTAAACCCTGTTCTGACTACTGCCTCTCCCTTATC
GTCAATCTTCTCGAGGATTGGGGACCCTGCGCTGAACACGGAGAACATCACATCAGGATTCCTA
GGACCCCTTCTCGTGTTACAGGCGGGGTTTTTCTTGTTGACAAGAATCCTCACAATACCGCAGA
GTCTAGACTCGTGGTGGACTTCTCTCAATTTTCTAGGGGGAACTACCGTGTGTCTTGGCCAAAA
TTCGCAGTCCCCAACCTCCAATCACTCACCAACCTCTTGTCCTCCAACTTGTCCTGGTTATCGC
TGGATGTGTCTGCGGCGTTTTATCATCTTCCTCTTCATCCTGCTGCTATGCCTCATCTTCTTGT
TGGTTCTTCTGGACTATCAAGGTATGTTGCCCGTTTGTCCTCTAATTCCAGGATCCTCAACAAC
CAGCACGGGACCATGCCGGACCTGCATGACTACTGCTCAAGGAACCTCTATGTATCCCTCCTGT
TGCTGTACCAAACCTTCGGACGGAAATTGCACCTGTATTCCCATCCCATCATCCTGGGCTTTCG
GAAAATTCCTATGGGAGTGGGCCTCAGCCCGTTTCTCCTGGCTCAGTTTACTAGTGCCATTTGT
TCAGTGGTTCGTAGGGCTTTCCCCCACTGTTTGGCTTTCAGTTATATGGATGATGTGGTATTGG
GGGCCAAGTCTGTACAGCATCTTGAGTCCCTTTTTACCGCTGTTACCAATTTTCTTTTGTCTTT
GGGTATACATTATGGCCTCCTCCGAGGACGTCATCAAGGAGTTCATGCGCTTCAAGGTGCGCAT
GGAGGGCTCCGTGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAG
GGCACCCAGACCGCCAAGCTGAAGGTGACCAAGGGCGGCCCCCTGCCCTTCGCCTGGGACATCC
TGTCCCCTCAGTTCCAGTACGGCTCCAAGGCCTACGTGAAGCACCCCGCCGACATTCCCCGACT
ACTTGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGG
CGTGGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGGCGAGTTCATCTACAAGGTGAAGCTG
CGCGGCACCAACTTCCCCTCCGACGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCCT
CCACCGAGCGGATGTACCCCGAGGACGGCGCCCTGAAGGGCGAGATCAAGATGAGGCTGAAGCT
GAAGGACGGCGGCCACTACGACGCCGAGGTCAAGACCACCTACATGGCCAAGAAGCCCGTGCAG
CTGCCCGGCGCCTACAAGACCGACATCAAGCTGGACATCACCTCCCACAACGAGGACTACACCA
TCGTGGAACAGTACGAGCGCGCCGAGGGCCGCCACTCCACCGGCGCCTAAGCATGCGCGGCCGC
TTCAGGGTGAGTTTGGGGACCCTTGATTGTTCTTTCTTTTTCGCTATTGTAAAATTCATGTTAT
ATGGAGGGGGCAAAGTTTTCAGGGTGTTGTTTAGAATGGGAAGATGTCCCTTGTATCACCATGG
ACCCTCATGATAATTTTGTTTCTTTCACTTTCTACTCTGTTGACAACCATTGTCTCCTCTTATT
TTCTTTTCATTTTCTGTAACTTTTTCGTTAAACTTTAGCTTGCATTTGTAACGAATTTTTAAAT
TCACTTTTGTTTATTTGTCAGATTGTAAGTACTTTCTCTAATCATTTTTTTTTCAAGGCAATCA
GGGTATATTATATTGTACTTCAGCACAGTTTTAGAGAACAATTGTTATAATTAAATGATAAGGT
AGAATATTTCTGCATATAAATTCTGGCTGGCGTGGAAATATTCTTATTGGTAGAAACAACTACA
CCCTGGTCATCATCCTGCCTTTCTCTTTATGGTTACAATGATATACACTGTTTGAGATGAGGAT
AAAATACTCTGAGTCCAAACCGGGCCCCTCTGCTAACCATGTTCATGCCTTCTTCTCTTTCCTA
CAGCTCCTGGGCAACGTGCTGGTTGTTGTGCTGTCTCATCATTTTGGCAAAGAATTCACTCCTC
AGGTGCAGGCTGCCTATCAGAAGGTGGTGGCTGGTGTGGCCAATGCCCTGGCTCACAAATACCA
CTGAGATCTTTTTCCCTCTGCCAAAAATTATGGGGACATCATGAAGCCCCTTGAGCATCTGACT
TCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCAC
TCGGAAGGACATATGGGAGGGCAAATCATTTAAAACATCAGAATGAGTATTTGGTTTAGAGTTT
GGCTAGCCCTATAGTGAGTCGTATTAATAGCTCGAATTGATCTGATCAAATTCCGTGTATTCTA
TAGTGTCACCTAAATCGTATGTGTATGATACATAAGGTTATGTATTAATTGTAGCCGCGTTCTA
ACGACAATATGTGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTT
CTTAGCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATA
CATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAA
GGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCT
TCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCA
CGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAG
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AACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGA
CGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCA
CCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAA
CCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAAC
CGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAAT
GAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCA
AACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGC
GGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAA
TCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCT
CCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGAT
CGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATA
CTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATA
ATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAA
GATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAA
CCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAA
CTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCA
CTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCT
GCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGC
AGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGA
ACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGAC
AGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACG
CCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATG
CTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCC
TTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTA
TTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGT
GAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCAT
TAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATG
TGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTG
TGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTG
CTTGGGCTGCAGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGC
CCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACG
ACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCA
TTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCAT
ATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGT
ACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCAT
GcatgGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATT
TCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGCAAAATCAACGGGACTTTCCAA
AATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTA
TATAAGCAGAGGTCTATATAAGCAGAGGTCGAGGATTGGGGACCCTGCGCTGAACATGGAGAAC
GGTACC 
 
 
pCH L-RFP An-b-glob 
(L-RFP sequence underlined) 
 
ATGGGGCAGAATCTTTCCACCAGCAATCCTCTGGGATTCTTTCCCGACCACCAGTTGGATCCAG
CCTTCAGAGCAAACACCGCAAATCCAGATTGGGACTTCAATCCCAACAAGGACACCTGGCCAGA
CGCCAACAAGGTAGGAGCTGGAGCATTCGGGCTGGGTTTCACCCCACCGCACGGAGGCCTTTTG
GGGTGGAGCCCTCAGGCTCAGGGCATACTACAAACTTTGCCAGCAAATCCGCCTCCTGCCTCCA
CCAATCGCCAGTCAGGAAGGCAGCCTACCCCGCTGTCTCCACCTTTGAGAAACACTCATCCTCA
GGCCAcGCAGTGGAATTCCACAACCTTCCACCAAACTCTGCAAGATCCCAGAGTGAGAGGCCTG
TATTTCCCTGCTGGTGGCTCCAGTTCAGGAACAGTAAACCCTGTTCTGACTACTGCCTCTCCCT
TATCGTCAATCTTCTCGAGGATTGGGGACCCTGCGCTGAACAAcGGAGAACATCACATCAGGAT
TCCTAGGACCCCTTCTCGTGTTACAGGCGGGGTTTTTCTTGTTGACAAGAATCCTCACAATACC
GCAGAGTCTAGACTCGTGGTGGACTTCTCTCAATTTTCTAGGGGGAACTACCGTGTGTCTTGGC
CAAAATTCGCAGTCCCCAACCTCCAATCACTCACCAACCTCTTGTCCTCCAACTTGTCCTGGTT
ATCGCTGGATGTGTCTGCGGCGTTTTATCATCTTCCTCTTCATCCTGCTGCTATGCCTCATCTT
CTTGTTGGTTCTTCTGGACTATCAAGGTATGTTGCCCGTTTGTCCTCTAATTCCAGGATCCTCA
ACAACCAGCACGGGACCATGCCGGACCTGCATGACTACTGCTCAAGGAACCTCTATGTATCCCT
CCTGTTGCTGTACCAAACCTTCGGACGGAAATTGCACCTGTATTCCCATCCCATCATCCTGGGC
TTTCGGAAAATTCCTATGGGAGTGGGCCTCAGCCCGTTTCTCCTGGCTCAGTTTACTAGTGCCA
                                                                                                                                      Sequences  
 187
TTTGTTCAGTGGTTCGTAGGGCTTTCCCCCACTGTTTGGCTTTCAGTTATATGGATGATGTGGT
ATTGGGGGCCAAGTCTGTACAGCATCTTGAGTCCCTTTTTACCGCTGTTACCAATTTTCTTTTG
TCTTTGGGTATACATTATGGCCTCCTCCGAGGACGTCATCAAGGAGTTCATGCGCTTCAAGGTG
CGCATGGAGGGCTCCGTGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCT
ACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGGGCGGCCCCCTGCCCTTCGCCTGGGA
CATCCTGTCCCCTCAGTTCCAGTACGGCTCCAAGGCCTACGTGAAGCACCCCGCCGACATTCCC
CGACTACTTGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGAC
GGCGGCGTGGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGGCGAGTTCATCTACAAGGTGA
AGCTGCGCGGCACCAACTTCCCCTCCGACGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGA
GGCCTCCACCGAGCGGATGTACCCCGAGGACGGCGCCCTGAAGGGCGAGATCAAGATGAGGCTG
AAGCTGAAGGACGGCGGCCACTACGACGCCGAGGTCAAGACCACCTACATGGCCAAGAAGCCCG
TGCAGCTGCCCGGCGCCTACAAGACCGACATCAAGCTGGACATCACCTCCCACAACGAGGACTA
CACCATCGTGGAACAGTACGAGCGCGCCGAGGGCCGCCACTCCACCGGCGCCTAAGCATGCGCG
GCCGCTTCAGGGTGAGTTTGGGGACCCTTGATTGTTCTTTCTTTTTCGCTATTGTAAAATTCAT
GTTATATGGAGGGGGCAAAGTTTTCAGGGTGTTGTTTAGAATGGGAAGATGTCCCTTGTATCAC
CATGGACCCTCATGATAATTTTGTTTCTTTCACTTTCTACTCTGTTGACAACCATTGTCTCCTC
TTATTTTCTTTTCATTTTCTGTAACTTTTTCGTTAAACTTTAGCTTGCATTTGTAACGAATTTT
TAAATTCACTTTTGTTTATTTGTCAGATTGTAAGTACTTTCTCTAATCATTTTTTTTTCAAGGC
AATCAGGGTATATTATATTGTACTTCAGCACAGTTTTAGAGAACAATTGTTATAATTAAATGAT
AAGGTAGAATATTTCTGCATATAAATTCTGGCTGGCGTGGAAATATTCTTATTGGTAGAAACAA
CTACACCCTGGTCATCATCCTGCCTTTCTCTTTATGGTTACAATGATATACACTGTTTGAGATG
AGGATAAAATACTCTGAGTCCAAACCGGGCCCCTCTGCTAACCATGTTCATGCCTTCTTCTCTT
TCCTACAGCTCCTGGGCAACGTGCTGGTTGTTGTGCTGTCTCATCATTTTGGCAAAGAATTCAC
TCCTCAGGTGCAGGCTGCCTATCAGAAGGTGGTGGCTGGTGTGGCCAATGCCCTGGCTCACAAA
TACCACTGAGATCTTTTTCCCTCTGCCAAAAATTATGGGGACATCATGAAGCCCCTTGAGCATC
TGACTTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCT
CTCACTCGGAAGGACATATGGGAGGGCAAATCATTTAAAACATCAGAATGAGTATTTGGTTTAG
AGTTTGGCTAGCCCTATAGTGAGTCGTATTAATAGCTCGAATTGATCTGATCAAATTCCGTGTA
TTCTATAGTGTCACCTAAATCGTATGTGTATGATACATAAGGTTATGTATTAATTGTAGCCGCG
TTCTAACGACAATATGTGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAAT
GGTTTCTTAGCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCT
AAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTG
AAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTT
TGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGG
GTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCC
CGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGT
ATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGT
ACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGC
CATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAG
CTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGC
TGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTT
GCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATG
GAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTG
ATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAA
GCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGA
CAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCAT
ATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTT
TGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTA
GAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAA
AAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAA
GGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGC
CACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGG
CTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAA
GGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTAC
ACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGG
CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGG
AAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTG
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TGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCC
TGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAA
CCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAG
TCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGA
TTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAAT
TAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATG
TTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCA
AGCTGCTTGGGCTGCAGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTC
ATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCC
CAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACT
TTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGT
ATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGC
CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATT
ACCATGcatgGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGG
GGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGCAAAATCAACGGGACTT
TCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAG
GTCTATATAAGCAGAGGTCTATATAAGCAGAGGTCGAGGATTGGGGACCCTGCGCTGAACATGG
AGAACGGTACC 
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